Literature for peptidase A02.001: HIV-1 retropepsin

Summary Alignment Sequences Sequence features Distribution Structure Literature Substrates Pharma

(Topics flags: A Assay, S Structure, T Target, P Specificity, E Expression, V Review, M Mutation, I Inhibitor, L Localization. To select only the references relevant to a single topic, click the link above. See explanation.)

2025

Chen,J., Fang,R., Wang,Z., Jiang,H., Xu,J. and Xiong,F.
Rational Design and Multi-tiered Computational Evaluation of Novel Darunavir Derivatives as HIV-1 Protease Inhibitors: an Integrated Approach Using QSAR Model, Molecular Docking, MD Simulations, DFT Analysis, and ADME Profiling
Chem Biodiverse03500-e03500. PubMed Europe PubMed DOI
Ghosh,A.K., Yadav,M., Sharma,A., Johnson,M., Ghosh,A.K., Prasad,R., Amano,M., Gerlits,O., Kovalevsky,A. and Mitsuya,H.
Potent HIVƒ_'1 protease inhibitors containing oxabicyclo octanol-derived P2-ligands: Design, synthesis, and Xƒ_'ray structural studies of inhibitor-HIV-1 protease complexes
Bioorg Med Chem Lett120, 130109-130109. PubMed Europe PubMed DOI I
Hsieh,S.H., Huang,K.J. and Wang,C.T.
A virus-like particle assembly system for probing the HIV-1 Gag-Pol dimerization domain: supporting evidence for reverse transcriptase involvement in protease activation by influencing Gag-Pol/Gag-Pol interaction
J Virole0223624-e0223624. PubMed Europe PubMed DOI
Hughes,I.K., Hood,J.B., Quinones-Molina,A.A., Akiyama,H. and Gummuluru,S.
Evasion of CARD8 Activation During HIV-1 Assembly
bioRxiv PubMed Europe PubMed DOI
Isaguliants,M., Zhitkevich,A., Petkov,S., Gorodnicheva,T., Mezale,D., Fridrihsone,I., Kuzmenko,Y., Kostyushev,D., Kostyusheva,A., Gordeychuk,I. and Bayurova,E.
Enzymatic activity of HIV-1 protease defines migration of tumor cells in vitro and enhances their metastatic activity in vivo
Biochimie228, 32-43. PubMed Europe PubMed DOI
Khuzwayo,S.S., Selepe,M.A., Meyer,D. and Gama,N.H.
The synthesis and investigation of novel 3-benzoylbenzofurans and pyrazole derivatives for anti-HIV activity
RSC Med Chem PubMed Europe PubMed DOI I
Panda,M., Purohit,P., Barik,D., Dansana,J. and Meher,B.R.
Bioactive fungal compounds as potential anti-HIV agents against HIV-1 protease: a multi-faceted molecular modelling approach for drug discovery
J Biomol Struct Dyn1-23. PubMed Europe PubMed DOI
Sahibzada,K.I., Shahid,S., Akhter,M., Abid,R., Azhar,M., Hu,Y. and Wei,D.Q.
HIV OctaScanner: A Machine Learning Approach to Unveil Proteolytic Cleavage Dynamics in HIV-1 Protease Substrates
J Chem Inf Model PubMed Europe PubMed DOI
Venkatachalam,S., Krishnan,S.R., Sayed,Y. and Gromiha,M.M.
Structural and Functional Studies on HIV Protease: Mechanism of Action, Subtypes, Inhibitors, and Drug Resistance
Methods Mol Biol2867, 185-200. PubMed Europe PubMed DOI V
Venkatachalam,S., Krishnan,S.R., Pandian,R., Sayed,Y. and Gromiha,M.M.
Structural Implications of HIV-1 Protease Subtype C Bound to Darunavir: A Molecular Dynamics Study
Proteins PubMed Europe PubMed DOI I
Vig,E., Sun,J. and Chang,C.A.
Pathway Specific Unbinding Free Energy Profiles of Ritonavir Dissociation from HIV-1 Protease
Biochemistry64, 940-952. PubMed Europe PubMed DOI I
Yoosefian,M.
Designing new pharmaceutical derivatives for potential inhibition of human immunodeficiency virus protease enzyme inhibition; a comprehensive in silico study
J Biomol Struct Dyn1-22. PubMed Europe PubMed DOI I

2024

Abimbola Salubi,C., Abbo,H.S., Jahed,N. and Titinchi,S.
Medicinal chemistry perspectives on the development of piperazine-containing HIV-1 inhibitors
Bioorg Med Chem99, 117605-117605. PubMed Europe PubMed DOI V
Albrijawi,M.T. and Alhajj,R.
LSTM-driven drug design using SELFIES for target-focused de novo generation of HIV-1 protease inhibitor candidates for AIDS treatment
PLoS ONE19, e0303597-e0303597. PubMed Europe PubMed DOI
Chagas,B.C.A., Zhou,X., Guerrero,M., Ilina,T.V. and Ishima,R.
Interplay between protease and reverse transcriptase dimerization in a model HIV-1 polyprotein
Protein Sci33, e5080-e5080. PubMed Europe PubMed DOI I
Chuntakaruk,H., Boonpalit,K., Kinchagawat,J., Nakarin,F., Khotavivattana,T., Aonbangkhen,C., Shigeta,Y., Hengphasatporn,K., Nutanong,S., Rungrotmongkol,T. and Hannongbua,S.
Machine learning-guided design of potent darunavir analogs targeting HIV-1 proteases: A computational approach for antiretroviral drug discovery
J Comput Chem45, 953-968. PubMed Europe PubMed DOI I
Chuntakaruk,H., Hengphasatporn,K., Shigeta,Y., Aonbangkhen,C., Lee,V.S., Khotavivattana,T., Rungrotmongkol,T. and Hannongbua,S.
FMO-guided design of darunavir analogs as HIV-1 protease inhibitors
Sci Rep14, 3639-3639. PubMed Europe PubMed DOI I
Ghosh,A.K., Lee,D., Sharma,A., Johnson,M.E., Ghosh,A.K., Wang,Y.F., Agniswamy,J., Amano,M., Hattori,S.I., Weber,I.T. and Mitsuya,H.
Design of substituted tetrahydrofuran derivatives for HIV-1 protease inhibitors: synthesis, biological evaluation, and X-ray structural studies
Org Biomol Chem22, 7354-7372. PubMed Europe PubMed DOI
Ghosh,A.K., Sharma,A. and Ghazi,S.
An Enzymatic Route to the Synthesis of Tricyclic Fused Hexahydrofuranofuran P2-Ligand for a Series of Highly Potent HIV-1 Protease Inhibitors
Tetrahedron Lett140, PubMed Europe PubMed DOI
Meng,S., Gao,Y., Qiang,G., Hu,Z., Shan,Q., Wang,J., Wang,Y. and Mou,J.
Rational design, synthesis and biological evaluation of novel HIV-1 protease inhibitors containing 2-phenylacetamide derivatives as P2 ligands with potent activity against DRV-Resistant HIV-1 variants
Bioorg Med Chem Lett101, 129651-129651. PubMed Europe PubMed DOI I
Mokhantso,T., Sherry,D., Worth,R., Pandian,R., Achilonu,I. and Sayed,Y.
Contrasting the effect of hinge region insertions and non-active site mutations on HIV protease-inhibitor interactions: Insights from altered flap dynamics
J Mol Graph Model133, 108850-108850. PubMed Europe PubMed DOI
Mulato,A., Lansdon,E., Aoyama,R., Voigt,J., Lee,M., Liclican,A., Lee,G., Singer,E., Stafford,B., Gong,R., Murray,B., Chan,J., Lee,J., Xu,Y., Ahmadyar,S., Gonzalez,A., Cho,A., Stepan,G.J., Schmitz,U., Schultz,B., Marchand,B., Brumshtein,B., Wang,R., Yu,H., Cihlar,T., Xu,L. and Yant,S.R.
Preclinical characterization of a non-peptidomimetic HIV protease inhibitor with improved metabolic stability
Antimicrob Agents Chemother68, e0137323-e0137323. PubMed Europe PubMed DOI I
Naumovich,V., Kandagalla,S. and Grishina,M.
Machine learning-based prediction of bioactivity in HIV-1 protease: insights from electron density analysis
Future Med Chem1-9. PubMed Europe PubMed DOI
Saez,J.A. and Vera,J.F.
Compact Class-conditional Attribute Category Clustering: Amino Acid Grouping for Enhanced HIV-1 Protease Cleavage Classification
IEEE/ACM Trans Comput Biol BioinformPP, PubMed Europe PubMed DOI
Sankaran,S.V., Krishnan,S.R., Sayed,Y. and Gromiha,M.M.
Mechanism of drug resistance in HIV-1 protease subtype C in the presence of Atazanavir
Curr Res Struct Biol7, 100132-100132. PubMed Europe PubMed DOI I
Sherry,D. and Sayed,Y.
Unveiling a Hidden Pocket in HIV-1 Protease: New Insights Into Retroviral Protease Cantilever-Tip Region Characteristics
Proteins92, 1398-1412. PubMed Europe PubMed DOI
Tabler,C.O. and Tilton,J.C.
Mechanism and Kinetics of HIV-1 Protease Activation
Viruses16, PubMed Europe PubMed DOI
Tran,T.T. and Fanucci,G.E.
Natural Polymorphisms D60E and I62V Stabilize a Closed Conformation in HIV-1 Protease in the Absence of an Inhibitor or Substrate
Viruses16, PubMed Europe PubMed DOI
Zheng,L., Pan,B., Tang,T., Xu,H., Hu,W., Zhang,Y., Wei,X., Liu,X., Wu,Q., Shi,Y., Yang,J., Zhou,Y. and Wei,Y.
Synthesis and evaluation of nitrogen-containing derivatives of 3,11-dioxo-olean-12-en-30-oic acid against HIV-1 protease
Nat Prod Res1-10. PubMed Europe PubMed DOI I

2023

Arrigoni,R., Santacroce,L., Ballini,A. and Palese,L.L.
AI-Aided Search for New HIV-1 Protease Ligands
Biomolecules13, PubMed Europe PubMed DOI
Baassi,M., Moussaoui,M., Soufi,H., Rajkhowa,S., Sharma,A., Sinha,S. and Belaaouad,S.
Towards designing of a potential new HIV-1 protease inhibitor using QSAR study in combination with Molecular docking and Molecular dynamics simulations
PLoS ONE18, e0284539-e0284539. PubMed Europe PubMed DOI
Centazzo,M., Manganaro,L. and Alvisi,G.
Cellular Targets of HIV-1 Protease: Just the Tip of the Iceberg?
Viruses15, PubMed Europe PubMed DOI
Clark,K.M., Wang,Q. and Shan,L.
CARD8 Inflammasome Activation by HIV-1 Protease
Methods Mol Biol2641, 67-79. PubMed Europe PubMed DOI
Clark,K.M., Kim,J.G., Wang,Q., Gao,H., Presti,R.M. and Shan,L.
Chemical inhibition of DPP9 sensitizes the CARD8 inflammasome in HIV-1-infected cells
Nat Chem Biol19, 431-439. PubMed Europe PubMed DOI
Dakshinamoorthy,A., Asmita,A. and Senapati,S.
Comprehending the Structure, Dynamics, and Mechanism of Action of Drug-Resistant HIV Protease
ACS Omega8, 9748-9763. PubMed Europe PubMed DOI V
Falcioni,F. and Popelier,P.L.A.
How to Compute Atomistic Insight in DFT Clusters: The REG-IQA Approach
J Chem Inf Model63, 4312-4327. PubMed Europe PubMed DOI
Guo,S., Saha,I., Saffarian,S. and Johnson,M.E.
Structure of the HIV immature lattice allows for essential lattice remodeling within budded virions
elife12, PubMed Europe PubMed DOI
Hsieh,S.H., Yu,F.H., Huang,K.J. and Wang,C.T.
HIV-1 reverse transcriptase stability correlates with Gag cleavage efficiency: reverse transcriptase interaction implications for modulating protease activation
J Virol97, e0094823-e0094823. PubMed Europe PubMed DOI
Kulsuptrakul,J., Turcotte,E.A., Emerman,M. and Mitchell,P.S.
A human-specific motif facilitates CARD8 inflammasome activation after HIV-1 infection
elife12, PubMed Europe PubMed DOI
Okafor,S.N., Meyer,A., Gadsden,J., Ahmed,F., Guzman,L., Ahmed,H., Romero,J.A.F. and Angsantikul,P.
Drug Reprofiling to Identify Potential HIV-1 Protease Inhibitors
Molecules28, PubMed Europe PubMed DOI I
Pan,B.W., Zheng,L.L., Shi,Y., Dong,Z.C., Feng,T.T., Yang,J., Wei,Y. and Zhou,Y.
Synthesis and Antiviral and Antitumor Activities of Novel 18beta-Glycyrrhetinic Acid Derivatives
Int J Mol Sci24, PubMed Europe PubMed DOI
Rahimi,M., Taghdir,M. and Abasi Joozdani,F.
Dynamozones are the most obvious sign of the evolution of conformational dynamics in HIV-1 protease
Sci Rep13, 14179-14179. PubMed Europe PubMed DOI
Rajendran,M., Ferran,M.C., Mouli,L., Babbitt,G.A. and Lynch,M.L.
Evolution of drug resistance drives destabilization of flap region dynamics in HIV-1 protease
Biophys Rep (N Y)3, 100121-100121. PubMed Europe PubMed DOI
Sheik Ismail,Z., Worth,R., Mosebi,S. and Sayed,Y.
HIV Protease Hinge Region Insertions at Codon 38 Affect Enzyme Kinetics, Conformational Stability and Dynamics
Protein J42, 490-501. PubMed Europe PubMed DOI
Souffrant,M., Yao,X.Q. and Hamelberg,D.
Evolving Mutational Buildup in HIV-1 Protease Shifts Conformational Dynamics to Gain Drug Resistance
J Chem Inf Model63, 3892-3902. PubMed Europe PubMed DOI
Tang,T.T., Li,S.M., Pan,B.W., Xiao,J.W., Pang,Y.X., Xie,S.X., Zhou,Y., Yang,J. and Wei,Y.
Identification of Flavonoids from Scutellaria barbata D. Don as Inhibitors of HIV-1 and Cathepsin L Proteases and Their Structure-Activity Relationships
Molecules28, PubMed Europe PubMed DOI I
Zhou,H., Ma,L., Dong,B., Wang,J., Zhang,G., Wang,M., Cen,S., Zhu,M., Shan,Q. and Wang,Y.
Design, synthesis, and biological evaluation of novel HIV-1 protease inhibitors containing pyrrolidine-derived P2 ligands to combat drug-resistant variant
Eur J Med Chem255, 115389-115389. PubMed Europe PubMed DOI I
Zhu,M., Shan,Q., Ma,L., Dong,B., Wang,J., Zhang,G., Wang,M., Zhou,J., Cen,S. and Wang,Y.
Structure based design and evaluation of benzoheterocycle derivatives as potential dual HIV-1 protease and reverse transcriptase inhibitors
Eur J Med Chem246, 114981-114981. PubMed Europe PubMed DOI I

2022

Ahsan,M., Pindi,C. and Senapati,S.
Mechanism of darunavir binding to monomeric HIV-1 protease: a step forward in the rational design of dimerization inhibitors
Phys Chem Chem Phys24, 7107-7120. PubMed Europe PubMed DOI I
Coimbra,J.T.S., Neves,R.P.P., Cunha,A.V., Ramos,M.J. and Fernandes,P.A.
Different Enzyme Conformations Induce Different Mechanistic Traits in HIV-1 Protease
Chemistry28, e202201066-e202201066. PubMed Europe PubMed DOI
Kim,J.G. and Shan,L.
Beyond Inhibition: A Novel Strategy of Targeting HIV-1 Protease to Eliminate Viral Reservoirs
Viruses14, PubMed Europe PubMed DOI V
Koivisto,J.M., Poulsen,N.R., Larsen,B.S., Weibull,M.G.M., Stein,A., Doro,F., Winther,J.R., Lindorff-Larsen,K. and Willemoes,M.
Co-evolution of drug resistance and broadened substrate recognition in HIV protease variants isolated from an Escherichia coli genetic selection system
Biochem J479, 479-501. PubMed Europe PubMed DOI
Kojima,E., Iimuro,A., Nakajima,M., Kinuta,H., Asada,N., Sako,Y., Nakata,Z., Uemura,K., Arita,S., Miki,S., Wakasa-Morimoto,C. and Tachibana,Y.
Pocket-to-Lead: Structure-Based De Novo Design of Novel Non-peptidic HIV-1 Protease Inhibitors Using the Ligand Binding Pocket as a Template
J Med Chem65, 6157-6170. PubMed Europe PubMed DOI I
Kusumoto,Y., Hayashi,K., Sato,S., Yamada,T., Kozono,I., Nakata,Z., Asada,N., Mitsuki,S., Watanabe,A., Wakasa-Morimoto,C., Uemura,K., Arita,S., Miki,S., Mizutare,T. and Mikamiyama,H.
Highly Potent and Oral Macrocyclic Peptides as a HIV-1 Protease Inhibitor: mRNA Display-Derived Hit-to-Lead Optimization
ACS Med Chem Lett13, 1634-1641. PubMed Europe PubMed DOI
Ma,L., Wen,J., Dong,B., Zhou,J., Hu,S., Wang,J., Wang,Y., Zhu,M. and Cen,S.
Design and Evaluation of Novel HIV-1 Protease Inhibitors Containing Phenols or Polyphenols as P2 Ligands with High Activity against DRV-Resistant HIV-1 Variants
Int J Mol Sci23, PubMed Europe PubMed DOI I
Majerova,T. and Konvalinka,J.
Viral proteases as therapeutic targets
Mol Aspects Med88, 101159-101159. PubMed Europe PubMed DOI V I
Onah,E., Uzor,P.F., Ugwoke,I.C., Eze,J.U., Ugwuanyi,S.T., Chukwudi,I.R. and Ibezim,A.
Prediction of HIV-1 protease cleavage site from octapeptide sequence information using selected classifiers and hybrid descriptors
BMC Bioinformatics23, 466-466. PubMed Europe PubMed DOI
Padariya,M., Baginski,M., Babak,M. and Kalathiya,U.
Organic solvents aggregating and shaping structural folding of protein, a case study of the protease enzyme
Biophys Chem291, 106909-106909. PubMed Europe PubMed DOI
Qian,C., Flemming,A., Muller,B. and Lamb,D.C.
Dynamics of HIV-1 Gag Processing as Revealed by Fluorescence Lifetime Imaging Microscopy and Single Virus Tracking
Viruses14, PubMed Europe PubMed DOI
Samant,N., Nachum,G., Tsepal,T. and Bolon,D.N.A.
Sequence dependencies and biophysical features both govern cleavage of diverse cut-sites by HIV protease
Protein Sci31, e4366-e4366. PubMed Europe PubMed DOI
Sherry,D., Pandian,R. and Sayed,Y.
Non-active site mutations in the HIV protease: Diminished drug binding affinity is achieved through modulating the hydrophobic sliding mechanism
Int J Biol Macromol217, 27-41. PubMed Europe PubMed DOI
Tabler,C.O., Wegman,S.J., Chen,J., Shroff,H., Alhusaini,N. and Tilton,J.C.
The HIV-1 Viral Protease Is Activated during Assembly and Budding Prior to Particle Release
J Virol96, e0219821-e0219821. PubMed Europe PubMed DOI
Wong-Sam,A., Wang,Y.F., Kneller,D.W., Kovalevsky,A.Y., Ghosh,A.K., Harrison,R.W. and Weber,I.T.
HIV-1 protease with 10 lopinavir and darunavir resistance mutations exhibits altered inhibition, structural rearrangements and extreme dynamics
J Mol Graph Model117, 108315-108315. PubMed Europe PubMed DOI I
Wu,S., Li,H. and Ma,A.
Exact reaction coordinates for flap opening in HIV-1 protease
Proc Natl Acad Sci U S A119, e2214906119-e2214906119. PubMed Europe PubMed DOI
Yu,F.H., Huang,K.J. and Wang,C.T.
Amino acid substitutions at the HIV-1 transframe region significantly impair virus infectivity
PLoS ONE17, e0262477-e0262477. PubMed Europe PubMed DOI

2021

Agniswamy,J., Kneller,D.W., Ghosh,A.K. and Weber,I.T.
Novel HIV PR inhibitors with C4-substituted bis-THF and bis-fluoro-benzyl target the two active site mutations of highly drug resistant mutant PR(S17)
Biochem Biophys Res Commun566, 30-35. PubMed Europe PubMed DOI I
C S,V. and Munusami,P.
Revealing the drug resistance mechanism of saquinavir due to G48V and V82F mutations in subtype CRF01_AE HIV-1 protease: molecular dynamics simulation and binding free energy calculations
J Biomol Struct Dyn1-18. PubMed Europe PubMed DOI
Eche,S. and Gordon,M.L.
Recombinant expression of HIV-1 protease using soluble fusion tags in Escherichia coli: A vital tool for functional characterization of HIV-1 protease
Virus Res295, 198289-198289. PubMed Europe PubMed DOI V
Han,D., Tan,J., Men,J., Li,C. and Zhang,X.
Quantitative structure activity/pharmacokinetics relationship studies of HIV-1 protease inhibitors using three modelling methods
Med Chem17, 396-406. PubMed Europe PubMed DOI I
Heilmann,E., Kimpel,J., Hofer,B., Rossler,A., Blaas,I., Egerer,L., Nolden,T., Urbiola,C., Krausslich,H.G., Wollmann,G. and von Laer,D.
Chemogenetic ON and OFF switches for RNA virus replication
Nat Commun12, 1362-1362. PubMed Europe PubMed DOI
Imamichi,T., Bernbaum,J.G., Laverdure,S., Yang,J., Chen,Q., Highbarger,H., Hao,M., Sui,H., Dewar,R., Chang,W. and Lane,H.C.
Natural Occurring Polymorphisms in HIV-1 Integrase and RNase H Regulate Viral Release and Autoprocessing
J VirolJVI0132321-JVI0132321. PubMed Europe PubMed DOI
Jeremiah,S.S., Miyakawa,K., Matsunaga,S., Nishi,M., Kudoh,A., Takaoka,A., Sawasaki,T. and Ryo,A.
Cleavage of TANK-Binding Kinase 1 by HIV-1 Protease Triggers Viral Innate Immune Evasion
Front Microbiol12, 643407-643407. PubMed Europe PubMed DOI
Kumar,P. and Dominiak,P.M.
Combining Molecular Dynamic Information and an Aspherical-Atom Data Bank in the Evaluation of the Electrostatic Interaction Energy in Multimeric Protein-Ligand Complex: A Case Study for HIV-1 Protease
Molecules26, PubMed Europe PubMed DOI
La Monica,G., Lauria,A., Bono,A. and Martorana,A.
Off-Target-Based Design of Selective HIV-1 PROTEASE Inhibitors
Int J Mol Sci22, PubMed Europe PubMed DOI
Leidner,F., Kurt Yilmaz,N. and Schiffer,C.A.
Deciphering Complex Mechanisms of Resistance and Loss of Potency through Coupled Molecular Dynamics and Machine Learning
J Chem Theory Comput17, 2054-2064. PubMed Europe PubMed DOI I
Samsudin,F., Gan,S.K. and Bond,P.J.
The impact of Gag non-cleavage site mutations on HIV-1 viral fitness from integrative modelling and simulations
Comput Struct Biotechnol J19, 330-342. PubMed Europe PubMed DOI
Wang,Q., Gao,H., Clark,K.M., Mugisha,C.S., Davis,K., Tang,J.P., Harlan,G.H., DeSelm,C.J., Presti,R.M., Kutluay,S.B. and Shan,L.
CARD8 is an inflammasome sensor for HIV-1 protease activity
Science371, eabe1707-eabe1707. PubMed Europe PubMed DOI
Weber,I.T., Wang,Y.F. and Harrison,R.W.
HIV Protease: Historical Perspective and Current Research
Viruses13, PubMed Europe PubMed DOI V
Zhu,M., Shan,Q., Ma,L., Wen,J., Dong,B., Zhang,G., Wang,M., Wang,J., Zhou,J., Cen,S. and Wang,Y.
Design and biological evaluation of cinnamic and phenylpropionic amide derivatives as novel dual inhibitors of HIV-1 protease and reverse transcriptase
Eur J Med Chem220, 113498-113498. PubMed Europe PubMed DOI I

2020

Ancy,I., Sivanandam,M. and Kumaradhas,P.
Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study
J Biomol Struct Dyn1-8. PubMed Europe PubMed DOI I
Badaya,A. and Sasidhar,Y.U.
Inhibition of the activity of HIV-1 protease through antibody binding and mutations probed by molecular dynamics simulations
Sci Rep10, 5501-5501. PubMed Europe PubMed DOI
Bastys,T., Gapsys,V., Walter,H., Heger,E., Doncheva,N.T., Kaiser,R., de Groot,B.L. and Kalinina,O.V.
Non-active site mutants of HIV-1 protease influence resistance and sensitisation towards protease inhibitors
Retrovirology17, 13-13. PubMed Europe PubMed DOI
Bulut,H., Hattori,S.I., Aoki-Ogata,H., Hayashi,H., Das,D., Aoki,M., Davis,D.A., Rao,K.V., Nyalapatla,P.R., Ghosh,A.K. and Mitsuya,H.
Single atom changes in newly synthesized HIV protease inhibitors reveal structural basis for extreme affinity, high genetic barrier, and adaptation to the HIV protease plasticity
Sci Rep10, 10664-10664. PubMed Europe PubMed DOI
Chiang,M. and Wang,C.
A Single Amino Acid Substitution at HIV-1 Protease Termini Dimer Interface Significantly Reduces Viral Particles Processing Efficiency
Jpn J Infect Dis PubMed Europe PubMed DOI
Chou,C.Y., Lin,C.Y., Wu,C.H. and Tai,D.F.
Sensing HIV Protease and Its Inhibitor Using "Helical Epitope"-Imprinted Polymers
Sensors (Basel)20, PubMed Europe PubMed DOI
Ergin,H.E., Inga,E.E., Maung,T.Z., Javed,M. and Khan,S.
HIV, Antiretroviral Therapy and Metabolic Alterations: A Review
Cureus12, e8059-e8059. PubMed Europe PubMed DOI
Fokam,J., Takou,D., Teto,G., Nforbih,S.E., Kome,O.P., Santoro,M.M., Ngoufack,E.S., Eyongetah,M., Palmer,D., Fokunang,E.T., Fokunang,C.N., Colizzi,V., Perno,C.F. and Ndjolo,A.
Pre-treatment drug resistance and HIV-1 genetic diversity in the rural and urban settings of Northwest-Cameroon
PLoS ONE15, e0235958-e0235958. PubMed Europe PubMed DOI
Ghosh,A.K., Kovela,S., Osswald,H.L., Amano,M., Aoki,M., Agniswamy,J., Wang,Y.F., Weber,I.T. and Mitsuya,H.
Structure-based design of highly potent HIV-1 protease inhibitors containing new tricyclic ring P2-ligands: design, synthesis, biological, and X-ray structural studies
J Med Chem63, 4867-4879. PubMed Europe PubMed DOI I
Hu,L., Hu,P., Yuan,X., Luo,X. and You,Z.H.
Incorporating the coevolving information of substrates in predicting HIV-1 protease cleavage sites
IEEE/ACM Trans Comput Biol Bioinform17, 2017-2028. PubMed Europe PubMed DOI
Kleinpeter,A.B. and Freed,E.O.
HIV-1 Maturation: Lessons Learned from Inhibitors
Viruses12, PubMed Europe PubMed DOI V
Lawal,M.M., Sanusi,Z.K., Govender,T., Maguire,G.E.M., Honarparvar,B. and Kruger,H.G.
From recognition to reaction mechanism: an overview on the interactions between HIV-1 protease and its natural targets
Curr Med Chem27, 2514-2549. PubMed Europe PubMed DOI
Lockbaum,G.J., Leidner,F., Royer,W.E., Kurt Yilmaz,N. and Schiffer,C.A.
Optimizing the refinement of merohedrally twinned P61 HIV-1 protease-inhibitor cocrystal structures
Acta Crystallogr D Struct Biol76, 302-310. PubMed Europe PubMed DOI S
Panthong,S., Itharat,A., Naknarin,S., Kuropakornpong,P., Ooraikul,B. and Sakpakdeejaroen,I.
Bactericidal Effect and Anti-Inflammatory Activity of Cassia garettiana Heartwood Extract
ScientificWorldJournal2020, 1653180-1653180. PubMed Europe PubMed DOI I
Schmidt,T., Louis,J.M. and Clore,G.M.
Probing the Interaction between HIV-1 Protease and the Homodimeric p66/p66' Reverse Transcriptase Precursor by Double Electron-Electron Resonance EPR Spectroscopy
Chembiochem21, 3051-3055. PubMed Europe PubMed DOI
Sherry,D., Worth,R. and Sayed,Y.
Two-step preparation of highly pure, soluble HIV protease from inclusion bodies recombinantly expressed in Escherichia coli
Curr Protoc Protein Sci100, e106-e106. PubMed Europe PubMed DOI E
Subbaiah,M.A.M., Ramar,T., Subramani,L., Desai,S.D., Sinha,S., Mandlekar,S., Jenkins,S.M., Krystal,M.R., Subramanian,M., Sridhar,S., Padmanabhan,S., Bhutani,P., Arla,R., Kadow,J.F. and Meanwell,N.A.
(Carbonyl)oxyalkyl linker-based amino acid prodrugs of the HIV-1 protease inhibitor atazanavir that enhance oral bioavailability and plasma trough concentration
Eur J Med Chem207, 112749-112749. PubMed Europe PubMed DOI I
Tran,T.T., Liu,Z. and Fanucci,G.E.
Conformational landscape of non-B variants of HIV-1 protease: A pulsed EPR study
Biochem Biophys Res Commun532, 219-224. PubMed Europe PubMed DOI
Yu,F.H., Huang,K.J. and Wang,C.T.
Conditional activation of an HIV-1 protease attenuated mutant by a leucine zipper dimerization motif
Virus Res198258-198258. PubMed Europe PubMed DOI
Zhou,H., Zhu,M., Ma,L., Zhou,J., Dong,B., Zhang,G., Cen,S., Wang,Y. and Wang,J.
Piperidine scaffold as the novel P2-ligands in cyclopropyl-containing HIV-1 protease inhibitors: Structure-based design, synthesis, biological evaluation and docking study
PLoS ONE15, e0235483-e0235483. PubMed Europe PubMed DOI
Zhu,M., Dou,Y., Ma,L., Dong,B., Zhang,F., Zhang,G., Wang,J., Zhou,J., Cen,S. and Wang,Y.
Novel HIV-1 Protease Inhibitors with Morpholine as the P2 Ligand to Enhance Activity against DRV-Resistant Variants
ACS Med Chem Lett11, 1196-1204. PubMed Europe PubMed DOI I

2019

Ahsan,M. and Senapati,S.
Water plays a cocatalytic role in epoxide ring opening reaction in aspartate proteases: a QM/MM study
J Phys Chem B123, 7955-7964. PubMed Europe PubMed DOI
Boucher,J.I., Whitfield,T.W., Dauphin,A., Nachum,G., Hollins,C., Zeldovich,K.B., Swanstrom,R., Schiffer,C.A., Luban,J. and Bolon,D.N.A.
Constrained mutational sampling of amino acids in HIV-1 protease evolution
Mol Biol Evol36, 798-810. PubMed Europe PubMed DOI
C S,V., Tamizhselvi,R. and Munusami,P.
Exploring the drug resistance mechanism of active site, non-active site mutations and their cooperative effects in CRF01_AE HIV-1 protease: molecular dynamics simulations and free energy calculations
J Biomol Struct Dyn37, 2608-2626. PubMed Europe PubMed DOI
Gardner,J.M. and Abrams,C.F.
Energetics of flap opening in HIV-1 protease: string method calculations
J Phys Chem B123, 9584-9591. PubMed Europe PubMed DOI
Ghosh,A.K., Williams,J.N., Kovela,S., Takayama,J., Simpson,H.M., Walters,D.E., Hattori,S.I., Aoki,M. and Mitsuya,H.
Potent HIV-1 protease inhibitors incorporating squaramide-derived P2 ligands: design, synthesis, and biological evaluation
Bioorg Med Chem Lett29, 2565-2570. PubMed Europe PubMed DOI I
Ghosh,A.K., Xia,Z., Kovela,S., Robinson,W.L., Johnson,M.E., Kneller,D.W., Wang,Y.F., Aoki,M., Takamatsu,Y., Weber,I.T. and Mitsuya,H.
Potent HIV-1 protease inhibitors containing carboxylic and boronic acids: effect on enzyme inhibition and antiviral activity and protein-ligand X-ray structural studies
ChemMedChem14, 1863-1872. PubMed Europe PubMed DOI S I
Hattori,S.I., Hayashi,H., Bulut,H., Rao,K.V., Nyalapatla,P.R., Hasegawa,K., Aoki,M., Ghosh,A.K. and Mitsuya,H.
Halogen bond interactions of novel HIV-1 protease inhibitors (PI)(GRL-001-15 and GRL-003-15) with the flap of protease are critical for their potent activity against wild-type and multi-PI-resistant HIV-1 variants
Antimicrob Agents Chemother63, e02635-18-e02635-18. PubMed Europe PubMed DOI I
Henes,M., Lockbaum,G.J., Kosovrasti,K., Leidner,F., Nachum,G.S., Nalivaika,E.A., Lee,S.K., Spielvogel,E., Zhou,S., Swanstrom,R., Bolon,D.N.A., Kurt Yilmaz,N. and Schiffer,C.A.
Picomolar to micromolar: elucidating the role of distal mutations in HIV-1 protease in conferring drug resistance
ACS Chem Biol14, 2441-2452. PubMed Europe PubMed DOI I
Huang,L., Li,L., Tien,C., LaBarbera,D.V. and Chen,C.
Targeting HIV-1 protease autoprocessing for high-throughput drug discovery and drug resistance assessment
Sci Rep9, 301-301. PubMed Europe PubMed DOI
Huang,S., Zhang,D., Mei,H., Kevin,M., Qu,S., Pan,X. and Lu,L.
SMD-based interaction-energy fingerprints can predict accurately the dissociation rate constants of HIV-1 protease inhibitors
J Chem Inf Model59, 159-169. PubMed Europe PubMed DOI I
Karnati,K.R. and Wang,Y.
Structural and binding insights into HIV-1 protease and P2-ligand interactions through molecular dynamics simulations, binding free energy and principal component analysis
J Mol Graph Model92, 112-122. PubMed Europe PubMed DOI S
Li,P., Wang,S., Wang,H. and Yan,H.
Synthesis and biological evaluation of 3,9-dioxatetraasteranes as C2-symmetric HIV-1 protease inhibitors and docking study
Biol Pharm Bull42, 261-267. PubMed Europe PubMed DOI I
Lockbaum,G.J., Leidner,F., Rusere,L.N., Henes,M., Kosovrasti,K., Nachum,G.S., Nalivaika,E.A., Ali,A., Yilmaz,N.K. and Schiffer,C.A.
Structural adaptation of darunavir analogues against primary mutations in HIV-1 protease
ACS Infect Dis5, 316-325. PubMed Europe PubMed DOI I
Maseko,S.B., Govender,D., Govender,T., Naicker,T., Lin,J., Maguire,G.E.M. and Kruger,H.G.
Optimized procedure for recovering HIV-1 protease (C-SA) from inclusion bodies
Protein J38, 30-36. PubMed Europe PubMed DOI E
Maximova,K., Wojtczak,J. and Trylska,J.
Enzymatic activity of human immunodeficiency virus type 1 protease in crowded solutions
Eur Biophys J48, 685-689. PubMed Europe PubMed DOI
Medina-O'Donnell,M., Rivas,F., Reyes-Zurita,F.J., Cano-Munoz,M., Martinez,A., Lupianez,J.A. and Parra,A.
Oleanolic acid derivatives as potential inhibitors of HIV-1 protease
J Nat Prod82, 2886-2896. PubMed Europe PubMed DOI I
Pawar,S., Wang,Y.F., Wong-Sam,A., Agniswamy,J., Ghosh,A.K., Harrison,R.W. and Weber,I.T.
Structural studies of antiviral inhibitor with HIV-1 protease bearing drug resistant substitutions of V32I, I47V and V82I
Biochem Biophys Res Commun514, 974-978. PubMed Europe PubMed DOI S I
Rusere,L.N., Lockbaum,G.J., Lee,S.K., Henes,M., Kosovrasti,K., Spielvogel,E., Nalivaika,E.A., Swanstrom,R., Yilmaz,N.K., Schiffer,C.A. and Ali,A.
HIV-1 protease inhibitors incorporating stereochemically defined P2' ligands to optimize hydrogen bonding in the substrate envelope
J Med Chem62, 8062-8079. PubMed Europe PubMed DOI I
Takamatsu,Y., Aoki,M., Bulut,H., Das,D., Amano,M., Sheri,V.R., Kovari,L.C., Hayashi,H., Delino,N.S., Ghosh,A.K. and Mitsuya,H.
Novel protease inhibitors containing C-5-modified bis-THF and aminobenzothiazole as P2 and P2' ligands that exert potent antiviral activity against highly multidrug-resistant HIV-1 with high genetic barrier against the emergence of drug resistance
Antimicrob Agents Chemother63, e00372-19-e00372-19. PubMed Europe PubMed DOI I
Tramutola,F., Armentano,M.F., Berti,F., Chiummiento,L., Lupattelli,P., D'Orsi,R., Miglionico,R., Milella,L., Bisaccia,F. and Funicello,M.
New heteroaryl carbamates: synthesis and biological screening in vitro and in mammalian cells of wild-type and mutant HIV-protease inhibitors
Bioorg Med Chem27, 1863-1870. PubMed Europe PubMed DOI I
Williams,A., Basson,A., Achilonu,I., Dirr,H.W., Morris,L. and Sayed,Y.
Double trouble? Gag in conjunction with double insert in HIV protease contributes to reduced DRV susceptibility
Biochem J476, 375-384. PubMed Europe PubMed DOI
Zhu,M., Dong,B., Zhang,G.N., Wang,J.X., Cen,S. and Wang,Y.C.
Synthesis and biological evaluation of new HIV-1 protease inhibitors with purine bases as P2-ligands
Bioorg Med Chem Lett29, 1541-1545. PubMed Europe PubMed DOI I
Zhu,M., Du,X.N., Li,Y.G., Zhang,G.N., Wang,J.X. and Wang,Y.C.
Design, synthesis and biological evaluation of novel HIV-1 protease inhibitors with pentacyclic triterpenoids as P2-ligands
Bioorg Med Chem Lett29, 357-361. PubMed Europe PubMed DOI I
Zondagh,J., Basson,A.E., Achilonu,I., Morris,L., Dirr,H.W. and Sayed,Y.
Drug susceptibility and replication capacity of a rare HIV-1 subtype C protease hinge region variant
Antivir Ther24, 333-342. PubMed Europe PubMed DOI I

2018

Amin,S.A., Adhikari,N., Bhargava,S., Jha,T. and Gayen,S.
Structural exploration of hydroxyethylamines as HIV-1 protease inhibitors: new features identified
SAR QSAR Environ Res29, 385-408. PubMed Europe PubMed DOI I
Aoki,M., Das,D., Hayashi,H., Aoki-Ogata,H., Takamatsu,Y., Ghosh,A.K. and Mitsuya,H.
Mechanism of Darunavir (DRV)'s high genetic barrier to HIV-1 resistance: a key V32I substitution in protease rarely occurs, but once it occurs, it predisposes HIV-1 to develop DRV resistance
MBio9, PubMed Europe PubMed DOI I
Bastys,T., Gapsys,V., Doncheva,N.T., Kaiser,R., de Groot,B.L. and Kalinina,O.V.
Consistent prediction of mutation effect on drug binding in HIV-1 protease using alchemical calculations
J Chem Theory Comput14, 3397-3408. PubMed Europe PubMed DOI
Delino,N.S., Aoki,M., Hayashi,H., Hattori,S.I., Chang,S.B., Takamatsu,Y., Martyr,C.D., Das,D., Ghosh,A.K. and Mitsuya,H.
GRL-079, a novel P2-Tp-THF-C5-alkylamine- and P2' -Abt-containing HIV-1 protease inhibitor, is extremely potent against multi-drug-resistant HIV-1 variants including HIVDRV(R)p51 and has a high genetic barrier against the emergence of resistant variants
Antimicrob Agents Chemother62, e02060-17-e02060-17. PubMed Europe PubMed DOI I
Ghosh,A.K., Rao,K.V., Nyalapatla,P.R., Kovela,S., Brindisi,M., Osswald,H.L., Sekhara Reddy,B., Agniswamy,J., Wang,Y.F., Aoki,M., Hattori,S.I., Weber,I.T. and Mitsuya,H.
Design of highly potent, dual-acting and central-nervous-system-penetrating HIV-1 protease inhibitors with excellent potency against multidrug-resistant HIV-1 variants
ChemMedChem13, 803-815. PubMed Europe PubMed DOI S I
Ghosh,A.K., Williams,J.N., Ho,R.Y., Simpson,H.M., Hattori,S.I., Hayashi,H., Agniswamy,J., Wang,Y.F., Weber,I.T. and Mitsuya,H.
Design and synthesis of potent HIV-1 protease inhibitors containing bicyclic oxazolidinone scaffold as the P2 ligands: structure-activity studies and biological and X-ray structural studies
J Med Chem61, 9722-9737. PubMed Europe PubMed DOI I
Ghosh,A.K., R Nyalapatla,P., Kovela,S., Rao,K.V., Brindisi,M., Osswald,H.L., Amano,M., Aoki,M., Agniswamy,J., Wang,Y.F., Weber,I.T. and Mitsuya,H.
Design and synthesis of highly potent HIV-1 protease inhibitors containing tricyclic fused ring systems as novel P2 ligands: structure-activity studies, biological and X-ray structural analysis
J Med Chem61, 4561-4577. PubMed Europe PubMed DOI I
Ghosh,A.K., Jadhav,R.D., Simpson,H., Kovela,S., Osswald,H., Agniswamy,J., Wang,Y.F., Hattori,S.I., Weber,I.T. and Mitsuya,H.
Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands
Eur J Med Chem160, 171-182. PubMed Europe PubMed DOI S I
Halder,A.K.
Finding the structural requirements of diverse HIV-1 protease inhibitors using multiple QSAR modelling for lead identification
SAR QSAR Environ Res29, 911-933. PubMed Europe PubMed DOI I
Hassan,S., Srikakulam,S.K., Chandramohan,Y., Thangam,M., Muthukumar,S., Gayathri Devi,P.K. and Hanna,L.E.
Exploring the conformational landscapes of HIV protease structural ensembles using principal component analysis
Proteins86, 990-1000. PubMed Europe PubMed DOI I
Hidaka,K., Kimura,T., Sankaranarayanan,R., Wang,J., McDaniel,K.F., Kempf,D.J., Kameoka,M., Adachi,M., Kuroki,R., Nguyen,J.T., Hayashi,Y. and Kiso,Y.
Identification of highly potent human immunodeficiency virus type-1 protease inhibitors against lopinavir and darunavir resistant viruses from allophenylnorstatine-based peptidomimetics with P2 tetrahydrofuranylglycine
J Med Chem61, 5138-5153. PubMed Europe PubMed DOI I
Khan,S.N., Persons,J.D., Paulsen,J.L., Guerrero,M., Schiffer,C.A., Kurt-Yilmaz,N. and Ishima,R.
Probing structural changes among analogous inhibitor-bound forms of HIV-1 protease and a drug-resistant mutant in solution by nuclear magnetic resonance
Biochemistry57, 1652-1662. PubMed Europe PubMed DOI I
Leidner,F., Kurt Yilmaz,N., Paulsen,J., Muller,Y.A. and Schiffer,C.A.
Hydration structure and dynamics of inhibitor-bound HIV-1 protease
J Chem Theory Comput14, 2784-2796. PubMed Europe PubMed DOI S
Li,Y., Tian,Y., Qin,Z. and Yan,A.
Classification of HIV-1 protease inhibitors by machine learning methods
ACS Omega3, 15837-15849. PubMed Europe PubMed DOI I
Maphumulo,S.I., Halder,A.K., Govender,T., Maseko,S., Maguire,G.E.M., Honarparvar,B. and Kruger,H.G.
Exploring the flap dynamics of the South African HIV subtype C protease in presence of FDA-approved inhibitors: MD study
Chem Biol Drug Des92, 1899-1913. PubMed Europe PubMed DOI
Miao,Y., Huang,Y.M., Walker,R.C., McCammon,J.A. and Chang,C.A.
Ligand binding pathways and conformational transitions of the HIV protease
Biochemistry57, 1533-1541. PubMed Europe PubMed DOI
Pawar,S.D., Freas,C., Weber,I.T. and Harrison,R.W.
Analysis of drug resistance in HIV protease
BMC Bioinformatics19, 362-362. PubMed Europe PubMed DOI I
Potempa,M., Lee,S.K., Kurt Yilmaz,N., Nalivaika,E.A., Rogers,A., Spielvogel,E., Carter CW Jr, Schiffer,C.A. and Swanstrom,R.
HIV-1 Protease uses bi-specific S2/S2' subsites to optimize cleavage of two classes of target sites
J Mol Biol430, 5182-5195. PubMed Europe PubMed DOI
Qureshi,A., Rajput,A., Kaur,G. and Kumar,M.
HIVprotI: an integrated web based platform for prediction and design of HIV proteins inhibitors
J Cheminform10, 12-12. PubMed Europe PubMed DOI I
Sanusi,Z.K., Govender,T., Maguire,G.E.M., Maseko,S.B., Lin,J., Kruger,H.G. and Honarparvar,B.
An insight to the molecular interactions of the FDA approved HIV PR drugs against L38L upward arrowN upward arrowL PR mutant
J Comput Aided Mol Des32, 459-471. PubMed Europe PubMed DOI M I
Tarasova,O., Biziukova,N., Filimonov,D. and Poroikov,V.
A computational approach for the prediction of HIV resistance based on amino acid and nucleotide descriptors
Molecules23, PubMed Europe PubMed DOI I
Thacker,J.C.R., Vincent,M.A. and Popelier,P.L.A.
Using the relative energy gradient method with interacting quantum atoms to determine the reaction mechanism and catalytic effects in the peptide hydrolysis in HIV-1 protease
Chemistry24, 11200-11210. PubMed Europe PubMed DOI
Tien,C., Huang,L., Watanabe,S.M., Speidel,J.T., Carter,C.A. and Chen,C.
Context-dependent autoprocessing of human immunodeficiency virus type 1 protease precursors
PLoS ONE13, e0191372-e0191372. PubMed Europe PubMed DOI
Triki,D., Billot,T., Visseaux,B., Descamps,D., Flatters,D., Camproux,A.C. and Regad,L.
Exploration of the effect of sequence variations located inside the binding pocket of HIV-1 and HIV-2 proteases
Sci Rep8, 5789-5789. PubMed Europe PubMed DOI
Windsor,I.W. and Raines,R.T.
A substrate selected by phage display exhibits enhanced side-chain hydrogen bonding to HIV-1 protease
Acta Crystallogr D Struct Biol74, 690-694. PubMed Europe PubMed DOI S
Windsor,I.W., Palte,M.J., Lukesh JC 3rd, Gold,B., Forest,K.T. and Raines,R.T.
Sub-picomolar inhibition of HIV-1 protease with a boronic acid
J Am Chem Soc140, 14015-14018. PubMed Europe PubMed DOI S I
Wong-Sam,A., Wang,Y.F., Zhang,Y., Ghosh,A.K., Harrison,R.W. and Weber,I.T.
Drug resistance mutation L76V alters nonpolar interactions at the flap-core interface of HIV-1 protease
ACS Omega3, 12132-12140. PubMed Europe PubMed DOI
Zhang,Y., Chen,X., Roozbahani,G.M. and Guan,X.
Graphene oxide-based biosensing platform for rapid and sensitive detection of HIV-1 protease
Anal Bioanal Chem410, 6177-6185. PubMed Europe PubMed DOI A

2017

Amano,M., Miguel Salcedo-Gomez,P., Yedidi,R.S., Delino,N.S., Nakata,H., Venkateswara Rao,K., Ghosh,A.K. and Mitsuya,H.
GRL-09510, a Unique P2-crown-tetrahydrofuranylurethane-containing HIV-1 protease inhibitor, maintains its favorable antiviral activity against highly-drug-resistant HIV-1 variants in vitr
Sci Rep7, 12235-12235. PubMed Europe PubMed DOI I
Aoki,M., Hayashi,H., Rao,K.V., Das,D., Higashi-Kuwata,N., Bulut,H., Aoki-Ogata,H., Takamatsu,Y., Yedidi,R.S., Davis,D.A., Hattori,S.I., Nishida,N., Hasegawa,K., Takamune,N., Nyalapatla,P.R., Osswald,H.L., Jono,H., Saito,H., Yarchoan,R., Misumi,S., Ghosh,A.K. and Mitsuya,H.
A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency
elife6, PubMed Europe PubMed DOI I
Appadurai,R. and Senapati,S.
How mutations can resist drug binding yet keep HIV-1 protease functional
Biochemistry56, 2907-2920. PubMed Europe PubMed DOI
Bai,X., Yang,Z., Zhu,M., Dong,B., Zhou,L., Zhang,G., Wang,J. and Wang,Y.
Design and synthesis of potent HIV-1 protease inhibitors with (S)-tetrahydrofuran-tertiary amine-acetamide as P2-ligand: structure-activity studies and biological evaluation
Eur J Med Chem137, 30-44. PubMed Europe PubMed DOI I
Barzegar,A., Naghizadeh,E., Zakariazadeh,M. and Azamat,J.
Molecular dynamics simulation study of the HIV-1 protease inhibition using fullerene and new fullerene derivatives of carbon nanostructures
Mini Rev Med Chem17, 633-647. PubMed Europe PubMed I
Bhargava,S., Adhikari,N., Amin,S.A., Das,K., Gayen,S. and Jha,T.
Hydroxyethylamine derivatives as HIV-1 protease inhibitors: a predictive QSAR modelling study based on Monte Carlo optimization
SAR QSAR Environ Res28, 973-990. PubMed Europe PubMed DOI I
Bungard,C.J., Williams,P.D., Schulz,J., Wiscount,C.M., Holloway,M.K., Loughran,H.M., Manikowski,J.J., Su,H.P., Bennett,D.J., Chang,L., Chu,X.J., Crespo,A., Dwyer,M.P., Keertikar,K., Morriello,G.J., Stamford,A.W., Waddell,S.T., Zhong,B., Hu,B., Ji,T., Diamond,T.L., Bahnck-Teets,C., Carroll,S.S., Fay,J.F., Min,X., Morris,W., Ballard,J.E., Miller,M.D. and McCauley,J.A.
Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease Inhibitors
ACS Med Chem Lett8, 1292-1297. PubMed Europe PubMed DOI I
Deshmukh,L., Tugarinov,V., Louis,J.M. and Clore,G.M.
Binding kinetics and substrate selectivity in HIV-1 protease-Gag interactions probed at atomic resolution by chemical exchange NMR
Proc Natl Acad Sci U S A114, E9855-E9855. PubMed Europe PubMed DOI
Duan,L.L., Zhu,T., Li,Y.C., Zhang,Q.G. and Zhang,J.Z.
Effect of polarization on HIV-1protease and fluoro-substituted inhibitors binding energies by large scale molecular dynamics simulations
Sci Rep7, 42223-42223. PubMed Europe PubMed DOI
Ehlert,F.G.R., Linde,K. and Diederich,W.E.
What are we missing? The detergent Triton X-100 added to avoid compound aggregation can affect assay results in an unpredictable manner
ChemMedChem12, 1419-1423. PubMed Europe PubMed DOI A I
Funicello,M., Chiummiento,L., Tramutola,F., Armentano,M.F., Bisaccia,F., Miglionico,R., Milella,L., Benedetti,F., Berti,F. and Lupattelli,P.
Synthesis and biological evaluation in vitro and in mammalian cells of new heteroaryl carboxyamides as HIV-protease inhibitors
Bioorg Med Chem25, 4715-4722. PubMed Europe PubMed DOI I
Gerlits,O., Keen,D.A., Blakeley,M.P., Louis,J.M., Weber,I.T. and Kovalevsky,A.
Room temperature neutron crystallography of drug resistant HIV-1 protease uncovers limitations of X-ray structural analysis at 100 K
J Med Chem60, 2018-2025. PubMed Europe PubMed DOI S I
Ghosh,A.K., Sean Fyvie,W., Brindisi,M., Steffey,M., Agniswamy,J., Wang,Y.F., Aoki,M., Amano,M., Weber,I.T. and Mitsuya,H.
Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands
Bioorg Med Chem Lett27, 4925-4931. PubMed Europe PubMed DOI I
Ghosh,A.K., Rao,K.V., Nyalapatla,P.R., Osswald,H.L., Martyr,C.D., Aoki,M., Hayashi,H., Agniswamy,J., Wang,Y.F., Bulut,H., Das,D., Weber,I.T. and Mitsuya,H.
Design and development of highly potent HIV-1 protease inhibitors with a crown-like oxotricyclic core as the P2-ligand to combat multidrug-resistant HIV variants
J Med Chem60, 4267-4278. PubMed Europe PubMed DOI I
Ghosh,A.K., Fyvie,W.S., Brindisi,M., Steffey,M., Agniswamy,J., Wang,Y.F., Aoki,M., Amano,M., Weber,I.T. and Mitsuya,H.
Design, synthesis, biological evaluation, and X-ray studies of HIV-1 protease inhibitors with modified P2' ligands of Darunavir
ChemMedChem12, 1942-1952. PubMed Europe PubMed DOI I
Heidari,A. and Fatemi,M.H.
Comparative molecular field analysis (CoMFA) topomer CoMFA and hologram QSAR studies on a series of novel HIV-1 protease inhibitors
Chem Biol Drug Des89, 918-931. PubMed Europe PubMed DOI I
Huang,Y.M., Raymundo,M.A., Chen,W. and Chang,C.A.
Mechanism of the association pathways for a pair of fast and slow binding ligands of HIV-1 protease
Biochemistry56, 1311-1323. PubMed Europe PubMed DOI I
Inoue,M., Oyama,D., Hidaka,K. and Kameoka,M.
Evaluation of novel protease inhibitors against darunavir-resistant variants of HIV type 1
FEBS Open Bio7, 88-95. PubMed Europe PubMed DOI I
Mitchell,M.L., Xu,L., Newby,Z.E. and Desai,M.C.
Synthesis of novel HIV-1 protease inhibitors via diastereoselective Henry reaction with nitrocyclopropane
Tetrahedron Lett58, 1123-1126. DOI I
Mohammadi,A.A., Taheri,S., Amouzegar,A., Ahdenov,R., Halvagar,M.R. and Sadr,A.S.
Diastereoselective synthesis and molecular docking studies of novel fused tetrahydropyridine derivatives as new inhibitors of HIV protease
J Mol Struct1139, 166-174. DOI I
Palese,L.L.
Analysis of the conformations of the HIV-1 protease from a large crystallographic data set
Data Brief15, 696-700. PubMed Europe PubMed DOI S
Palese,L.L.
Conformations of the HIV-1 protease: a crystal structure data set analysis
Biochim Biophys Acta1865, 1416-1422. PubMed Europe PubMed DOI S
Paulsen,J.L., Leidner,F., Ragland,D.A., Kurt Yilmaz,N. and Schiffer,C.A.
Interdependence of inhibitor recognition in HIV-1 protease
J Chem Theory Comput13, 2300-2309. PubMed Europe PubMed DOI I
Rosner,H.I., Caldarini,M., Prestel,A., Vanoni,M.A., Broglia,R.A., Aliverti,A., Tiana,G. and Kragelund,B.B.
Cold denaturation of the HIV-1 protease monomer
Biochemistry56, 1029-1032. PubMed Europe PubMed DOI
Subbaiah,M.A.M., Meanwell,N.A. and Kadow,J.F.
Design strategies in the prodrugs of HIV-1 protease inhibitors to improve the pharmaceutical properties
Eur J Med Chem139, 865-883. PubMed Europe PubMed DOI I
Tong,J., Wu,Y., Bai,M. and Zhan,P.
3D-QSAR and molecular docking studies on HIV protease inhibitors
J Mol Struct1129, 17-22. DOI I
Zakharova,M.Y., Kuznetsova,A.A., Kaliberda,E.N., Dronina,M.A., Kolesnikov,A.V., Kozyr,A.V., Smirnov,I.V., Rumsh,L.D., Fedorova,O.S., Knorre,D.G., Gabibov,A.G. and Kuznetsov,N.A.
Evolution of inhibitor-resistant natural mutant forms of HIV-1 protease probed by pre-steady state kinetic analysis
Biochimie142, 125-134. PubMed Europe PubMed DOI I

2016

Amano,M., Salcedo-Gomez,P.M., Zhao,R., Yedidi,R.S., Das,D., Bulut,H., Delino,N.S., Sheri,V.R., Ghosh,A.K. and Mitsuya,H.
A modified P1 moiety enhances in vitro antiviral activity against various multidrug-resistant HIV-1 variants and in vitro central nervous system penetration properties of a novel nonpeptidic protease inhibitor, GRL-10413
Antimicrob Agents Chemother60, 7046-7059. PubMed Europe PubMed DOI I
Benko,Z., Elder,R.T., Li,G., Liang,D. and Zhao,R.Y.
HIV-1 protease in the fission yeast Schizosaccharomyces pombe
PLoS ONE11, e0151286-e0151286. PubMed Europe PubMed DOI
Bungard,C.J., Williams,P.D., Ballard,J.E., Bennett,D.J., Beaulieu,C., Bahnck-Teets,C., Carroll,S.S., Chang,R.K., Dubost,D.C., Fay,J.F., Diamond,T.L., Greshock,T.J., Hao,L., Holloway,M.K., Felock,P.J., Gesell,J.J., Su,H.P., Manikowski,J.J., McKay,D.J., Miller,M., Min,X., Molinaro,C., Moradei,O.M., Nantermet,P.G., Nadeau,C., Sanchez,R.I., Satyanarayana,T., Shipe,W.D., Singh,S.K., Truong,V.L., Vijayasaradhi,S., Wiscount,C.M., Vacca,J.P., Crane,S.N. and McCauley,J.A.
Discovery of MK-8718, an HIV protease inhibitor containing a novel morpholine aspartate binding group
ACS Med Chem Lett7, 702-707. PubMed Europe PubMed DOI I
Chetty,S., Bhakat,S., Martin,A.J. and Soliman,M.E.
Multi-drug resistance profile of PR20 HIV-1 protease is attributed to distorted conformational and drug binding landscape: molecular dynamics insights
J Biomol Struct Dyn34, 135-151. PubMed Europe PubMed DOI
Gerlits,O., Wymore,T., Das,A., Shen,C.H., Parks,J.M., Smith,J.C., Weiss,K.L., Keen,D.A., Blakeley,M.P., Louis,J.M., Langan,P., Weber,I.T. and Kovalevsky,A.
Long-range electrostatics-induced two-proton transfer captured by neutron crystallography in an enzyme catalytic site
Angew Chem Int Ed Engl55, 4924-4927. PubMed Europe PubMed DOI S I
Ghosh,A.K., Osswald,H.L. and Prato,G.
Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV/AIDS
J Med Chem59, 5172-5208. PubMed Europe PubMed DOI I
Hu,G., Ma,A., Dou,X., Zhao,L. and Wang,J.
Computational studies of a mechanism for binding and drug resistance in the wild type and four mutations of HIV-1 protease with a GRL-0519 inhibitor
Int J Mol Sci17, PubMed Europe PubMed DOI I
Huang,J., Zhu,Y., Sun,B., Yao,Y. and Liu,J.
Determination of the protonation state of the Asp dyad: conventional molecular dynamics versus thermodynamic integration
J Mol Model22, 58-58. PubMed Europe PubMed DOI
Krzeminska,A., Moliner,V. and Swiderek,K.
Dynamic and Electrostatic Effects on the Reaction Catalyzed by HIV-1 Protease
J Am Chem Soc138, 16283-16298. PubMed Europe PubMed DOI
Liu,Z., Huang,X., Hu,L., Pham,L., Poole,K.M., Tang,Y., Mahon,B.P., Tang,W., Li,K., Goldfarb,N.E., Dunn,B.M., McKenna,R. and Fanucci,G.E.
Effects of hinge-region natural polymorphisms on human immunodeficiency virus-type 1 protease structure, dynamics and drug-pressure evolution
J Biol Chem291, 22741-22756. PubMed Europe PubMed DOI I
Lockhat,H.A., Silva,J.R., Alves,C.N., Govender,T., Lameira,J., Maguire,G.E., Sayed,Y. and Kruger,H.G.
Binding free energy calculations of nine FDA-approved protease inhibitors against HIV-1 subtype C I36T containing 100 amino acids per monomer
Chem Biol Drug Des87, 487-498. PubMed Europe PubMed DOI I
Manning,T. and Walsh,P.
The importance of physicochemical characteristics and nonlinear classifiers in determining HIV-1 protease specificity
Bioengineered7, 65-78. PubMed Europe PubMed DOI P
Maseko,S.B., Natarajan,S., Sharma,V., Bhattacharyya,N., Govender,T., Sayed,Y., Maguire,G.E., Lin,J. and Kruger,H.G.
Purification and characterization of naturally occurring HIV-1 (South African subtype C) protease mutants from inclusion bodies
Protein Expr Purif122, 90-96. PubMed Europe PubMed DOI E
Mattei,S., Schur,F.K. and Briggs,J.A.
Retrovirus maturation-an extraordinary structural transformation
Curr Opin Virol18, 27-35. PubMed Europe PubMed DOI
Nakashima,M., Ode,H., Suzuki,K., Fujino,M., Maejima,M., Kimura,Y., Masaoka,T., Hattori,J., Matsuda,M., Hachiya,A., Yokomaku,Y., Suzuki,A., Watanabe,N., Sugiura,W. and Iwatani,Y.
Unique flap conformation in an HIV-1 protease with high-level darunavir resistance
Front Microbiol7, 61-61. PubMed Europe PubMed DOI I
Qu,S., Huang,S., Pan,X., Yang,L. and Mei,H.
Constructing interconsistent, reasonable, and predictive models for both the kinetic and thermodynamic properties of HIV-1 protease inhibitors
J Chem Inf Model56, 2061-2068. PubMed Europe PubMed DOI I
Ravichandran,V., Venkateskumar,K., Shalini,S. and Harish,R.
Exploring the structure-activity relationship of oxazolidinones as HIV-1 protease inhibitors-QSAR and pharmacophore modelling studies
Chemometr Intelligent Lab Syst154, 52-61. DOI I
Singh,O. and Su,E.C.
Prediction of HIV-1 protease cleavage site using a combination of sequence, structural, and physicochemical features
BMC Bioinform17, 478-478. PubMed Europe PubMed DOI
Soares,R.O., Torres,P.H., Da Silva,M.L. and Pascutti,P.G.
Dataset showing the impact of the protonation states on molecular dynamics of HIV protease
Data Brief8, 1144-1150. PubMed Europe PubMed DOI
Soares,R.O., Torres,P.H., Da Silva,M.L. and Pascutti,P.G.
Unraveling HIV protease flaps dynamics by constant pH molecular dynamics simulations
J Struct Biol195, 216-226. PubMed Europe PubMed DOI
Su,C.T., Ling,W.L., Lua,W.H., Haw,Y.X. and Gan,S.K.
Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance
BMC Bioinform17, 500-500. PubMed Europe PubMed DOI I
Tong,J., Zhan,P., Bai,M. and Yao,T.
Molecular modeling studies of human immunodeficiency virus type 1 protease inhibitors using three-dimensional quantitative structure-activity relationship, virtual screening, and docking simulations
J Chemometr30, 523-536. DOI I
Xanthopoulos,D., Kritsi,E., Supuran,C.T., Papadopoulos,M.G., Leonis,G. and Zoumpoulakis,P.
Discovery of HIV type 1 aspartic protease hit compounds through combined computational approaches
ChemMedChem11, 1646-1652. PubMed Europe PubMed DOI I

2015

J Comput Chem36, i-iI. I
Agniswamy,J., Louis,J.M., Shen,C.H., Yashchuk,S., Ghosh,A.K. and Weber,I.T.
Substituted bis-THF protease inhibitors with improved potency against highly resistant mature HIV-1 protease PR20
J Med Chem58, 5088-5095. PubMed Europe PubMed DOI I
Amano,M., Tojo,Y., Salcedo-Gomez,P.M., Parham,G.L., Nyalapatla,P.R., Das,D., Ghosh,A.K. and Mitsuya,H.
A novel tricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor, GRL-0739, effectively inhibits the replication of multidrug-resistant HIV-1 variants and has a desirable central nervous system penetration property in vitro
Antimicrob Agents Chemother59, 2625-2635. PubMed Europe PubMed DOI I
Casey,T.M. and Fanucci,G.E.
Spin labeling and double electron-electron resonance (DEER) to deconstruct conformational ensembles of HIV protease
Methods Enzymol564, 153-187. PubMed Europe PubMed DOI
Chauhan,J., Chen,S.E., Fenstermacher,K.J., Naser-Tavakolian,A., Reingewertz,T., Salmo,R., Lee,C., Williams,E., Raje,M., Sundberg,E., DeStefano,J.J., Freire,E. and Fletcher,S.
Synthetic, structural mimetics of the beta-hairpin flap of HIV-1 protease inhibit enzyme function
Bioorg Med Chem23, 7095-7109. PubMed Europe PubMed DOI I
Chen,J., Wang,X., Zhu,T., Zhang,Q. and Zhang,J.Z.
A comparative insight into amprenavir resistance of mutations V32I, G48V, I50V, I54V, and I84V in HIV-1 protease based on thermodynamic integration and MM-PBSA methods
J Chem Inf Model55, 1903-1913. PubMed Europe PubMed DOI I
Counts,C.J., Ho,P.S., Donlin,M.J., Tavis,J.E. and Chen,C.
A functional interplay between human immunodeficiency virus type 1 protease residues 77 and 93 involved in differential regulation of precursor autoprocessing and mature protease activity
PLoS ONE10, e0123561- PubMed Europe PubMed DOI
De Conto,V., Braz,A.S., Perahia,D. and Scott,L.P.
Recovery of the wild type atomic flexibility in the HIV-1 protease double mutants
J Mol Graph Model59, 107-116. PubMed Europe PubMed DOI
Deng,N., Forli,S., He,P., Perryman,A., Wickstrom,L., Vijayan,R.S., Tiefenbrunn,T., Stout,D., Gallicchio,E., Olson,A.J. and Levy,R.M.
Distinguishing binders from false positives by free energy calculations: fragment screening against the flap site of HIV protease
J Phys Chem B119, 976-988. PubMed Europe PubMed DOI I
Duan,R., Lazim,R. and Zhang,D.
Understanding the basis of I50V-induced affinity decrease in HIV-1 protease via molecular dynamics simulations using polarized force field
J Comput Chem36, 1885-1892. PubMed Europe PubMed DOI
Duclair,S., Gautam,A., Ellington,A. and Prasad,V.R.
High-affinity RNA aptamers against the HIV-1 protease inhibit both in vitro protease activity and late events of viral replication
Mol Ther Nucleic Acids4, e228-e228. PubMed Europe PubMed DOI I
Fatemi,M.H., Heidari,A. and Gharaghani,S.
QSAR prediction of HIV-1 protease inhibitory activities using docking derived molecular descriptors
J Theor Biol369C, 13-22. PubMed Europe PubMed DOI I
Ghosh,A.K., Takayama,J., Kassekert,L.A., Ella-Menye,J.R., Yashchuk,S., Agniswamy,J., Wang,Y.F., Aoki,M., Amano,M., Weber,I.T. and Mitsuya,H.
Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands
Bioorg Med Chem Lett25, 4903-4909. PubMed Europe PubMed DOI I
Ghosh,A.K., Martyr,C.D., Kassekert,L.A., Nyalapatla,P.R., Steffey,M., Agniswamy,J., Wang,Y.F., Weber,I.T., Amano,M. and Mitsuya,H.
Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands
Org Biomol Chem13, 11607-11621. PubMed Europe PubMed DOI I
Ghosh,A.K., Yu,X., Osswald,H.L., Agniswamy,J., Wang,Y.F., Amano,M., Weber,I.T. and Mitsuya,H.
Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies
J Med Chem58, 5334-5343. PubMed Europe PubMed DOI I
Ghosh,A.K., Yashchuk,S., Mizuno,A., Chakraborty,N., Agniswamy,J., Wang,Y.F., Aoki,M., Gomez,P.M., Amano,M., Weber,I.T. and Mitsuya,H.
Design of gem-difluoro-bis-tetrahydrofuran as P2 ligand for HIV-1 protease inhibitors to improve brain penetration: synthesis, X-ray studies, and biological evaluation
ChemMedChem10, 107-115. PubMed Europe PubMed DOI I
Ghosh,A.K., Martyr,C.D., Osswald,H.L., Sheri,V.R., Kassekert,L.A., Chen,S., Agniswamy,J., Wang,Y.F., Hayashi,H., Aoki,M., Weber,I.T. and Mitsuya,H.
Design of HIV-1 protease inhibitors with amino-bis-tetrahydrofuran derivatives as P2-ligands to enhance backbone-binding interactions: synthesis, biological evaluation, and protein-ligand X-ray studies
J Med Chem58, 6994-7006. PubMed Europe PubMed DOI S I
Goldfarb,N.E., Ohanessian,M., Biswas,S., McGee,T.D., Jr., Mahon,B.P., Ostrov,D.A., Garcia,J., Tang,Y., McKenna,R., Roitberg,A. and Dunn,B.M.
Defective hydrophobic sliding mechanism and active site expansion in HIV-1 protease drug resistant variant Gly48Thr/Leu89Met: mechanisms for the loss of saquinavir binding potency
Biochemistry54, 422-433. PubMed Europe PubMed DOI I
Gupta,A., Jamal,S., Goyal,S., Jain,R., Wahi,D. and Grover,A.
Structural studies on molecular mechanisms of nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease
BMC Bioinformatics16 Suppl 19, S10-S10. PubMed Europe PubMed DOI I
Hohlfeld,K., Wegner,J.K., Kesteleyn,B., Linclau,B. and Unge,J.
Disubstituted bis-THF moieties as new P2 ligands in nonpeptidal HIV-1 protease inhibitors (II)
J Med Chem58, 4029-4038. PubMed Europe PubMed DOI I
Honarparvar,B., Pawar,S.A., Alves,C.N., Lameira,J., Maguire,G.E., Silva,J.R., Govender,T. and Kruger,H.G.
Pentacycloundecane lactam vs lactone norstatine type protease HIV inhibitors: binding energy calculations and DFT study
J Biomed Sci22, 15- PubMed Europe PubMed DOI I
Ingr,M., Lange,R., Halabalova,V., Yehya,A., Hrncirik,J., Chevalier-Lucia,D., Palmade,L., Blayo,C., Konvalinka,J. and Dumay,E.
Inhibitor and substrate binding induced stability of HIV-1 protease against sequential dissociation and unfolding revealed by high pressure spectroscopy and kinetics
PLoS ONE10, e0119099-e0119099. PubMed Europe PubMed DOI
Islam,M.A. and Pillay,T.S.
Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification
J Mol Graph Model56C, 20-30. PubMed Europe PubMed DOI I
Jaskolski,M., Miller,M., Mohana Rao,J.K., Gustchina,A. and Wlodawer,A.
Elucidation of the structure of retroviral proteases: a reminiscence
FEBS J282, 4059-4066. PubMed Europe PubMed DOI S
Katebi,A.R., Sankar,K., Jia,K. and Jernigan,R.L.
The use of experimental structures to model protein dynamics
Methods Mol Biol1215, 213-236. PubMed Europe PubMed DOI S
Konvalinka,J., Krausslich,H.-G. and Muller,B.
Retroviral proteases and their roles in virion maturation
Virology479-480, 403-417. PubMed Europe PubMed DOI V
Kuiper,B.D., Keusch,B.J., Dewdney,T.G., Chordia,P., Ross,K., Brunzelle,J.S., Kovari,I.A., MacArthur,R., Salimnia,H. and Kovari,L.C.
The L33F darunavir resistance mutation acts as a molecular anchor reducing the flexibility of the HIV-1 protease 30s and 80s loops
Biochem Biophys Rep2, 160-165. PubMed Europe PubMed DOI
Laco,G.S.
HIV-1 protease substrate-groove: role in substrate recognition and inhibitor resistance
Biochimie118, 90-103. PubMed Europe PubMed DOI
Li,N., Ainsworth,R.I., Ding,B., Hou,T. and Wang,W.
Using hierarchical virtual screening to combat drug resistance of the HIV-1 protease
J Chem Inf Model55, 1400-1412. PubMed Europe PubMed DOI I
Liu,H., Shi,X., Guo,D., Zhao,Z. and Yimin
Feature selection combined with neural network structure optimization for HIV-1 protease cleavage site prediction
Biomed Res Int2015, 263586- PubMed Europe PubMed DOI
Louis,J.M., Deshmukh,L., Sayer,J.M., Aniana,A. and Clore,G.M.
Mutations proximal to sites of autoproteolysis and the alpha-helix that co-evolve under drug pressure modulate the autoprocessing and vitality of HIV-1 protease
Biochemistry54, 5414-5424. PubMed Europe PubMed DOI
Meher,B.R. and Wang,Y.
Exploring the drug resistance of V32I and M46L mutant HIV-1 protease to inhibitor TMC114: flap dynamics and binding mechanism
J Mol Graph Model56C, 60-73. PubMed Europe PubMed DOI I
Meng,J., Lai,M.T., Munshi,V., Grobler,J., McCauley,J., Zuck,P., Johnson,E.N., Uebele,V.N., Hermes,J.D. and Adam,G.C.
Screening of HIV-1 protease using a combination of an ultra-high-throughput fluorescent-based assay and RapidFire mass spectrometry
J Biomol Screen20, 606-615. PubMed Europe PubMed DOI A
Ngo,S.T., Mai,B.K., Hiep,D.M. and Li,M.S.
Estimation of the binding free energy of AC1NX476 to HIV-1 protease wild type and mutations using free energy perturbation method
Chem Biol Drug Des86, 546-558. PubMed Europe PubMed DOI I
Nguyen,H.L., Nguyen,T.T., Vu,Q.T., Le,H.T., Pham,Y., Trinh,P.L., Bui,T.P. and Phan,T.N.
An efficient procedure for the expression and purification of HIV-1 protease from inclusion bodies
Protein Expr Purif116, 59-65. PubMed Europe PubMed DOI E
Ozahata,M., Sabino,E., Diaz,R., Cesar-Jr,R.M. and Ferreira,J.
Data-intensive analysis of HIV mutations
BMC Bioinformatics16, 35-35. PubMed Europe PubMed DOI
Ozer,N., Ozen,A., Schiffer,C.A. and Haliloglu,T.
Drug-resistant HIV-1 protease regains functional dynamics through cleavage site coevolution
Evol Appl8, 185-198. PubMed Europe PubMed DOI
Pietrucci,F., Vargiu,A.V. and Kranjc,A.
HIV-1 protease dimerization dynamics reveals a transient druggable binding pocket at the interface
Sci Rep5, 18555-18555. PubMed Europe PubMed DOI
Potempa,M., Nalivaika,E., Ragland,D., Lee,S.K., Schiffer,C.A. and Swanstrom,R.
A direct interaction with RNA dramatically enhances the catalytic activity of the HIV-1 protease in vitro
J Mol Biol427, 2360-2378. PubMed Europe PubMed DOI
Prashar,V., Bihani,S.C., Ferrer,J.L. and Hosur,M.V.
Structural basis of why nelfinavir-resistant D30N mutant of HIV-1 protease remains susceptible to saquinavir
Chem Biol Drug Des86, 302-308. PubMed Europe PubMed DOI S I
Qi,Y.K., Chang,H.N., Pan,K.M., Tian,C.L. and Zheng,J.S.
Total chemical synthesis of the site-selective azide-labeled [I66A]HIV-1 protease
Chem Commun (Camb)51, 14632-14635. PubMed Europe PubMed DOI
Razzaghi-Asl,N., Sepehri,S., Ebadi,A., Miri,R. and Shahabipour,S.
Effect of biomolecular conformation on docking simulation: a case study on a potent HIV-1 protease inhibitor
Iran J Pharm Res14, 785-802. PubMed Europe PubMed I
Roche,J., Louis,J.M. and Bax,A.
Conformation of inhibitor-free HIV-1 protease derived from NMR spectroscopy in a weakly oriented solution
Chembiochem16, 214-218. PubMed Europe PubMed DOI S
Rognvaldsson,T., You,L. and Garwicz,D.
State of the art prediction of HIV-1 protease cleavage sites
Bioinformatics31, 1204-1210. PubMed Europe PubMed DOI P
Schimer,J., Pavova,M., Anders,M., Pachl,P., Sacha,P., Cigler,P., Weber,J., Majer,P., Rezacova,P., Krausslich,H.G., Muller,B. and Konvalinka,J.
Triggering HIV polyprotein processing by light using rapid photodegradation of a tight-binding protease inhibitor
Nat Commun6, 6461-6461. PubMed Europe PubMed DOI I
Shen,C.H., Chang,Y.C., Agniswamy,J., Harrison,R.W. and Weber,I.T.
Conformational variation of an extreme drug resistant mutant of HIV protease
J Mol Graph Model62, 87-96. PubMed Europe PubMed DOI
Shen,Y., Radhakrishnan,M.L. and Tidor,B.
Molecular mechanisms and design principles for promiscuous inhibitors to avoid drug resistance: lessons learned from HIV-1 protease inhibition
Proteins83, 351-372. PubMed Europe PubMed DOI I
Singh,A. and Pal,T.K.
Docking analysis of gallic acid derivatives as HIV-1 protease inhibitors
Int J Bioinform Res Appl11, 540-546. PubMed Europe PubMed I
Sroczynski,D., Malinowski,Z., Szczesniak,A.K. and Pakulska,W.
New 1(2H)-phthalazinone derivatives as potent nonpeptidic HIV-1 protease inhibitors: molecular docking studies, molecular dynamics simulation, oral bioavailability and ADME prediction
Mol Simul42, 628-641. DOI I
Strom,T.A., Durdagi,S., Ersoz,S.S., Salmas,R.E., Supuran,C.T. and Barron,A.R.
Fullerene-based inhibitors of HIV-1 protease
J Pept Sci21, 862-870. PubMed Europe PubMed DOI I
Wagner,R.N., Reed,J.C. and Chanda,S.K.
HIV-1 protease cleaves the serine-threonine kinases RIPK1 and RIPK2
Retrovirology12, 74-74. PubMed Europe PubMed DOI
Weber,I.T., Kneller,D.W. and Wong-Sam,A.
Highly resistant HIV-1 proteases and strategies for their inhibition
Future Med Chem7, 1023-1038. PubMed Europe PubMed DOI I
Wei,Y., Li,J., Chen,Z., Wang,F., Huang,W., Hong,Z. and Lin,J.
Multistage virtual screening and identification of novel HIV-1 protease inhibitors by integrating SVM, shape, pharmacophore and docking methods
Eur J Med Chem101, 409-418. PubMed Europe PubMed DOI I
Windsor,I.W. and Raines,R.T.
Fluorogenic assay for inhibitors of HIV-1 protease with sub-picomolar affinity
Sci Rep5, 11286-11286. PubMed Europe PubMed DOI A I
Yang,Z.H., Bai,X.G., Zhou,L., Wang,J.X., Liu,H.T. and Wang,Y.C.
Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands
Bioorg Med Chem Lett25, 1880-1883. PubMed Europe PubMed DOI I
Yu,Y., Wang,J., Shao,Q., Shi,J. and Zhu,W.
Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by amprenavir and darunavir
Sci Rep5, 10517-10517. PubMed Europe PubMed DOI I
Zhou,H., Li,S., Badger,J., Nalivaika,E., Cai,Y., Foulkes-Murzycki,J., Schiffer,C. and Makowski,L.
Modulation of HIV protease flexibility by the T80N mutation
Proteins83, 1929-1939. PubMed Europe PubMed DOI

2014

New FRET probes for protease inhibitor discovery
Biotechnol Bioeng111, vi-vi. DOI A
Ahmed,S.M., Maguire,G.E., Kruger,H.G. and Govender,T.
The impact of active site mutations of South African HIV PR on drug resistance: insight from molecular dynamics simulations, binding free energy and per-residue footprints
Chem Biol Drug Des83, 472-481. PubMed Europe PubMed DOI I
Antunes,D.A., Rigo,M.M., Sinigaglia,M., de Medeiros,R.M., Junqueira,D.M., Almeida,S.E. and Vieira,G.F.
New insights into the in silico prediction of HIV protease resistance to nelfinavir
PLoS ONE9, e87520-e87520. PubMed Europe PubMed DOI I
Benedetti,F., Berti,F., Campaner,P., Fanfoni,L., Demitri,N., Olajuyigbe,F.M., De March,M. and Geremia,S.
Impact of stereochemistry on ligand binding: X-ray crystallographic analysis of an epoxide-based HIV protease inhibitor
ACS Med Chem Lett5, 968-972. PubMed Europe PubMed DOI I
Berti,F., Frecer,V. and Miertus,S.
Inhibitors of HIV-Protease from computational design. A history of theory and synthesis still to be fully appreciated
Curr Pharm Des20, 3398-3411. PubMed Europe PubMed DOI I
Bonini,C., Chiummiento,L., Di Blasio,N., Funicello,M., Lupattelli,P., Tramutola,F., Berti,F., Ostric,A., Miertus,S., Frecer,V. and Kong,D.X.
Synthesis and biological evaluation of new simple indolic non peptidic HIV protease inhibitors: the effect of different substitution patterns
Bioorg Med Chem22, 4792-4802. PubMed Europe PubMed DOI I
Cai,Y., Myint,W., Paulsen,J.L., Schiffer,C.A., Ishima,R. and Kurt Yilmaz,N.
Drug resistance mutations alter dynamics of inhibitor-bound HIV-1 protease
J Chem Theory Comput10, 3438-3448. PubMed Europe PubMed DOI I
Caldarini,M., Sonar,P., Valpapuram,I., Tavella,D., Volonte,C., Pandini,V., Vanoni,M.A., Aliverti,A., Broglia,R.A., Tiana,G. and Cecconi,C.
The complex folding behavior of HIV-1-protease monomer revealed by optical-tweezer single-molecule experiments and molecular dynamics simulations
Biophys Chem195, 32-42. PubMed Europe PubMed DOI
Calugi,C., Guarna,A. and Trabocchi,A.
Identification of constrained peptidomimetic chemotypes as HIV protease inhibitors
Eur J Med Chem84, 444-453. PubMed Europe PubMed DOI I
Capel,E., Parera,M. and Martinez,M.A.
Epistasis as a determinant of the HIV-1 protease's robustness to mutation
PLoS ONE9, e116301-e116301. PubMed Europe PubMed DOI
Cella,L.N., Biswas,P., Yates,M.V., Mulchandani,A. and Chen,W.
Quantitative assessment of in vivo HIV protease activity using genetically engineered QD-based FRET probes
Biotechnol Bioeng111, 1082-1087. PubMed Europe PubMed DOI A
Costa,M.G., Benetti-Barbosa,T.G., Desdouits,N., Blondel,A., Bisch,P.M., Pascutti,P.G. and Batista,P.R.
Impact of M36I polymorphism on the interaction of HIV-1 protease with its substrates: insights from molecular dynamics
BMC Genomics15 Suppl 7, S5-S5. PubMed Europe PubMed DOI
De Rosa,M., Unge,J., Motwani,H.V., Rosenquist,A., Vrang,L., Wallberg,H. and Larhed,M.
Synthesis of P1'-functionalized macrocyclic transition-state mimicking HIV-1 protease inhibitors encompassing a tertiary alcohol
J Med Chem57, 6444-6457. PubMed Europe PubMed DOI I
Fanelli,R., Ressurreicao,A.S., Dufau,L., Soulier,J.-L., Vidu,A., Tonali,N., Bernadat,G., Reboud-Ravaux,M. and Ongeri,S.
Introduction of polar groups on the naphthalene scaffold of molecular tongs inhibiting wild-type and mutated HIV-1 protease dimerization
MedChemComm5, 719-727. DOI I
Fuwa,H., Muto,T., Sekine,K. and Sasaki,M.
Total synthesis and structure revision of didemnaketal B
Chemistry20, 1848-1860. PubMed Europe PubMed DOI I
Grantz Saskova,K., Kozisek,M., Stray,K., de Jong,D., Rezacova,P., Brynda,J., van Maarseveen,N.M., Nijhuis,M., Cihlar,T. and Konvalinka,J.
GS-8374, a prototype phosphonate-containing inhibitor of HIV-1 protease, effectively inhibits protease mutants with amino acid insertions
J Virol88, 3586-3590. PubMed Europe PubMed DOI I
Hayashi,H., Takamune,N., Nirasawa,T., Aoki,M., Morishita,Y., Das,D., Koh,Y., Ghosh,A.K., Misumi,S. and Mitsuya,H.
Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir
Proc Natl Acad Sci U S A111, 12234-12239. PubMed Europe PubMed DOI I
Jensen,J.H., Willemoes,M., Winther,J.R. and De Vico,L.
In silico prediction of mutant HIV-1 proteases cleaving a target sequence
PLoS ONE9, e95833-e95833. PubMed Europe PubMed DOI
Khadra,K.A., Mizyed,S., Marji,D., Haddad,S.F., Ashram,M. and Foudeh,A.
Synthesis of novel p-tert-butylcalix[4]arene Schiff bases and their complexes with C60, potential HIV-protease inhibitors
Spectrochim Acta A Mol Biomol Spectrosc136, 1869-1874. PubMed Europe PubMed DOI I
Kimura,S., Caldarini,M., Broglia,R.A., Dokholyan,N.V. and Tiana,G.
The maturation of HIV-1 protease precursor studied by discrete molecular dynamics
Proteins82, 633-639. PubMed Europe PubMed DOI
Kolli,M., Ozen,A., Kurt-Yilmaz,N. and Schiffer,C.A.
HIV-1 protease-substrate coevolution in nelfinavir resistance
J Virol88, 7145-7154. PubMed Europe PubMed DOI I
Kozisek,M., Lepsik,M., Grantz Saskova,K., Brynda,J., Konvalinka,J. and Rezacova,P.
Thermodynamic and structural analysis of HIV protease resistance to darunavir - analysis of heavily mutated patient-derived HIV-1 proteases
FEBS J281, 1834-1847. PubMed Europe PubMed DOI I
Kunze,J., Todoroff,N., Schneider,P., Rodrigues,T., Geppert,T., Reisen,F., Schreuder,H., Saas,J., Hessler,G., Baringhaus,K.H. and Schneider,G.
Targeting dynamic pockets of HIV-1 protease by structure-based computational screening for allosteric inhibitors
J Chem Inf Model54, 987-991. PubMed Europe PubMed DOI I
Kutalkova,E., Hrncirik,J. and Ingr,M.
Pressure induced structural changes and dimer destabilization of HIV-1 protease studied by molecular dynamics simulations
Phys Chem Chem Phys16, 25906-25915. PubMed Europe PubMed DOI
Levita,J., Chao,K.H. and Mutakin
Interactions of ganoderiol-F with aspartic proteases of HIV and plasmepsin for anti-HIV and anti-malaria discovery
Int J Pharmcy Pharm Sci6, 561-566. I
Li,D., Zhang,Y., Zhao,R.N., Fan,S. and Han,J.G.
Investigation on the mechanism for the binding and drug resistance of wild type and mutations of G86 residue in HIV-1 protease complexed with Darunavir by molecular dynamic simulation and free energy calculation
J Mol Model20, 2122-2122. PubMed Europe PubMed DOI I
Mata-Munguia,C., Escoto-Delgadillo,M., Torres-Mendoza,B., Flores-Soto,M., Vazquez-Torres,M., Galvez-Gastelum,F., Viniegra-Osorio,A., Castillero-Manzano,M. and Vazquez-Valls,E.
Natural polymorphisms and unusual mutations in HIV-1 protease with potential antiretroviral resistance: a bioinformatic analysis
BMC Bioinformatics15, 72-72. PubMed Europe PubMed DOI
Mattei,S., Anders,M., Konvalinka,J., Krausslich,H.G., Briggs,J.A. and Muller,B.
Induced maturation of human immunodeficiency virus
J Virol88, 13722-13731. PubMed Europe PubMed DOI
McGee,T.D., Jr., Edwards,J. and Roitberg,A.E.
pH-REMD simulations indicate that the catalytic aspartates of HIV-1 protease exist primarily in a monoprotonated state
J Phys Chem B118, 12577-12585. PubMed Europe PubMed DOI
Meher,B.R., Kumar,M.V. and Bandyopadhyay,P.
Interchain hydrophobic clustering promotes rigidity in HIV-1 protease flap dynamics: new insights from molecular dynamics
J Biomol Struct Dyn32, 899-915. PubMed Europe PubMed DOI
Mendonca,L.M., Poeys,S.C., Abreu,C.M., Tanuri,A. and Costa,L.J.
HIV-1 Nef inhibits protease activity and its absence alters protein content of mature viral particles
PLoS ONE9, e95352-e95352. PubMed Europe PubMed DOI
Naicker,P., Stoychev,S., Dirr,H.W. and Sayed,Y.
Amide hydrogen exchange in HIV-1 subtype B and C proteases - insights into reduced drug susceptibility and dimer stability
FEBS J281, 5395-5410. PubMed Europe PubMed DOI
Ozen,A., Lin,K.H., Kurt Yilmaz,N. and Schiffer,C.A.
Structural basis and distal effects of Gag substrate coevolution in drug resistance to HIV-1 protease
Proc Natl Acad Sci U S A111, 15993-15998. PubMed Europe PubMed DOI S
Pang,X., Liu,Z. and Zhai,G.
Advances in non-peptidomimetic HIV protease inhibitors
Curr Med Chem21, 1997-2011. PubMed Europe PubMed DOI V I
Patel,R.V. and Park,S.W.
Journey describing the discoveries of anti-HIV triterpene acid families targeting HIV-entry/fusion, protease functioning and maturation stages
Curr Top Med Chem14, 1940-1966. PubMed Europe PubMed I
Poveda,E.
Multi-step inhibition against HIV lifecycle-underlying the "magic" of protease inhibitors
AIDS Rev16, 52-52. PubMed Europe PubMed I
Qi,F., Fudo,S., Neya,S. and Hoshino,T.
A cluster analysis on the structural diversity of protein crystals, exemplified by human immunodeficiency virus type 1 protease
Chem Pharm Bull (Tokyo)62, 568-577. PubMed Europe PubMed DOI S
Qiu,X., Zhao,G.D., Tang,L.Q. and Liu,Z.P.
Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands
Bioorg Med Chem Lett24, 2465-2468. PubMed Europe PubMed DOI I
Ragland,D.A., Nalivaika,E.A., Nalam,M.N., Prachanronarong,K.L., Cao,H., Bandaranayake,R.M., Cai,Y., Kurt-Yilmaz,N. and Schiffer,C.A.
Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease
J Am Chem Soc136, 11956-11963. PubMed Europe PubMed DOI I
Saleh,N.A.
The QSAR and docking calculations of fullerene derivatives as HIV-1 protease inhibitors
Spectrochim Acta A Mol Biomol Spectrosc136, 1523-1529. PubMed Europe PubMed DOI I
Schimer,J. and Konvalinka,J.
Unorthodox inhibitors of HIV protease: looking beyond active-site-directed peptidomimetics
Curr Pharm Des20, 3389-3397. PubMed Europe PubMed DOI I
Shing,C.-Y., Whiteley,C.G. and Lee,D.-J.
HIV protease: multiple fold inhibition by silver nanoparticles - spectrofluorimetric, thermodynamic and kinetic analysis
J Taiwan Inst Chem Eng45, 1140-1148. DOI I
Tiefenbrunn,T., Forli,S., Happer,M., Gonzalez,A., Tsai,Y., Soltis,M., Elder,J.H., Olson,A.J. and Stout,C.D.
Crystallographic fragment-based drug discovery: use of a brominated fragment library targeting HIV protease
Chem Biol Drug Des83, 141-148. PubMed Europe PubMed DOI I
Tingjun,H., Wei,Z., Jian,W. and Wei,W.
Predicting drug resistance of the HIV-1 protease using molecular interaction energy components
Proteins Struct Funct Bioinformatics82, 1099-1099. DOI I
Ung,P.M., Dunbar,J.B., Jr., Gestwicki,J.E. and Carlson,H.A.
An allosteric modulator of HIV-1 protease shows equipotent inhibition of wild-type and drug-resistant proteases
J Med Chem57, 6468-6478. PubMed Europe PubMed DOI I
Wright,D.W., Hall,B.A., Kenway,O.A., Jha,S. and Coveney,P.V.
Computing clinically relevant binding free energies of HIV-1 protease inhibitors
J Chem Theory Comput10, 1228-1241. PubMed Europe PubMed DOI I
Yang,M., Jiang,X. and Jiang,N.
Protonation state and free energy calculation of HIV-1 protease-inhibitor complex based on electrostatic polarisation effect
Mol Phys112, 1659-1669. DOI I
Yang,Z.-H., Bai,X.-G., Wang,J.-X. and Wang,Y.-C.
Recent advance in research and development of HIV-1 protease inhibitors
Chin J New Drugs23, 2246-2254. I
Yedidi,R.S., Garimella,H., Aoki,M., Aoki-Ogata,H., Desai,D.V., Chang,S.B., Davis,D.A., Fyvie,W.S., Kaufman,J.D., Smith,D.W., Das,D., Wingfield,P.T., Maeda,K., Ghosh,A.K. and Mitsuya,H.
A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV
Antimicrob Agents Chemother58, 3679-3688. PubMed Europe PubMed DOI I
Yedidi,R.S., Liu,Z., Kovari,I.A., Woster,P.M. and Kovari,L.C.
P1 and P1' para-fluoro phenyl groups show enhanced binding and favorable predicted pharmacological properties: structure-based virtual screening of extended lopinavir analogs against multi-drug resistant HIV-1 protease
J Mol Graph Model47, 18-24. PubMed Europe PubMed DOI I
Yedidi,R.S., Proteasa,G., Martin,P.D., Liu,Z., Vickrey,J.F., Kovari,I.A. and Kovari,L.C.
A multi-drug resistant HIV-1 protease is resistant to the dimerization inhibitory activity of TLF-PafF
J Mol Graph Model53, 105-111. PubMed Europe PubMed DOI I
Yu,X., Weber,I.T. and Harrison,R.W.
Prediction of HIV drug resistance from genotype with encoded three-dimensional protein structure
BMC Genomics15 Suppl 5, S1-S1. PubMed Europe PubMed DOI I
Zhang,Y., Chang,Y.C., Louis,J.M., Wang,Y.F., Harrison,R.W. and Weber,I.T.
Structures of Darunavir-Resistant HIV-1 Protease Mutant Reveal Atypical Binding of Darunavir to Wide Open Flaps
ACS Chem Biol9, 1351-1358. PubMed Europe PubMed DOI S I

2013

Agniswamy,J., Shen,C.H., Wang,Y.F., Ghosh,A.K., Rao,K.V., Xu,C.X., Sayer,J.M., Louis,J.M. and Weber,I.T.
Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran
J Med Chem56, 4017-4027. PubMed Europe PubMed DOI S I
Amano,M., Tojo,Y., Salcedo-Gomez,P.M., Campbell,J.R., Das,D., Aoki,M., Xu,C.X., Rao,K.V., Ghosh,A.K. and Mitsuya,H.
GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro
Antimicrob Agents Chemother57, 2036-2046. PubMed Europe PubMed DOI I
Asahchop,E.L., Oliveira,M., Quashie,P.K., Moisi,D., Martinez-Cajas,J.L., Brenner,B.G., Tremblay,C.L. and Wainberg,M.A.
In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor
J Antimicrob Chemother68, 105-112. PubMed Europe PubMed DOI I
Borchani,H., Bielza,C., Toro,C. and Larranaga,P.
Predicting human immunodeficiency virus inhibitors using multi-dimensional Bayesian network classifiers
Artif Intell Med57, 219-229. PubMed Europe PubMed DOI I
Calugi,C., Guarna,A. and Trabocchi,A.
Insight into the structural similarity between HIV protease and secreted aspartic protease-2 and binding mode analysis of HIV-Candida albicans inhibitors
J Enzyme Inhib Med Chem28, 936-943. PubMed Europe PubMed DOI
Calugi,C., Guarna,A. and Trabocchi,A.
Heterocyclic HIV-protease inhibitors
Curr Med Chem20, 3693-3710. PubMed Europe PubMed DOI I
Charpentier,C., Lambert-Niclot,S., Alteri,C., Storto,A., Flandre,P., Svicher,V., Perno,C.F., Brun-Vezinet,F., Calvez,V., Marcelin,A.G., Ceccherini-Silberstein,F. and Descamps,D.
Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes
PLoS ONE8, e54381-e54381. PubMed Europe PubMed DOI
Dayer,M.R. and Dayer,M.S.
Whiskers-less HIV-protease: a possible way for HIV-1 deactivation
J Biomed Sci20, 67-67. PubMed Europe PubMed DOI I
de Vera,I.M., Smith,A.N., Dancel,M.C., Huang,X., Dunn,B.M. and Fanucci,G.E.
Elucidating a relationship between conformational sampling and drug resistance in HIV-1 protease
Biochemistry52, 3278-3288. PubMed Europe PubMed DOI
Esseghaier,C., Ng,A. and Zourob,M.
A novel and rapid assay for HIV-1 protease detection using magnetic bead mediation
Biosens Bioelectron41, 335-341. PubMed Europe PubMed DOI A
Foulkes-Murzycki,J.E., Rosi,C., Kurt Yilmaz,N., Shafer,R.W. and Schiffer,C.A.
Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease
ACS Chem Biol8, 513-518. PubMed Europe PubMed DOI
Ghosh,A.K., Parham,G.L., Martyr,C.D., Nyalapatla,P.R., Osswald,H.L., Agniswamy,J., Wang,Y.F., Amano,M., Weber,I.T. and Mitsuya,H.
Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies
J Med Chem56, 6792-6802. PubMed Europe PubMed DOI I
Ghosh,A.K. and Chapsal,B.D.
Design of the anti-HIV protease inhibitor darunavir
Introd to Bio and Small Molecule Drug Res and Develop2013, 355-384. DOI I
Huang,L. and Chen,C.
Understanding HIV-1 protease autoprocessing for novel therapeutic development
Future Med Chem5, 1215-1229. PubMed Europe PubMed DOI
Huang,X., de Vera,I.M., Veloro,A.M., Rocca,J.R., Simmerling,C., Dunn,B.M. and Fanucci,G.E.
Backbone 1H, 13C, and 15N chemical shift assignment for HIV-1 protease subtypes and multi-drug resistant variant MDR 769
Biomol NMR Assign7, 199-202. PubMed Europe PubMed DOI S
Jones,S.A., Neilsen,P.M., Siew,L., Callen,D.F., Goldfarb,N.E., Dunn,B.M. and Abell,A.D.
A template-based approach to inhibitors of calpain 2, 20S proteasome, and HIV-1 protease
ChemMedChem8, 1918-1921. PubMed Europe PubMed DOI I
Joshi,A., Veron,J.B., Unge,J., Rosenquist,A., Wallberg,H., Samuelsson,B., Hallberg,A. and Larhed,M.
Design and synthesis of P1-P3 macrocyclic tertiary-alcohol-comprising HIV-1 protease inhibitors
J Med Chem56, 8999-9007. PubMed Europe PubMed DOI I
Kar,P., Lipowsky,R. and Knecht,V.
Importance of Polar Solvation and Configurational Entropy for Design of Antiretroviral Drugs Targeting HIV-1 Protease
J Phys Chem B117, 5793-5805. PubMed Europe PubMed DOI I
Koh,Y.
[Study of HIV protease dimerization (PD) and identification of novel PD inhibitors (PDIs)]
Jpn J Antibiot66, 45-53. PubMed Europe PubMed I
Lee,S.K., Cheng,N., Hull-Ryde,E., Potempa,M., Schiffer,C.A., Janzen,W. and Swanstrom,R.
A sensitive assay using a native protein substrate for screening HIV-1 maturation inhibitors targeting the protease cleavage site between the matrix and capsid
Biochemistry52, 4929-4940. PubMed Europe PubMed DOI A I
Liu,Z., Yedidi,R.S., Wang,Y., Dewdney,T.G., Reiter,S.J., Brunzelle,J.S., Kovari,I.A. and Kovari,L.C.
Insights into the mechanism of drug resistance: X-ray structure analysis of multi-drug resistant HIV-1 protease ritonavir complex
Biochem Biophys Res Commun431, 232-238. PubMed Europe PubMed DOI S I
Liu,Z., Yedidi,R.S., Wang,Y., Dewdney,T.G., Reiter,S.J., Brunzelle,J.S., Kovari,I.A. and Kovari,L.C.
Crystallographic study of multi-drug resistant HIV-1 protease lopinavir complex: Mechanism of drug recognition and resistance
Biochem Biophys Res Commun437, 199-204. PubMed Europe PubMed DOI S I
Liu,Z., Wang,Y., Yedidi,R.S., Dewdney,T.G., Reiter,S.J., Brunzelle,J.S., Kovari,I.A. and Kovari,L.C.
Conserved hydrogen bonds and water molecules in MDR HIV-1 protease substrate complexes
Biochem Biophys Res Commun430, 1022-1027. PubMed Europe PubMed DOI S
Louis,J.M., Tozser,J., Roche,J., Matuz,K., Aniana,A. and Sayer,J.M.
Enhanced stability of monomer fold correlates with extreme drug resistance of HIV-1 protease
Biochemistry52, 7678-7688. PubMed Europe PubMed DOI I
Mittal,S., Bandaranayake,R.M., King,N.M., Prabu-Jeyabalan,M., Nalam,M.N., Nalivaika,E.A., Kurt Yilmaz,N. and Schiffer,C.A.
Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50
J Virol87, 4176-4184. PubMed Europe PubMed DOI I
Naicker,P., Achilonu,I., Fanucchi,S., Fernandes,M., Ibrahim,M.A., Dirr,H.W., Soliman,M.E. and Sayed,Y.
Structural insights into the South African HIV-1 subtype C protease: impact of hinge region dynamics and flap flexibility in drug resistance
J Biomol Struct Dyn31, 1370-1380. PubMed Europe PubMed DOI S
Nalam,M.N., Ali,A., Reddy,G.S., Cao,H., Anjum,S.G., Altman,M.D., Yilmaz,N.K., Tidor,B., Rana,T.M. and Schiffer,C.A.
Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance
Chem Biol20, 1116-1124. PubMed Europe PubMed DOI I
Ni,Z., Chen,H., Qi,X. and Jin,R.
Why is substrate peptide binding unsusceptible to multidrug-resistant mutations in HIV-1 protease? A structural and energetic analysis
Int J Pept Res Ther20, 43-51. DOI I
Niu,B., Yuan,X.C., Roeper,P., Su,Q., Peng,C.R., Yin,J.Y., Ding,J., Li,H. and Lu,W.C.
HIV-1 protease cleavage site prediction based on two-stage feature selection method
Protein Pept Lett20, 290-298. PubMed Europe PubMed
Oehme,D.P., Brownlee,R.T. and Wilson,D.J.
Can cyclic HIV protease inhibitors bind in a non-preferred form? An ab initio, DFT and MM-PB(GB)SA study
J Mol Model19, 1125-1142. PubMed Europe PubMed DOI I
Ozturk,O., Aksac,A., Elsheikh,A., Ozyer,T. and Alhajj,R.
A consistency-based feature selection method allied with linear SVMs for HIV-1 protease cleavage site prediction
PLoS ONE8, e63145-e63145. PubMed Europe PubMed DOI
Pokorna,J., Heyda,J. and Konvalinka,J.
Ion specific effects of alkali cations on the catalytic activity of HIV-1 protease
Faraday Discuss160, 359-370. PubMed Europe PubMed DOI
Rabi,S.A., Laird,G.M., Durand,C.M., Laskey,S., Shan,L., Bailey,J.R., Chioma,S., Moore,R.D. and Siliciano,R.F.
Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance
J Clin Invest123, 3848-3860. PubMed Europe PubMed DOI I
Rout,M.K., Reddy,J.G., Phillips,M. and Hosur,R.V.
Single point mutation induced alterations in the equilibrium structural transitions on the folding landscape of HIV-1 protease
J Biomol Struct Dyn31, 684-693. PubMed Europe PubMed DOI
Salcedo Gomez,P.M., Amano,M., Yashchuk,S., Mizuno,A., Das,D., Ghosh,A.K. and Mitsuya,H.
GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration
Antimicrob Agents Chemother57, 6110-6121. PubMed Europe PubMed DOI I
Tiefenbrunn,T., Forli,S., Baksh,M.M., Chang,M.W., Happer,M., Lin,Y.C., Perryman,A.L., Rhee,J.K., Torbett,B.E., Olson,A.J., Elder,J.H., Finn,M.G. and Stout,C.D.
Small molecule regulation of protein conformation by binding in the flap of HIV protease
ACS Chem Biol8, 1223-1231. PubMed Europe PubMed DOI
Weber,I.T., Waltman,M.J., Mustyakimov,M., Blakeley,M.P., Keen,D.A., Ghosh,A.K., Langan,P. and Kovalevsky,A.Y.
Joint X-ray/neutron crystallographic study of HIV-1 protease with clinical inhibitor amprenavir: insights for drug design
J Med Chem56, 5631-5635. PubMed Europe PubMed DOI S I
Weikl,T.R. and Hemmateenejad,B.
How conformational changes can affect catalysis, inhibition and drug resistance of enzymes with induced-fit binding mechanism such as the HIV-1 protease
Biochim Biophys Acta1834, 867-873. PubMed Europe PubMed DOI
Yedidi,R.S., Maeda,K., Fyvie,W.S., Steffey,M., Davis,D.A., Palmer,I., Aoki,M., Kaufman,J.D., Stahl,S.J., Garimella,H., Das,D., Wingfield,P.T., Ghosh,A.K. and Mitsuya,H.
P2' benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moiety
Antimicrob Agents Chemother57, 4920-4927. PubMed Europe PubMed DOI I
Yedidi,R.S., Muhuhi,J.M., Liu,Z., Bencze,K.Z., Koupparis,K., O'Connor,C.E., Kovari,I.A., Spaller,M.R. and Kovari,L.C.
Design, synthesis and evaluation of a potent substrate analog inhibitor identified by scanning Ala/Phe mutagenesis, mimicking substrate co-evolution, against multidrug-resistant HIV-1 protease
Biochem Biophys Res Commun438, 703-708. PubMed Europe PubMed DOI I
Zhang,H., Wang,Y.F., Shen,C.H., Agniswamy,J., Rao,K.V., Xu,C.X., Ghosh,A.K., Harrison,R.W. and Weber,I.T.
Novel P2 tris-tetrahydrofuran group in antiviral compound 1 (GRL-0519) fills the S2 binding pocket of selected mutants of HIV-1 protease
J Med Chem56, 1074-1083. PubMed Europe PubMed DOI I

2012

Adamson,C.S.
Protease-mediated maturation of HIV: inhibitors of protease and the maturation process
Mol Biol Int2012, 604261-604261. PubMed Europe PubMed DOI I
Agniswamy,J., Shen,C.H., Aniana,A., Sayer,J.M., Louis,J.M. and Weber,I.T.
HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements
Biochemistry51, 2819-2828. PubMed Europe PubMed DOI I
Agniswamy,J., Sayer,J.M., Weber,I.T. and Louis,J.M.
Terminal Interface Conformations Modulate Dimer Stability Prior to Amino Terminal Autoprocessing of HIV-1 Protease
Biochemistry51, 1041-1050. PubMed Europe PubMed DOI I
Alvizo,O., Mittal,S., Mayo,S.L. and Schiffer,C.A.
Structural, kinetic, and thermodynamic studies of specificity designed HIV-1 protease
Protein Sci21, 1029-1041. PubMed Europe PubMed DOI P
Benedetti,F., Berti,F., Budal,S., Campaner,P., Dinon,F., Tossi,A., Argirova,R., Genova,P., Atanassov,V. and Hinkov,A.
Synthesis and biological activity of potent HIV-1 protease inhibitors based on Phe-Pro dihydroxyethylene isosteres
J Med Chem55, 3900-3910. PubMed Europe PubMed DOI I
Buzon,M.J., Erkizia,I., Pou,C., Minuesa,G., Puertas,M.C., Esteve,A., Castello,A., Santos,J.R., Prado,J.G., Izquierdo-Useros,N., Pattery,T., Van Houtte,M., Carrasco,L., Clotet,B., Ruiz,L. and Martinez-Picado,J.
A non-infectious cell-based phenotypic assay for the assessment of HIV-1 susceptibility to protease inhibitors
J Antimicrob Chemother67, 32-38. PubMed Europe PubMed DOI I
Cai,Y. and Schiffer,C.
Decomposing the energetic impact of drug-resistant mutations: the example of HIV-1 protease-DRV binding
Methods Mol Biol819, 551-560. PubMed Europe PubMed DOI I
Chang,Y.C., Yu,X., Zhang,Y., Tie,Y., Wang,Y.F., Yashchuk,S., Ghosh,A.K., Harrison,R.W. and Weber,I.T.
Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring
J Med Chem55, 3387-3397. PubMed Europe PubMed DOI I
Chiummiento,L., Funicello,M., Lupattelli,P., Tramutola,F., Berti,F. and Marino-Merlo,F.
Synthesis and biological evaluation of novel small non-peptidic HIV-1 PIs: the benzothiophene ring as an effective moiety
Bioorg Med Chem Lett22, 2948-2950. PubMed Europe PubMed DOI I
Davis,D.A., Soule,E.E., Davidoff,K.S., Daniels,S.I., Naiman,N.E. and Yarchoan,R.
Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing
Antimicrob Agents Chemother56, 3620-3628. PubMed Europe PubMed DOI I
Dominguez,J.L., Gossas,T., Carmen Villaverde,M., Helena Danielson,U. and Sussman,F.
Experimental and 'in silico' analysis of the effect of pH on HIV-1 protease inhibitor affinity: implications for the charge state of the protein ionogenic groups
Bioorg Med Chem20, 4838-4847. PubMed Europe PubMed DOI I
Dufau,L., Marques Ressurreicao,A.S., Fanelli,R., Kihal,N., Vidu,A., Milcent,T., Soulier,J.L., Rodrigo,J., Desvergne,A., Leblanc,K., Bernadat,G., Crousse,B., Reboud-Ravaux,M. and Ongeri,S.
Carbonylhydrazide-based molecular tongs inhibit wild-type and mutated HIV-1 protease dimerization
J Med Chem55, 6762-6775. PubMed Europe PubMed DOI I
Eissenstat,M., Guerassina,T., Gulnik,S., Afonina,E., Silva,A.M., Ludtke,D., Yokoe,H., Yu,B. and Erickson,J.
Enamino-oxindole HIV protease inhibitors
Bioorg Med Chem Lett22, 5078-5083. PubMed Europe PubMed DOI I
Ershov,P.V., Gnedenko,O.V., Molnar,A.A., Lisitsa,A.V., Ivanov,A.S. and Archakov,A.I.
Thermodynamic analysis of dimerization inhibitors binding to HIV protease monomers
Biomeditsinskaya Khim58, 43-49. I
Esseghaier,C., Ng,A. and Zourob,M.
A novel assay for rapid HIV-1 protease detection using optical sensors and magnetic carriers
Proc SPIE Int Soc Opt Eng8412, Article-Article. A
Flausino,O.A., Dufau,L., Regasini,L.O., Petronio,M.S., Silva,D.H., Rose,T., Bolzani,V.S. and Reboud-Ravaux,M.
Alkyl hydroxybenzoic acid derivatives that inhibit HIV-1 protease dimerization
Curr Med Chem19, 4534-4540. PubMed Europe PubMed DOI I
Ghosh,A.K., Chapsal,B.D., Steffey,M., Agniswamy,J., Wang,Y.F., Amano,M., Weber,I.T. and Mitsuya,H.
Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors
Bioorg Med Chem Lett22, 2308-2311. PubMed Europe PubMed DOI S I
Goldfarb,N.E. and Dunn,B.M.
Human immunodeficiency virus 1 retropepsin
[ISSN:978-0-12-407744-7]3, 190-199. DOI
Haidara,A., Chamberland,A., Sylla,M., Aboubacrine,S.A., Cisse,M., Traore,H.A., Maiga,M.Y., Tounkara,A., Nguyen,V.K. and Tremblay,C.L.
Drug resistance pathways and impact of protease mutation L10I/V in HIV-1 non-B subtypes
J Antivirals Antiretrovirals4, 43-50. DOI I
Hall,B.A., Wright,D.W., Jha,S. and Coveney,P.V.
Quantized water access to the HIV-1 protease active site as a proposed mechanism for cooperative mutations in drug affinity
Biochemistry51, 6487-6489. PubMed Europe PubMed DOI I
Henderson,G.J., Lee,S.K., Irlbeck,D.M., Harris,J., Kline,M., Pollom,E., Parkin,N. and Swanstrom,R.
Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity
Antimicrob Agents Chemother56, 623-633. PubMed Europe PubMed DOI
Honarparvar,B., Makatini,M.M., Pawar,S.A., Petzold,K., Soliman,M.E., Arvidsson,P.I., Sayed,Y., Govender,T., Maguire,G.E. and Kruger,H.G.
Pentacycloundecane-diol-based HIV-1 protease inhibitors: biological screening, 2D NMR, and molecular simulation studies
ChemMedChem7, 1009-1019. PubMed Europe PubMed DOI I
Huang,D. and Caflisch,A.
How does darunavir prevent HIV-1 protease dimerization?
J Chem Theory Comput8, 1786-1794. PubMed Europe PubMed DOI I
Huang,X., de Vera,I.M., Veloro,A.M., Blackburn,M.E., Kear,J.L., Carter,J.D., Rocca,J.R., Simmerling,C., Dunn,B.M. and Fanucci,G.E.
Inhibitor-induced conformational shifts and ligand-exchange dynamics for HIV-1 protease measured by pulsed EPR and NMR spectroscopy
J Phys Chem B116, 14235-14244. PubMed Europe PubMed DOI I
Impens,F., Timmerman,E., Staes,A., Moens,K., Arien,K.K., Verhasselt,B., Vandekerckhove,J. and Gevaert,K.
A catalogue of putative HIV-1 protease host cell substrates
Biol Chem393, 915-931. PubMed Europe PubMed DOI P
Kar,P. and Knecht,V.
Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir
J Comput Aided Mol Des26, 215-232. PubMed Europe PubMed DOI I
Karpoormath,R., Sayed,Y., Govender,P., Govender,T., Kruger,H.G., Soliman,M.E. and Maguire,G.E.
Pentacycloundecane derived hydroxy acid peptides: a new class of irreversible non-scissile ether bridged type isoster as potential HIV-1 wild type C-SA protease inhibitors
Bioorg Chem40, 19-29. PubMed Europe PubMed DOI I
Kimura,S., Broglia,R.A. and Tiana,G.
Thermodynamics of strongly allosteric inhibition: a model study of HIV-1 protease
Eur Biophys J41, 991-1001. PubMed Europe PubMed DOI I
King,N.M., Prabu-Jeyabalan,M., Bandaranayake,R.M., Nalam,M.N., Nalivaika,E.A., Ozen,A., Haliloglu,T., Yilmaz,N.K. and Schiffer,C.A.
Extreme entropy-enthalpy compensation in a drug-resistant variant of HIV-1 protease
ACS Chem Biol7, 1536-1546. PubMed Europe PubMed DOI
Kitidee,K., Nangola,S., Hadpech,S., Laopajon,W., Kasinrerk,W. and Tayapiwatana,C.
A drug discovery platform: a simplified immunoassay for analyzing HIV protease activity
J Virol Methods186, 21-29. PubMed Europe PubMed DOI I
Kozisek,M., Henke,S., Saskova,K.G., Jacobs,G.B., Schuch,A., Buchholz,B., Muller,V., Krausslich,H.G., Rezacova,P., Konvalinka,J. and Bodem,J.
Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease
Antimicrob Agents Chemother56, 4320-4330. PubMed Europe PubMed DOI
Lee,S.K., Potempa,M., Kolli,M., Ozen,A., Schiffer,C.A. and Swanstrom,R.
Context surrounding processing sites is crucial in determining cleavage rate of a subset of processing sites in HIV-1 Gag and Gag-Pro-Pol polyprotein precursors by viral protease
J Biol Chem287, 13279-13290. PubMed Europe PubMed DOI P
Lemmon,G., Kaufmann,K. and Meiler,J.
Prediction of HIV-1 protease/inhibitor affinity using RosettaLigand
Chem Biol Drug Des79, 888-896. PubMed Europe PubMed DOI I
Li,D., Han,J.G., Chen,H., Li,L., Zhao,R.N., Liu,G. and Duan,Y.
Insights into the structural function of the complex of HIV-1 protease with TMC-126: molecular dynamics simulations and free-energy calculations
J Mol Model18, 1841-1854. PubMed Europe PubMed DOI I
Li,D., Liu,M.S., Ji,B., Hwang,K.C. and Huang,Y.
Identifying the molecular mechanics and binding dynamics characteristics of potent inhibitors to HIV-1 protease
Chem Biol Drug Des80, 440-454. PubMed Europe PubMed DOI I
Liu,X., Gan,M., Dong,B., Zhang,T., Li,Y., Zhang,Y., Fan,X., Wu,Y., Bai,S., Chen,M., Yu,L., Tao,P., Jiang,W. and Si,S.
4862F, a new inhibitor of HIV-1 protease, from the culture of Streptomyces I03A-04862
Molecules18, 236-243. PubMed Europe PubMed DOI I
Matuz,K., Motyan,J., Li,M., Wlodawer,A. and Tozser,J.
Inhibition of XMRV and HIV-1 proteases by pepstatin A and acetyl-pepstatin
FEBS J279, 3276-3286. PubMed Europe PubMed DOI I
Meher,B.R. and Wang,Y.
Interaction of I50V mutant and I50L/A71V double mutant HIV-protease with inhibitor TMC114 (darunavir): molecular dynamics simulation and binding free energy studies
J Phys Chem B116, 1884-1900. PubMed Europe PubMed DOI I
Meher,B.R., Satish Kumar,M.V., Sharma,S. and Bandyopadhyay,P.
Conformational dynamics of HIV-1 protease: a comparative molecular dynamics simulation study with multiple AMBER force fields
J Bioinform Comput Biol10, 1250018-1250018. PubMed Europe PubMed DOI
Mittal,S., Cai,Y., Nalam,M.N., Bolon,D.N. and Schiffer,C.A.
Hydrophobic core flexibility modulates enzyme activity in HIV-1 protease
J Am Chem Soc134, 4163-4168. PubMed Europe PubMed DOI
Oehme,D.P., Brownlee,R.T. and Wilson,D.J.
Effect of atomic charge, solvation, entropy, and ligand protonation state on MM-PB(GB)SA binding energies of HIV protease
J Comput Chem33, 2566-2580. PubMed Europe PubMed DOI
Palma,A.C., Covens,K., Snoeck,J., Vandamme,A.M., Camacho,R.J. and Van Laethem,K.
HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G
J Antimicrob Chemother67, 1075-1079. PubMed Europe PubMed DOI M
Pan,Y.Y., Wang,S.M., Huang,K.J., Chiang,C.C. and Wang,C.T.
Placement of leucine zipper motifs at the carboxyl terminus of HIV-1 protease significantly reduces virion production
PLoS ONE7, e32845-e32845. PubMed Europe PubMed DOI
Pawar,S.A., Jabgunde,A.M., Govender,P., Maguire,G.E., Kruger,H.G., Parboosing,R., Soliman,M.E., Sayed,Y., Dhavale,D.D. and Govender,T.
Synthesis and molecular modelling studies of novel carbapeptide analogs for inhibition of HIV-1 protease
Eur J Med Chem53, 13-21. PubMed Europe PubMed DOI I
Sadiq,S.K., Noe,F. and De Fabritiis,G.
Kinetic characterization of the critical step in HIV-1 protease maturation
Proc Natl Acad Sci U S A109, 20449-20454. PubMed Europe PubMed DOI
Santos,J.R., Llibre,J.M., Imaz,A., Domingo,P., Iribarren,J.A., Marino,A., Miralles,C., Galindo,M.J., Ornelas,A., Moreno,S., Schapiro,J.M. and Clotet,B.
Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens
J Antimicrob Chemother67, 1462-1469. PubMed Europe PubMed DOI I
Saranya,N. and Selvaraj,S.
QSAR studies on HIV-1 protease inhibitors using non-linearly transformed descriptors
Curr Comput Aided Drug Des8, 10-49. PubMed Europe PubMed DOI I
Schimer,J., Cigler,P., Vesely,J., Grantz Saskova,K., Lepsik,M., Brynda,J., Rezacova,P., Kozisek,M., Cisarova,I., Oberwinkler,H., Kraeusslich,H.G. and Konvalinka,J.
Structure-aided design of novel inhibitors of HIV protease based on a benzodiazepine scaffold
J Med Chem55, 10130-10135. PubMed Europe PubMed DOI I
Shen,C.H., Tie,Y., Yu,X., Wang,Y.F., Kovalevsky,A.Y., Harrison,R.W. and Weber,I.T.
Capturing the reaction pathway in near-atomic-resolution crystal structures of HIV-1 protease
Biochemistry51, 7726-7732. PubMed Europe PubMed DOI S
Tang,M.W., Liu,T.F. and Shafer,R.W.
The HIVdb system for HIV-1 genotypic resistance interpretation
Intervirology55, 98-101. PubMed Europe PubMed DOI
Torbeev,V.Y. and Kent,S.B.
Ionization state of the catalytic dyad Asp25/25' in the HIV-1 protease: NMR studies of site-specifically 13C labelled HIV-1 protease prepared by total chemical synthesis
Org Biomol Chem10, 5887-5891. PubMed Europe PubMed DOI
Wu,X., Ohrngren,P., Joshi,A.A., Trejos,A., Persson,M., Arvela,R.K., Wallberg,H., Vrang,L., Rosenquist,A., Samuelsson,B.B., Unge,J. and Larhed,M.
Synthesis, X-ray analysis, and biological evaluation of a new class of stereopure lactam-based HIV-1 protease inhibitors
J Med Chem55, 2724-2736. PubMed Europe PubMed DOI I
Yadav,D., Paliwal,S., Yadav,R., Pal,M. and Pandey,A.
Identification of novel HIV 1-protease inhibitors: application of ligand and structure based pharmacophore mapping and virtual screening
PLoS ONE7, e48942-e48942. PubMed Europe PubMed DOI I
Yan,J., Huang,N., Li,S., Yang,L.M., Xing,W., Zheng,Y.T. and Hu,Y.
Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors
Bioorg Med Chem Lett22, 1976-1979. PubMed Europe PubMed DOI I
Yang,H., Nkeze,J. and Zhao,R.Y.
Effects of HIV-1 protease on cellular functions and their potential applications in antiretroviral therapy
Cell Biosci2, 32-32. PubMed Europe PubMed DOI I
Yedidi,R.S., Liu,Z., Wang,Y., Brunzelle,J.S., Kovari,I.A., Woster,P.M., Kovari,L.C. and Gupta,D.
Crystal structures of multidrug-resistant HIV-1 protease in complex with two potent anti-malarial compounds
Biochem Biophys Res Commun421, 413-417. PubMed Europe PubMed DOI S I
Ziolkowska,N.E., Bujacz,A., Randad,R.S., Erickson,J.W., Skalova,T., Hasek,J. and Bujacz,G.
New active HIV-1 protease inhibitors derived from 3-hexanol: conformation study of the free inhibitors in crystalline state and in complex with the enzyme
Chem Biol Drug Des79, 798-809. PubMed Europe PubMed DOI I

2011

Batista,P.R., Pandey,G., Pascutti,P.G., Bisch,P.M., Perahia,D. and Robert,C.H.
Free energy profiles along consensus normal modes provide insight into HIV-1 protease flap opening
J Chem Theory Comput7, 2348-2352. PubMed Europe PubMed DOI
Biswas,P., Cella,L.N., Kang,S.H., Mulchandani,A., Yates,M.V. and Chen,W.
A quantum-dot based protein module for in vivo monitoring of protease activity through fluorescence resonance energy transfer
Chem Commun (Camb)47, 5259-5261. PubMed Europe PubMed DOI A
Blum,A., Bottcher,J., Dorr,S., Heine,A., Klebe,G. and Diederich,W.E.
Two solutions for the same problem: multiple binding modes of pyrrolidine-based HIV-1 protease inhibitors
J Mol Biol410, 745-755. PubMed Europe PubMed DOI S I
Borkar,A.N., Rout,M.K. and Hosur,R.V.
Visualization of early events in acetic acid denaturation of HIV-1 protease: a molecular dynamics study
PLoS ONE6, e19830-e19830. PubMed Europe PubMed DOI
Breuer,S., Sepulveda,H., Chen,Y., Trotter,J. and Torbett,B.E.
A cleavage enzyme-cytometric bead array provides biochemical profiling of resistance mutations in HIV-1 gag and protease
Biochemistry50, 4371-4381. PubMed Europe PubMed DOI A
Callebaut,C., Stray,K., Tsai,L., Williams,M., Yang,Z.Y., Cannizzaro,C., Leavitt,S.A., Liu,X., Wang,K., Murray,B.P., Mulato,A., Hatada,M., Priskich,T., Parkin,N., Swaminathan,S., Lee,W., He,G.X., Xu,L. and Cihlar,T.
In vitro characterization of GS-8374, a novel phosphonate-containing inhibitor of HIV-1 protease with a favorable resistance profile
Antimicrob Agents Chemother55, 1366-1376. PubMed Europe PubMed DOI I
Chang,M.W. and Torbett,B.E.
Accessory mutations maintain stability in drug-resistant HIV-1 protease
J Mol Biol410, 756-760. PubMed Europe PubMed DOI I
Degoey,D.A., Grampovnik,D.J., Chen,H.J., Flosi,W.J., Klein,L.L., Dekhtyar,T., Stoll,V., Mamo,M., Molla,A. and Kempf,D.J.
P1-Substituted symmetry-based human immunodeficiency virus protease inhibitors with potent antiviral activity against drug-resistant viruses
J Med Chem54, 7094-7104. PubMed Europe PubMed DOI I
Deng,N.J., Zheng,W., Gallicchio,E. and Levy,R.M.
Insights into the dynamics of HIV-1 protease: a kinetic network model constructed from atomistic simulations
J Am Chem Soc133, 9387-9394. PubMed Europe PubMed DOI
Dierynck,I., Van Marck,H., Van Ginderen,M., Jonckers,T.H., Nalam,M.N., Schiffer,C.A., Raoof,A., Kraus,G. and Picchio,G.
TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors
Antimicrob Agents Chemother55, 5723-5731. PubMed Europe PubMed DOI I
Elgadi,M.M. and Piliero,P.J.
Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial
Drugs R D11, 295-302. PubMed Europe PubMed DOI I
Ferreira,L.G., Leitao,A., Montanari,C.A. and Andricopulo,A.D.
Comparative molecular field analysis of a series of inhibitors of HIV-1 protease
Med Chem7, 71-79. PubMed Europe PubMed I
Flor-Parra,F., Perez-Pulido,A.J., Pachon,J. and Perez-Romero,P.
The HIV type 1 protease L10I minor mutation decreases replication capacity and confers resistance to protease inhibitors
AIDS Res Hum Retroviruses27, 65-70. PubMed Europe PubMed DOI
Ganguly,A.K., Alluri,S.S., Caroccia,D., Biswas,D., Wang,C.H., Kang,E., Zhang,Y., McPhail,A.T., Carroll,S.S., Burlein,C., Munshi,V., Orth,P. and Strickland,C.
Design, synthesis, and X-ray crystallographic analysis of a novel class of HIV-1 protease inhibitors
J Med Chem54, 7176-7183. PubMed Europe PubMed DOI S I
Gao,B.L., Zhang,C.M., Yin,Y.Z., Tang,L.Q. and Liu,Z.P.
Design and synthesis of potent HIV-1 protease inhibitors incorporating hydroxyprolinamides as novel P2 ligands
Bioorg Med Chem Lett21, 3730-3733. PubMed Europe PubMed DOI I
Ghosh,A.K., Chapsal,B.D., Parham,G.L., Steffey,M., Agniswamy,J., Wang,Y.F., Amano,M., Weber,I.T. and Mitsuya,H.
Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure
J Med Chem54, 5890-5901. PubMed Europe PubMed DOI S I
Ghosh,A.K. and Anderson,D.D.
Tetrahydrofuran, tetrahydropyran, triazoles and related heterocyclic derivatives as HIV protease inhibitors
Future Med Chem3, 1181-1197. PubMed Europe PubMed DOI I
Ghosh,A.K., Chapsal,B.D., Baldridge,A., Steffey,M.P., Walters,D.E., Koh,Y., Amano,M. and Mitsuya,H.
Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation
J Med Chem54, 622-634. PubMed Europe PubMed DOI I
Ghosh,A.K., Martyr,C.D., Steffey,M., Wang,Y.F., Agniswamy,J., Amano,M., Weber,I.T. and Mitsuya,H.
Design of substituted bis-tetrahydrofuran (bis-THF)-derived potent HIV-1 protease inhibitors, protein-ligand X-ray structure, and convenient syntheses of bis-THF and substituted bis-THF ligands
ACS Med Chem Lett2, 298-302. PubMed Europe PubMed DOI S I
Grotto,R.M., Corvino,S.M., Munhoz,L., Ghedini,C.G. and Pardini,M.I.
A first case of protease codon 35 amino acid insertion in a HIV-1 subtype B sequence detected in the Bauru region, state of Sao Paulo, Brazil: case report
Rev Soc Bras Med Trop44, 392-394. PubMed Europe PubMed M
Hallengard,D., Haller,B.K., Petersson,S., Boberg,A., Maltais,A.K., Isaguliants,M., Wahren,B. and Brave,A.
Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity
Vaccine29, 839-848. PubMed Europe PubMed DOI
Heal,J.W., Wells,S.A., Jimenez-Roldan,E., Freedman,R.F. and Romer,R.A.
Rigidity analysis of HIV-1 protease
J Phys Conf Ser286, 012006-012006. DOI
Huang,L., Li,Y. and Chen,C.
Flexible catalytic site conformations implicated in modulation of HIV-1 protease autoprocessing reactions
Retrovirology8, 79-79. PubMed Europe PubMed DOI
Ide,K., Aoki,M., Amano,M., Koh,Y., Yedidi,R.S., Das,D., Leschenko,S., Chapsal,B., Ghosh,A.K. and Mitsuya,H.
Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants
Antimicrob Agents Chemother55, 1717-1727. PubMed Europe PubMed DOI I
Jin,S., Ellis,E., Veetil,J.V., Yao,H. and Ye,K.
Visualization of human immunodeficiency virus protease inhibition using a novel Forster resonance energy transfer molecular probe
Biotechnol Prog27, 1107-1114. PubMed Europe PubMed DOI A
Karthik,S. and Senapati,S.
Dynamic flaps in HIV-1 protease adopt unique ordering at different stages in the catalytic cycle
Proteins79, 1830-1840. PubMed Europe PubMed DOI
Kipp,D.R., Silva,R.G. and Schramm,V.L.
Mass-dependent bond vibrational dynamics influence catalysis by HIV-1 protease
J Am Chem Soc133, 19358-19361. PubMed Europe PubMed DOI
Koh,Y., Aoki,M., Danish,M.L., Aoki-Ogata,H., Amano,M., Das,D., Shafer,R.W., Ghosh,A.K. and Mitsuya,H.
Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1
J Virol85, 10079-10089. PubMed Europe PubMed DOI I
Kuznetsov,N.A., Kozyr,A.V., Dronina,M.A., Smirnov,I.V., Kaliberda,E.N., Mikhailova,A.G., Rumsh,L.D., Fedorova,O.S., Gabibov,A.G. and Kolesnikov,A.V.
Pre-steady-state kinetics of interaction of wild-type and multiple drug-resistant HIV protease with first and second generation inhibitory drugs
Dokl Biochem Biophys440, 239-243. PubMed Europe PubMed DOI I
Lexa,K.W. and Carlson,H.A.
Binding to the open conformation of HIV-1 protease
Proteins79, 2282-2290. PubMed Europe PubMed DOI S
Li,D., Ji,B., Hwang,K.C. and Huang,Y.
Strength of hydrogen bond network takes crucial roles in the dissociation process of inhibitors from the HIV-1 protease binding pocket
PLoS ONE6, e19268-e19268. PubMed Europe PubMed DOI I
Liu,X., Dai,Q., Li,L. and Xiu,Z.
Resistant mechanism against nelfinavir of subtype C human immunodeficiency virus type 1 proteases
J Mol Struct986, 30-38. DOI I
Liu,Z., Wang,Y., Brunzelle,J., Kovari,I.A. and Kovari,L.C.
Nine crystal structures determine the substrate envelope of the MDR HIV-1 protease
Protein J30, 173-183. PubMed Europe PubMed DOI S I
Louis,J.M., Zhang,Y., Sayer,J.M., Wang,Y.F., Harrison,R.W. and Weber,I.T.
The L76V drug resistance mutation decreases the dimer stability and rate of autoprocessing of HIV-1 protease by reducing internal hydrophobic contacts
Biochemistry50, 4786-4795. PubMed Europe PubMed DOI S
Magiorkinis,E., Paraskevis,D., Detsika,M.G., Lu,L., Magiorkinis,G., Lazanas,M., Imbrechts,S., Van Laethem,K., Vandamme,A.M., Pilot-Matias,T., Molla,A., Camacho,R.J. and Hatzakis,A.
Appearance of a single amino acid insertion at position 33 in HIV type 1 protease under a lopinavir-containing regimen, associated with reduced protease inhibitor susceptibility
AIDS Res Hum Retroviruses27, 1223-1229. PubMed Europe PubMed DOI M I
Makatini,M.M., Petzold,K., Sriharsha,S.N., Ndlovu,N., Soliman,M.E., Honarparvar,B., Parboosing,R., Naidoo,A., Arvidsson,P.I., Sayed,Y., Govender,P., Maguire,G.E., Kruger,H.G. and Govender,T.
Synthesis and structural studies of pentacycloundecane-based HIV-1 PR inhibitors: a hybrid 2D NMR and docking/QM/MM/MD approach
Eur J Med Chem46, 3976-3985. PubMed Europe PubMed DOI I
Mao,Y.
Dynamical basis for drug resistance of HIV-1 protease
BMC Struct Biol11, 31-31. PubMed Europe PubMed DOI I
Neogi,U., Sahoo,P.N., Kumar,R., De Costa,A. and Shet,A.
Characterization of HIV type 1 subtype C protease gene: selection of L63P mutation in protease inhibitor-naive Indian patients
AIDS Res Hum Retroviruses27, 1249-1253. PubMed Europe PubMed DOI
Nishitsuji,H., Yokoyama,M., Sato,H., Yamauchi,S. and Takaku,H.
Identification of amino acid residues in HIV-1 reverse transcriptase that are critical for the proteolytic processing of Gag-Pol precursors
FEBS Lett585, 3372-3377. PubMed Europe PubMed DOI P
Oehme,D.P., Wilson,D.J. and Brownlee,R.T.
Effect of structural stress on the flexibility and adaptability of HIV-1 protease
J Chem Inf Model51, 1064-1073. PubMed Europe PubMed DOI
Ohrngren,P., Wu,X., Persson,M., Ekegren,J.K., Wallberg,H., Vrang,L., Rosenquist,A., Samuelsson,B., Unge,T. and Larhed,M.
HIV-1 protease inhibitors with a tertiary alcohol containing transition-state mimic and various P2 and P1' substituents
MedChemComm2, 701-709. DOI I
Olajuyigbe,F., Demitri,N. and Geremia,S.
Investigation of 2-fold disorder of inhibitors and relative potency by crystallizations of HIV-1 protease in ritonavir and saquinavir mixtures
Cryst Growth Des11, 4378-4385. DOI I
Ozen,A., Haliloglu,T. and Schiffer,C.A.
Dynamics of preferential substrate recognition in HIV-1 protease: redefining the substrate envelope
J Mol Biol410, 726-744. PubMed Europe PubMed DOI P
Pecina,A., Prenosil,O., Fanfrlik,J., Rezac,J., Granatier,J., Hobza,P. and Lepsik,M.
On the reliability of the corrected semiempirical quantum chemical method (PM6-DH2) for assigning the protonation states in HIV-1 protease/inhibitor complexes
Collect Czech Chem Commun76, 457-479. DOI I
Pizzocolo,C., Castagna,A. and Lazzarin,A.
HIV protease inhibitors: present and future
Future Virol6, 571-580. DOI V I
Purohit,R., Rajendran,V. and Sethumadhavan,R.
Studies on adaptability of binding residues and flap region of TMC-114 resistance HIV-1 protease mutants
J Biomol Struct Dyn29, 137-152. PubMed Europe PubMed DOI I
Rajapakse,H.A., Walji,A.M., Moore,K.P., Zhu,H., Mitra,A.W., Gregro,A.R., Tinney,E., Burlein,C., Touch,S., Paton,B.L., Carroll,S.S., Distefano,D.J., Lai,M.T., Grobler,J.A., Sanchez,R.I., Williams,T.M., Vacca,J.P. and Nantermet,P.G.
Strategies towards improving the pharmacokinetic profile of epsilon-substituted lysinol-derived HIV protease inhibitors
ChemMedChem6, 253-257. PubMed Europe PubMed DOI I
Ravichandran,V., Mourya,V.K. and Agrawal,R.K.
Prediction of HIV-1 protease inhibitory activity of 4-hydroxy-5,6-dihydropyran-2-ones: QSAR study
J Enzyme Inhib Med Chem26, 288-294. PubMed Europe PubMed DOI I
Rucker,P., Horn,A.H.C., Meiselbach,H. and Sticht,H.
A comparative study of HIV-1 and HTLV-I protease structure and dynamics reveals a conserved residue interaction network
J Mol Model17, 2693-2705. PubMed Europe PubMed DOI
Santos,A.F. and Soares,M.A.
The impact of the nelfinavir resistance-conferring mutation D30N on the susceptibility of HIV-1 subtype B to other protease inhibitors
Mem Inst Oswaldo Cruz106, 177-181. PubMed Europe PubMed M I
Singh,M.K., Streu,K., McCrone,A.J. and Dominy,B.N.
The evolution of catalytic function in the HIV-1 protease
J Mol Biol408, 792-805. PubMed Europe PubMed DOI
Torbeev,V.Y., Raghuraman,H., Hamelberg,D., Tonelli,M., Westler,W.M., Perozo,E. and Kent,S.B.
Protein conformational dynamics in the mechanism of HIV-1 protease catalysis
Proc Natl Acad Sci U S A108, 20982-20987. PubMed Europe PubMed DOI
Torbeev,V.Y., Myong,S.A., Ha,T. and Kent,S.B.H.
Single-molecule studies of HIV-1 protease catalysis enabled by chemical protein synthesis
Isr J Chem51, 960-967. DOI
Tzoupis,H., Leonis,G., Durdagi,S., Mouchlis,V., Mavromoustakos,T. and Papadopoulos,M.G.
Binding of novel fullerene inhibitors to HIV-1 protease: insight through molecular dynamics and molecular mechanics Poisson-Boltzmann surface area calculations
J Comput Aided Mol Des25, 959-976. PubMed Europe PubMed DOI I
Ungwitayatorn,J., Wiwat,C., Samee,W., Nunthanavanit,P. and Phosrithong,N.
Synthesis, in vitro evaluation, and docking studies of novel chromone derivatives as HIV-1 protease inhibitor
J Mol Struct100, 152-161. DOI I
Volonte,F., Piubelli,L. and Pollegioni,L.
Optimizing HIV-1 protease production in Escherichia coli as fusion protein
Microb Cell Fact10, 53-53. PubMed Europe PubMed DOI E
Wang,Y., Liu,Z., Brunzelle,J.S., Kovari,I.A., Dewdney,T.G., Reiter,S.J. and Kovari,L.C.
The higher barrier of darunavir and tipranavir resistance for HIV-1 protease
Biochem Biophys Res Commun412, 737-742. PubMed Europe PubMed DOI I
Weber,I.T. and Wang,Y.
HIV-1 protease: role in viral replication, protein-ligand x-ray crystal structures and inhibitor design
Aspartic Acid Proteases as Therapeutic Targets45, 107-137. DOI
Wright,D.W. and Coveney,P.V.
Resolution of discordant HIV-1 protease resistance rankings using molecular dynamics simulations
J Chem Inf Model51, 2636-2649. PubMed Europe PubMed DOI I
Yedidi,R.S., Proteasa,G., Martinez,J.L., Vickrey,J.F., Martin,P.D., Wawrzak,Z., Liu,Z., Kovari,I.A. and Kovari,L.C.
Contribution of the 80s loop of HIV-1 protease to the multidrug-resistance mechanism: crystallographic study of MDR769 HIV-1 protease variants
Acta Crystallogr D Biol Crystallogr67, 524-532. PubMed Europe PubMed DOI S

2010

Adrian Meredith,J., Wallberg,H., Vrang,L., Oscarson,S., Parkes,K., Hallberg,A. and Samuelsson,B.
Design and synthesis of novel P2 substituents in diol-based HIV protease inhibitors
Eur J Med Chem45, 160-170. PubMed Europe PubMed DOI I
Ali,A., Reddy,G.S., Nalam,M.N., Anjum,S.G., Cao,H., Schiffer,C.A. and Rana,T.M.
Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones
J Med Chem53, 7699-7708. PubMed Europe PubMed DOI I
Ali,A., Bandaranayake,R.M., Cai,Y., King,N.M., Kolli,M., Mittal,S., Murzycki,J.F., Nalam,M.N.L., Nalivaika,E.A., Ozen,A., Prabu-Jeyabalan,M.M., Thayer,K. and Schiffer,C.A.
Molecular basis for drug resistance in HIV-1 protease
Viruses2, 2509-2535. PubMed Europe PubMed DOI I
Bonini,C., Chiummiento,L., De Bonis,M., Di Blasio,N., Funicello,M., Lupattelli,P., Pandolfo,R., Tramutola,F. and Berti,F.
Synthesis of new thienyl ring containing HIV-1 protease inhibitors: promising preliminary pharmacological evaluation against recombinant HIV-1 proteases
J Med Chem53, 1451-1457. PubMed Europe PubMed DOI I
Bonomi,M., Barducci,A., Gervasio,F.L. and Parrinello,M.
Multiple routes and milestones in the folding of HIV-1 protease monomer
PLoS ONE5, e13208-e13208. PubMed Europe PubMed DOI
Chang,M.W., Giffin,M.J., Muller,R., Savage,J., Lin,Y.C., Hong,S., Jin,W., Whitby,L.R., Elder,J.H., Boger,D.L. and Torbett,B.E.
Identification of broad-based HIV-1 protease inhibitors from combinatorial libraries
Biochem J429, 527-532. PubMed Europe PubMed DOI I
Chen,J., Zhang,S., Liu,X. and Zhang,Q.
Insights into drug resistance of mutations D30N and I50V to HIV-1 protease inhibitor TMC-114: free energy calculation and molecular dynamic simulation
J Mol Model16, 459-468. PubMed Europe PubMed DOI I
Choi,Y., Lee,J., Kim,K., Kim,H., Sommer,P. and Song,R.
Fluorogenic assay and live cell imaging of HIV-1 protease activity using acid-stable quantum dot-peptide complex
Chem Commun (Camb)46, 9146-9148. PubMed Europe PubMed DOI A L
Coburger,C., Lage,H., Molnar,J., Langner,A. and Hilgeroth,A.
Multidrug resistance reversal properties and cytotoxic evaluation of representatives of a novel class of HIV-1 protease inhibitors
J Pharm Pharmacol62, 1704-1710. PubMed Europe PubMed DOI I
Das,A., Mahale,S., Prashar,V., Bihani,S., Ferrer,J.L. and Hosur,M.V.
X-ray snapshot of HIV-1 protease in action: observation of tetrahedral intermediate and short ionic hydrogen bond SIHB with catalytic aspartate
J Am Chem Soc132, 6366-6373. PubMed Europe PubMed DOI S I
Dirauf,P., Meiselbach,H. and Sticht,H.
Effects of the V82A and I54V mutations on the dynamics and ligand binding properties of HIV-1 protease
J Mol Model16, 1577-1583. PubMed Europe PubMed DOI I
Friedman,R. and Caflisch,A.
On the orientation of the catalytic dyad in aspartic proteases
Proteins78, 1575-1582. PubMed Europe PubMed DOI S
Ghosh,A.K., Gemma,S., Simoni,E., Baldridge,A., Walters,D.E., Ide,K., Tojo,Y., Koh,Y., Amano,M. and Mitsuya,H.
Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands
Bioorg Med Chem Lett20, 1241-1246. PubMed Europe PubMed DOI I
Ghosh,A.K., Xu,C.X., Rao,K.V., Baldridge,A., Agniswamy,J., Wang,Y.F., Weber,I.T., Aoki,M., Miguel,S.G., Amano,M. and Mitsuya,H.
Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors
ChemMedChem5, 1850-1854. PubMed Europe PubMed DOI I
Hamacher,K.
Temperature dependence of fluctuations in HIV1-protease
Eur Biophys J39, 1051-1056. PubMed Europe PubMed DOI
Hao,G.F., Yang,G.F. and Zhan,C.G.
Computational mutation scanning and drug resistance mechanisms of HIV-1 protease inhibitors
J Phys Chem B114, 9663-9676. PubMed Europe PubMed DOI I
He,M., Zhang,H., Yao,X., Eckart,M., Zuo,E. and Yang,M.
Design, biologic evaluation, and SAR of novel pseudo-peptide incorporating benzheterocycles as HIV-1 protease inhibitors
Chem Biol Drug Des76, 174-180. PubMed Europe PubMed DOI I
He,M., Yang,N., Sun,C., Yao,X. and Yang,M.
Modification and biological evaluation of novel 4-hydroxy-pyrone derivatives as non-peptidic HIV-1 protease inhibitors
Med Chem Res20, 200-209. DOI I
Hilton,B.J. and Wolkowicz,R.
An assay to monitor HIV-1 protease activity for the identification of novel inhibitors in T-cells
PLoS ONE5, e10940-e10940. PubMed Europe PubMed DOI A
Hu,G.D., Zhu,T., Zhang,S.L., Wang,D. and Zhang,Q.G.
Some insights into mechanism for binding and drug resistance of wild type and I50V V82A and I84V mutations in HIV-1 protease with GRL-98065 inhibitor from molecular dynamic simulations
Eur J Med Chem45, 227-235. PubMed Europe PubMed DOI I
Huang,L., Hall,A. and Chen,C.
Cysteine 95 and other residues influence the regulatory effects of histidine 69 mutations on human immunodeficiency virus type 1 protease autoprocessing
Retrovirology7, 24-24. PubMed Europe PubMed DOI
Ishima,R., Gong,Q., Tie,Y., Weber,I.T. and Louis,J.M.
Highly conserved glycine 86 and arginine 87 residues contribute differently to the structure and activity of the mature HIV-1 protease
Proteins78, 1015-1025. PubMed Europe PubMed DOI S
Johnson,V.A., Brun-Vezinet,F., Clotet,B., Gunthard,H.F., Kuritzkes,D.R., Pillay,D., Schapiro,J.M. and Richman,D.D.
Update of the drug resistance mutations in HIV-1: December 2010
Top HIV Med18, 156-163. PubMed Europe PubMed
Jones,K.L., Holloway,M.K., Su,H.P., Carroll,S.S., Burlein,C., Touch,S., Distefano,D.J., Sanchez,R.I., Williams,T.M., Vacca,J.P. and Coburn,C.A.
Epsilon substituted lysinol derivatives as HIV-1 protease inhibitors
Bioorg Med Chem Lett20, 4065-4068. PubMed Europe PubMed DOI I
Khedkar,V.M., Ambre,P.K., Verma,J., Shaikh,M.S., Pissurlenkar,R.R.S. and Coutinho,E.C.
Molecular docking and 3D-QSAR studies of HIV-1 protease inhibitors
J Mol Model16, 1251-1268. PubMed Europe PubMed DOI I
Kim,K.S., Jin,D.B., Ahn,S.S., Park,K.S., Seo,S.H., Suh,Y.S. and Sung,Y.C.
HIV-1 protease has a genetic T-cell adjuvant effect which is negatively regulated by proteolytic activity
J Virol84, 7743-7749. PubMed Europe PubMed DOI
Knops,E., Kemper,I., Schulter,E., Pfister,H., Kaiser,R. and Verheyen,J.
The evolution of protease mutation 76V is associated with protease mutation 46I and gag mutation 431V
AIDS24, 779-781. PubMed Europe PubMed DOI
Lee,S.G. and Chmielewski,J.
Cross-linked peptoid-based dimerization inhibitors of HIV-1 protease
Chembiochem11, 1513-1516. PubMed Europe PubMed DOI I
Lentini,A., Tabolacci,C., Melino,S., Provenzano,B. and Beninati,S.
Post-translational modification of glutamine and lysine residues of HIV-1 aspartyl protease by transglutaminase increases its catalytic activity
Biochem Biophys Res Commun393, 546-550. PubMed Europe PubMed DOI
Li,D., Ji,B., Hwang,K. and Huang,Y.
Crucial roles of the subnanosecond local dynamics of the flap tips in the global conformational changes of HIV-1 protease
J Phys Chem B114, 3060-3069. PubMed Europe PubMed DOI
Li,X., Hu,H. and Shu,L.
Predicting human immunodeficiency virus protease cleavage sites in nonlinear projection space
Mol Cell Biochem339, 127-133. PubMed Europe PubMed DOI
Lin,Y.C., Huang,Y.M. and Leu,J.J.Y.
A new logic correlation rule for HIV-1 protease mutation
Expert Syst Appl38, 5448-5455. DOI I
Lisovsky,I., Schader,S.M., Martinez-Cajas,J.L., Oliveira,M., Moisi,D. and Wainberg,M.A.
HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes
Antimicrob Agents Chemother54, 2878-2885. PubMed Europe PubMed DOI I
Lu,D., Sham,Y.Y. and Vince,R.
Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease
Bioorg Med Chem18, 2037-2048. PubMed Europe PubMed DOI I
Lu,T., Chen,Y. and Li,X.Y.
An insight into the opening path to semi-open conformation of HIV-1 protease by molecular dynamics simulation
AIDS24, 1121-1125. PubMed Europe PubMed DOI
Mahalingam,A.K., Axelsson,L., Ekegren,J.K., Wannberg,J., Kihlstrom,J., Unge,T., Wallberg,H., Samuelsson,B., Larhed,M. and Hallberg,A.
HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells
J Med Chem53, 607-615. PubMed Europe PubMed DOI I
Mahmoud,K.A. and Luong,J.H.T.
A sensitive electrochemical assay for early detection of HIV-1 protease using ferrocenepeptide conjugate/AU nanoparticle/single walled carbon nanotube modified electrode
Anal Lett43, 1680-1687. DOI A
Manosuthi,W., Butler,D.M., Perez-Santiago,J., Poon,A.F., Pillai,S.K., Mehta,S.R., Pacold,M.E., Richman,D.D., Pond,S.K. and Smith,D.M.
Protease polymorphisms in HIV-1 subtype CRF01_AE represent selection by antiretroviral therapy and host immune pressure
AIDS24, 411-416. PubMed Europe PubMed DOI
Miller,M.
The early years of retroviral protease crystal structures
Biopolymers94, 521-529. PubMed Europe PubMed DOI V S I
Nalam,M.N., Ali,A., Altman,M.D., Reddy,G.S., Chellappan,S., Kairys,V., Ozen,A., Cao,H., Gilson,M.K., Tidor,B., Rana,T.M. and Schiffer,C.A.
Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance
J Virol84, 5368-5378. PubMed Europe PubMed DOI I
Perez,M.A., Fernandes,P.A. and Ramos,M.J.
Substrate recognition in HIV-1 protease: a computational study
J Phys Chem B114, 2525-2532. PubMed Europe PubMed DOI
Perryman,A.L., Zhang,Q., Soutter,H.H., Rosenfeld,R., McRee,D.E., Olson,A.J., Elder,J.E. and David Stout,C.
Fragment-based screen against HIV protease
Chem Biol Drug Des75, 257-268. PubMed Europe PubMed DOI S I
Prashar,V., Bihani,S.C., Das,A., Rao,D.R. and Hosur,M.V.
Insights into the mechanism of drug resistance: X-ray structure analysis of G48V/C95F tethered HIV-1 protease dimer/saquinavir complex
Biochem Biophys Res Commun396, 1018-1023. PubMed Europe PubMed DOI I
Reddy,A.S., Kumar,S. and Garg,R.
Hybrid-genetic algorithm based descriptor optimization and QSAR models for predicting the biological activity of Tipranavir analogs for HIV protease inhibition
J Mol Graph Model28, 852-862. PubMed Europe PubMed DOI I
Robbins,A.H., Coman,R.M., Bracho-Sanchez,E., Fernandez,M.A., Gilliland,C.T., Li,M., Agbandje-McKenna,M., Wlodawer,A., Dunn,B.M. and McKenna,R.
Structure of the unbound form of HIV-1 subtype A protease: comparison with unbound forms of proteases from other HIV subtypes
Acta Crystallogr D Biol Crystallogr66, 233-242. PubMed Europe PubMed DOI S
Sayer,J.M., Agniswamy,J., Weber,I.T. and Louis,J.M.
Autocatalytic maturation, physical/chemical properties, and crystal structure of group N HIV-1 protease: relevance to drug resistance
Protein Sci19, 2055-2072. PubMed Europe PubMed DOI S
Shen,C.H., Wang,Y.F., Kovalevsky,A.Y., Harrison,R.W. and Weber,I.T.
Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters
FEBS J277, 3699-3714. PubMed Europe PubMed DOI I
Singh,S., Singh,S. and Shukla,P.
Modeling of novel HIV-1 protease inhibitors incorporating N-aryl-oxazolidinone-5-carboxamides as P2 ligands using quantum chemical and topological finger print descriptors
Med Chem Res20, 1556-1565. DOI I
Soares,R.O., Batista,P.R., Costa,M.G., Dardenne,L.E., Pascutti,P.G. and Soares,M.A.
Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations
J Mol Graph Model29, 137-147. PubMed Europe PubMed DOI I
Steuber,H. and Hilgenfeld,R.
Recent advances in targeting viral proteases for the discovery of novel antivirals
Curr Top Med Chem10, 323-345. PubMed Europe PubMed DOI V
Tojo,Y., Koh,Y., Amano,M., Aoki,M., Das,D., Kulkarni,S., Anderson,D.D., Ghosh,A.K. and Mitsuya,H.
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro
Antimicrob Agents Chemother54, 3460-3470. PubMed Europe PubMed DOI I
Vidu,A., Dufau,L., Bannwarth,L., Soulier,J.L., Sicsic,S., Piarulli,U., Reboud-Ravaux,M. and Ongeri,S.
Toward the first nonpeptidic molecular tong inhibitor of wild-type and mutated HIV-1 protease dimerization
ChemMedChem5, 1899-1906. PubMed Europe PubMed DOI I
Waheed,A.A., Ablan,S.D., Sowder,R.C., Roser,J.D., Schaffner,C.P., Chertova,E. and Freed,E.O.
Effect of mutations in the human immunodeficiency virus type 1 protease on cleavage of the GP41 cytoplasmic tail
J Virol84, 3121-3126. PubMed Europe PubMed DOI
Young,T.P., Parkin,N.T., Stawiski,E., Pilot-Matias,T., Trinh,R., Kempf,D.J. and Norton,M.
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease
Antimicrob Agents Chemother54, 4903-4906. PubMed Europe PubMed DOI M
Yu,Z., Kabashima,T., Tang,C., Shibata,T., Kitazato,K., Kobayashi,N., Lee,M.K. and Kai,M.
Selective and facile assay of human immunodeficiency virus protease activity by a novel fluorogenic reaction
Anal Biochem397, 197-201. PubMed Europe PubMed DOI A

2009

Adachi,M., Ohhara,T., Kurihara,K., Tamada,T., Honjo,E., Okazaki,N., Arai,S., Shoyama,Y., Kimura,K., Matsumura,H., Sugiyama,S., Adachi,H., Takano,K., Mori,Y., Hidaka,K., Kimura,T., Hayashi,Y., Kiso,Y. and Kuroki,R.
Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography
Proc Natl Acad Sci U S A106, 4641-4646. PubMed Europe PubMed DOI S I
Alcaro,S., Artese,A., Ceccherini-Silberstein,F., Ortuso,F., Perno,C.F., Sing,T. and Svicher,V.
Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance
J Chem Inf Model49, 1751-1761. PubMed Europe PubMed DOI I
Bihani,S., Das,A., Prashar,V., Ferrer,J.L. and Hosur,M.V.
X-ray structure of HIV-1 protease in situ product complex
Proteins74, 594-602. PubMed Europe PubMed DOI S
Bihani,S.C., Das,A., Prashar,V., Ferrer,J.L. and Hosur,M.V.
Resistance mechanism revealed by crystal structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S
Biochem Biophys Res Commun389, 295-300. PubMed Europe PubMed DOI S I
Blackburn,M.E., Veloro,A.M. and Fanucci,G.E.
Monitoring inhibitor-induced conformational population shifts in HIV-1 protease by pulsed EPR spectroscopy
Biochemistry48, 8765-8767. PubMed Europe PubMed DOI
Boda,D., Valisko,M., Henderson,D., Gillespie,D., Eisenberg,B. and Gilson,M.K.
Ions and inhibitors in the binding site of HIV protease: comparison of Monte Carlo simulations and the linearized Poisson-Boltzmann theory
Biophys J96, 1293-1306. PubMed Europe PubMed DOI
Bowman,M.J. and Chmielewski,J.
Sidechain-linked inhibitors of HIV-1 protease dimerization
Bioorg Med Chem17, 967-976. PubMed Europe PubMed DOI I
Chaudhury,S. and Gray,J.J.
Identification of structural mechanisms of HIV-1 protease specificity using computational peptide docking: implications for drug resistance
Structure17, 1636-1648. PubMed Europe PubMed DOI
Chen,J., Yang,M., Hu,G., Shi,S., Yi,C. and Zhang,Q.
Insights into the functional role of protonation states in the HIV-1 protease-BEA369 complex: molecular dynamics simulations and free energy calculations
J Mol Model15, 1245-1252. PubMed Europe PubMed DOI I
Chen,J.Z., Yang,M.Y., Yi,C.H., Shi,S.H. and Zhang,Q.G.
Molecular dynamics simulation and free energy calculations of symmetric fluoro-substituted diol-based HIV-1 protease inhibitors
Theochem899, 1-8. DOI I
Chiummiento,L., Funicello,M., Lupattelli,P., Tramutola,F. and Campaner,P.
New indolic non-peptidic HIV protease inhibitors from (S)-glycidol: synthesis and preliminary biological activity
Tetrahedron65, 5984-5989. DOI I
Degoey,D.A., Grampovnik,D.J., Flentge,C.A., Flosi,W.J., Chen,H.J., Yeung,C.M., Randolph,J.T., Klein,L.L., Dekhtyar,T., Colletti,L., Marsh,K.C., Stoll,V., Mamo,M., Morfitt,D.C., Nguyen,B., Schmidt,J.M., Swanson,S.J., Mo,H., Kati,W.M., Molla,A. and Kempf,D.J.
2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects
J Med Chem52, 2571-2586. PubMed Europe PubMed DOI I
Fong,P., McNamara,J.P., Hillier,I.H. and Bryce,R.A.
Assessment of QM/MM scoring functions for molecular docking to HIV-1 protease
J Chem Inf Model49, 913-924. PubMed Europe PubMed DOI I
Galiano,L., Ding,F., Veloro,A.M., Blackburn,M.E., Simmerling,C. and Fanucci,G.E.
Drug pressure selected mutations in HIV-1 protease alter flap conformations
J Am Chem Soc131, 430-431. PubMed Europe PubMed DOI
Galiano,L., Blackburn,M.E., Veloro,A.M., Bonora,M. and Fanucci,G.E.
Solute effects on spin labels at an aqueous-exposed site in the flap region of HIV-1 protease
J Phys Chem B113, 1673-1680. PubMed Europe PubMed DOI
Ghosh,A.K., Leshchenko-Yashchuk,S., Anderson,D.D., Baldridge,A., Noetzel,M., Miller,H.B., Tie,Y., Wang,Y.F., Koh,Y., Weber,I.T. and Mitsuya,H.
Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies
J Med Chem52, 3902-3914. PubMed Europe PubMed DOI I
Ghosh,A.K., Kulkarni,S., Anderson,D.D., Hong,L., Baldridge,A., Wang,Y.F., Chumanevich,A.A., Kovalevsky,A.Y., Tojo,Y., Amano,M., Koh,Y., Tang,J., Weber,I.T. and Mitsuya,H.
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance
J Med Chem52, 7689-7705. PubMed Europe PubMed DOI I
Hernandez,N., Kiralj,R., Ferreira,M.M.C. and Talavera,I.
Critical comparative analysis, validation and interpretation of SVM and PLS regression models in a QSAR study on HIV-1 protease inhibitors
Chemometr Intelligent Lab Syst98, 65-77. DOI I
Heyda,J., Pokorna,J., Vrbka,L., Vacha,R., Jagoda-Cwiklik,B., Konvalinka,J., Jungwirth,P. and Vondrasek,J.
Ion specific effects of sodium and potassium on the catalytic activity of HIV-1 protease
Phys Chem Chem Phys11, 7599-7604. PubMed Europe PubMed DOI
Hidaka,K., Kimura,T., Abdel-Rahman,H.M., Nguyen,J.T., McDaniel,K.F., Kohlbrenner,W.E., Molla,A., Adachi,M., Tamada,T., Kuroki,R., Katsuki,N., Tanaka,Y., Matsumoto,H., Wang,J., Hayashi,Y., Kempf,D.J. and Kiso,Y.
Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket
J Med Chem52, 7604-7617. PubMed Europe PubMed DOI I
Jochim,A.L., Miller,S.E., Angelo,N.G. and Arora,P.S.
Evaluation of triazolamers as active site inhibitors of HIV-1 protease
Bioorg Med Chem Lett19, 6023-6026. PubMed Europe PubMed DOI I
Johnson,V.A., Brun-Vezinet,F., Clotet,B., Gunthard,H.F., Kuritzkes,D.R., Pillay,D., Schapiro,J.M. and Richman,D.D.
Update of the drug resistance mutations in HIV-1: December 2009
Top HIV Med17, 138-145. PubMed Europe PubMed
Kogo,H., Takeuchi,K., Inoue,H., Kihara,H., Kojima,M. and Takahashi,K.
Urea-dependent unfolding of HIV-1 protease studied by circular dichroism and small-angle X-ray scattering
Biochim Biophys Acta1794, 70-74. PubMed Europe PubMed DOI
Koh,Y., Das,D., Leschenko,S., Nakata,H., Ogata-Aoki,H., Amano,M., Nakayama,M., Ghosh,A.K. and Mitsuya,H.
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro
Antimicrobial Agents Chemother53, 997-1006. PubMed Europe PubMed DOI I
Kolli,M., Stawiski,E., Chappey,C. and Schiffer,C.A.
Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance
J Virol83, 11027-11042. PubMed Europe PubMed DOI
Kontijevskis,A., Petrovska,R., Yahorava,S., Komorowski,J. and Wikberg,J.E.
Proteochemometrics mapping of the interaction space for retroviral proteases and their substrates
Bioorg Med Chem17, 5229-5237. PubMed Europe PubMed DOI V I
Krauchenco,S., Martins,N.H., Sanches,M. and Polikarpov,I.
Effectiveness of commercial inhibitors against subtype F HIV-1 protease
J Enzyme Inhib Med Chem24, 638-645. PubMed Europe PubMed DOI I
Lexa,K.W., Damm,K.L., Quintero,J.J., Gestwicki,J.E. and Carlson,H.A.
Clarifying allosteric control of flap conformations in the 1TW7 crystal structure of HIV-1 protease
Proteins74, 872-880. PubMed Europe PubMed DOI S
Liu,X., Xiu,Z. and Hao,C.
Drug-resistant molecular mechanism of CRF01_AE HIV-1 protease due to V82F mutation
J Comput Aided Mol Des23, 261-272. PubMed Europe PubMed DOI I
Niu,B., Lu,L., Liu,L., Gu,T.H., Feng,K.Y., Lu,W.C. and Cai,Y.D.
HIV-1 protease cleavage site prediction based on amino acid property
J Comput Chem30, 33-39. PubMed Europe PubMed DOI
Noel,A.F., Bilsel,O., Kundu,A., Wu,Y., Zitzewitz,J.A. and Matthews,C.R.
The folding free-energy surface of HIV-1 protease: insights into the thermodynamic basis for resistance to inhibitors
J Mol Biol387, 1002-1016. PubMed Europe PubMed DOI I
Ocul,H.
Variable context Markov chains for HIV protease cleavage site prediction
Biosystems96, 246-250. PubMed Europe PubMed DOI
Pandey,R.B. and Farmer,B.L.
Residue energy and mobility in sequence to global structure and dynamics of a HIV-1 protease (1DIFA) by a coarse-grained Monte Carlo simulation
J Chem Phys130, 044906-044906. PubMed Europe PubMed DOI
Prashar,V., Bihani,S., Das,A., Ferrer,J.L. and Hosur,M.
Catalytic water co-existing with a product peptide in the active site of HIV-1 protease revealed by X-ray structure analysis
PLoS ONE4, e7860-e7860. PubMed Europe PubMed DOI
Purohit,R. and Sethumadhavan,R.
Structural basis for the resilience of Darunavir (TMC114) resistance major flap mutations of HIV-1 protease
Interdiscip Sci1, 320-328. PubMed Europe PubMed DOI I
Ravichandran,V., Jain,A.K., Mourya,V.K. and Agrawal,R.K.
Prediction of HIV-1 protease inhibitory activity of (4-hydroxy-6-phenyl-2-oxo-2h-pyran-3-yl) thiomethanes: QSAR study
Curr Trends Biotechnol Pharm3, 149-154. I
Rezacova,P., Pokorna,J., Brynda,J., Kozisek,M., Cigler,P., Lepsik,M., Fanfrlik,J., Rezac,J., Grantz Saskova,K., Sieglova,I., Plesek,J., Sicha,V., Gruner,B., Oberwinkler,H., Sedlacek',J., Krausslich,H.G., Hobza,P., Kral,V. and Konvalinka,J.
Design of HIV protease inhibitors based on inorganic polyhedral metallacarboranes
J Med Chem52, 7132-7141. PubMed Europe PubMed DOI I
Rognvaldsson,T., Etchells,T.A., You,L., Garwicz,D., Jarman,I. and Lisboa,P.J.
How to find simple and accurate rules for viral protease cleavage specificities
BMC Bioinformatics10, 149-149. PubMed Europe PubMed DOI P
Saskova,K.G., Kozisek,M., Rezacova,P., Brynda,J., Yashina,T., Kagan,R.M. and Konvalinka,J.
Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir
J Virol83, 8810-8818. PubMed Europe PubMed DOI I
Sayer,J.M. and Louis,J.M.
Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin
Proteins75, 556-568. PubMed Europe PubMed DOI I
Soares,E.A., Santos,A.F., Gonzalez,L.M., Lalonde,M.S., Tebit,D.M., Tanuri,A., Arts,E.J. and Soares,M.A.
Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage
J Antimicrob Chemother64, 938-944. PubMed Europe PubMed DOI
Takkis,K. and Sild,S.
QSAR modeling of HIV-1 protease inhibition on six- and seven-membered cyclic ureas
QSAR Comb Sci28, 52-58. DOI I
Tiana,G. and Broglia,R.A.
The molecular evolution of HIV-1 protease simulated at atomic detail
Proteins76, 895-910. PubMed Europe PubMed DOI
Torbeev,V.Y., Raghuraman,H., Mandal,K., Senapati,S., Perozo,E. and Kent,S.B.
Dynamics of "flap" structures in three HIV-1 protease/inhibitor complexes probed by total chemical synthesis and pulse-EPR spectroscopy
J Am Chem Soc131, 884-885. PubMed Europe PubMed DOI I
Van Marck,H., Dierynck,I., Kraus,G., Hallenberger,S., Pattery,T., Muyldermans,G., Geeraert,L., Borozdina,L., Bonesteel,R., Aston,C., Shaw,E., Chen,Q., Martinez,C., Koka,V., Lee,J., Chi,E., de Bethune,M.P. and Hertogs,K.
The impact of individual human immunodeficiency virus type 1 protease mutations on drug susceptibility is highly influenced by complex interactions with the background protease sequence
J Virol83, 9512-9520. PubMed Europe PubMed DOI M
Verkhivker,G.M.
Coarse-grained modeling of the HIV-1 protease binding mechanisms: I. Targeting structural flexibility of the protease flaps and implications for drug design
Lect Notes Comput Sci5488 LNBI, 1-12. DOI
Verkhivker,G.M.
Coarse-grained modeling of the HIV-1 protease binding mechanisms: II. Folding inhibition
Lect Notes Comput Sci5488 LNBI, 13-24. DOI
Waibel,M., Pitrat,D. and Hasserodt,J.
On the inhibition of HIV-1 protease by hydrazino-ureas displaying the N - >C=O interaction
Bioorg Med Chem17, 3671-3679. PubMed Europe PubMed DOI I

2008

Altman,M.D., Ali,A., Reddy,G.S., Nalam,M.N., Anjum,S.G., Cao,H., Chellappan,S., Kairys,V., Fernandes,M.X., Gilson,M.K., Schiffer,C.A., Rana,T.M. and Tidor,B.
HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants
J Am Chem Soc130, 6099-6113. PubMed Europe PubMed DOI I
Altman,M.D., Nalivaika,E.A., Prabu-Jeyabalan,M., Schiffer,C.A. and Tidor,B.
Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV-1 protease
Proteins70, 678-694. PubMed Europe PubMed DOI
Bandaranayake,R.M., Prabu-Jeyabalan,M., Kakizawa,J., Sugiura,W. and Schiffer,C.A.
Structural analysis of human immunodeficiency virus type 1 CRF01_AE protease in complex with the substrate p1-p6
J Virol82, 6762-6766. PubMed Europe PubMed DOI S
Blum,A., Bottcher,J., Heine,A., Klebe,G. and Diederich,W.E.
Structure-guided design of C2-symmetric HIV-1 protease inhibitors based on a pyrrolidine scaffold
J Med Chem51, 2078-2087. PubMed Europe PubMed DOI T I
Bottcher,J., Blum,A., Heine,A., Diederich,W.E. and Klebe,G.
Structural and kinetic analysis of pyrrolidine-based inhibitors of the drug-resistant Ile84Val mutant of HIV-1 protease
J Mol Biol383, 347-357. PubMed Europe PubMed DOI T I
Bottcher,J., Blum,A., Dorr,S., Heine,A., Diederich,W.E. and Klebe,G.
Targeting the open-flap conformation of HIV-1 protease with pyrrolidine-based inhibitors
ChemMedChem3, 1337-1344. PubMed Europe PubMed DOI S I
Broglia,R., Levy,Y. and Tiana,G.
HIV-1 protease folding and the design of drugs which do not create resistance
Curr Opin Struct Biol18, 60-66. PubMed Europe PubMed DOI I
Carnevale,V., Raugei,S., Piana,S. and Carloni,P.
On the nature of the reaction intermediate in the HIV-1 protease: a quantum chemical study
Comput Phys Commun179, 120-123. DOI
Clemente,J.C., Robbins,A., Grana,P., Paleo,M.R., Correa,J.F., Villaverde,M.C., Sardina,F.J., Govindasamy,L., Agbandje-McKenna,M., McKenna,R., Dunn,B.M. and Sussman,F.
Design, synthesis, evaluation, and crystallographic-based structural studies of HIV-1 protease inhibitors with reduced response to the V82A mutation
J Med Chem51, 852-860. PubMed Europe PubMed DOI S I
Coman,R.M., Robbins,A.H., Goodenow,M.M., Dunn,B.M. and McKenna,R.
High-resolution structure of unbound human immunodeficiency virus 1 subtype C protease: implications of flap dynamics and drug resistance
Acta Crystallogr D Biol CrystallogrD64, 754-763. PubMed Europe PubMed DOI S
Coman,R.M., Robbins,A.H., Fernandez,M.A., Gilliland,C.T., Sochet,A.A., Goodenow,M.M., McKenna,R. and Dunn,B.M.
The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics of HIV-1 subtype C protease
Biochemistry47, 731-743. PubMed Europe PubMed DOI
Damm,K.L., Ung,P.M., Quintero,J.J., Gestwicki,J.E. and Carlson,H.A.
A poke in the eye: inhibiting HIV-1 protease through its flap-recognition pocket
Biopolymers89, 643-652. PubMed Europe PubMed DOI I
Dandache,S., Coburn,C.A., Oliveira,M., Allison,T.J., Holloway,M.K., Wu,J.J., Stranix,B.R., Panchal,C., Wainberg,M.A. and Vacca,J.P.
PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study
J Med Virol80, 2053-2063. PubMed Europe PubMed DOI I
Dekhtyar,T., Ng,T.I., Lu,L., Masse,S., Degoey,D.A., Flosi,W.J., Grampovnik,D.J., Klein,L.L., Kempf,D.J. and Molla,A.
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742
Antimicrob Agents Chemother52, 1337-1344. PubMed Europe PubMed DOI I
Ding,F., Layten,M. and Simmerling,C.
Solution structure of HIV-1 protease flaps probed by comparison of molecular dynamics simulation ensembles and EPR experiments
J Am Chem Soc130, 7184-7185. PubMed Europe PubMed DOI S
Eizert,H., Bander,P., Bagossi,P., Sperka,T., Miklossy,G., Boross,P., Weber,I.T. and Tozser,J.
Amino acid preferences of retroviral proteases for amino-terminal positions in a type 1 cleavage site
J Virol82, 10111-10117. PubMed Europe PubMed DOI P
Frecer,V., Berti,F., Benedetti,F. and Miertus,S.
Design of peptidomimetic inhibitors of aspartic protease of HIV-1 containing -PhePsiPro- core and displaying favourable ADME-related properties
J Mol Graph Model27, 376-387. PubMed Europe PubMed DOI I
Garg,R. and Bhhatarai,B.
Possible allosteric interactions of monoindazole-substituted P2 cyclic urea analogues with wild-type and mutant HIV-1 protease
J Comput Aided Mol Des22, 737-745. PubMed Europe PubMed DOI I
Ghosh,A.K., Gemma,S., Baldridge,A., Wang,Y.F., Kovalevsky,A.Y., Koh,Y., Weber,I.T. and Mitsuya,H.
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies
J Med Chem51, 6021-6033. PubMed Europe PubMed DOI I
Ghosh,A.K., Chapsal,B.D., Weber,I.T. and Mitsuya,H.
Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance
Acc Chem Res41, 78-86. PubMed Europe PubMed DOI I
Ghosh,A.K., Gemma,S., Takayama,J., Baldridge,A., Leshchenko-Yashchuk,S., Miller,H.B., Wang,Y.F., Kovalevsky,A.Y., Koh,Y., Weber,I.T. and Mitsuya,H.
Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies
Org Biomol Chem6, 3703-3713. PubMed Europe PubMed DOI I
Ghosh,A.K., Chapsal,B.D., Baldridge,A., Ide,K., Koh,Y. and Mitsuya,H.
Design and synthesis of stereochemically defined novel spirocyclic P2-ligands for HIV-1 protease inhibitors
Org Lett10, 5135-5138. PubMed Europe PubMed DOI I
Giffin,M.J., Heaslet,H., Brik,A., Lin,Y.C., Cauvi,G., Wong,C.H., McRee,D.E., Elder,J.H., Stout,C.D. and Torbett,B.E.
A copper(I)-catalyzed 1,2,3-triazole azide-alkyne click compound is a potent inhibitor of a multidrug-resistant HIV-1 protease variant
J Med Chem51, 6263-6270. PubMed Europe PubMed DOI I
Gonzalez,L.M., Santos,A.F., Abecasis,A.B., Van Laethem,K., Soares,E.A., Deforche,K., Tanuri,A., Camacho,R., Vandamme,A.M. and Soares,M.A.
Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates
J Antimicrob Chemother61, 1201-1204. PubMed Europe PubMed DOI
Gulnik,S.V. and Eissenstat,M.
Approaches to the design of HIV protease inhibitors with improved resistance profiles
Curr Opin HIV AIDS3, 633-641. PubMed Europe PubMed DOI V I
Hamacher,K.
Relating sequence evolution of HIV1-protease to its underlying molecular mechanics
Gene422, 30-36. PubMed Europe PubMed DOI
Hosur,M.V. and Prashar,V.
HIV-1 protease crystallography at BARC
J Indian Inst Sci88, 95-105. S
Ishima,R. and Louis,J.M.
A diverse view of protein dynamics from NMR studies of HIV-1 protease flaps
Proteins70, 1408-1415. PubMed Europe PubMed DOI S
Johnson,V.A., Brun-Vezinet,F., Clotet,B., Gunthard,H.F., Kuritzkes,D.R., Pillay,D., Schapiro,J.M. and Richman,D.D.
Update of the drug resistance mutations in HIV-1: Spring 2008
Top HIV Med16, 62-68. PubMed Europe PubMed
Kim,R. and Baxter,J.D.
Protease inhibitor resistance update: where are we now?
AIDS Patient Care STDS22, 267-277. PubMed Europe PubMed DOI I
Kona,J.
Theoretical study on the mechanism of a ring-opening reaction of oxirane by the active-site aspartic dyad of HIV-1 protease
Org Biomol Chem6, 359-365. PubMed Europe PubMed DOI I
Kovalevsky,A.Y., Ghosh,A.K. and Weber,I.T.
Solution Kinetics Measurements Suggest HIV-1 Protease Has Two Binding Sites for Darunavir and Amprenavir
J Med Chem51, 6599-6603. PubMed Europe PubMed DOI I
Kozisek,M., Saskova,K.G., Rezacova,P., Brynda,J., van Maarseveen,N.M., de Jong,D., Boucher,C.A., Kagan,R.M., Nijhuis,M. and Konvalinka,J.
Ninety-nine is not enough: molecular characterization of inhibitor-resistant human immunodeficiency virus type 1 protease mutants with insertions in the flap region
J Virol82, 5869-5878. PubMed Europe PubMed DOI
Kozisek,M., Cigler,P., Lepsik,M., Fanfrlik,J., Rezacova,P., Brynda,J., Pokorna,J., Plesek,J., Gruner,B., Grantz Saskova,K., Vaclavikova,J., Kral,V. and Konvalinka,J.
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance
J Med Chem51, 4839-4843. PubMed Europe PubMed DOI I
Kumar,S., Garg,R., Alla,S.R., Zhang,X. and Jalahalli,V.K.
3D-shape analysis of the HIV-1 protease ligand binding site
[ISSN:ISBN 978-1-4244-1778-0]2008, 151-158. DOI S
Lambert-Niclot,S., Flandre,P., Canestri,A., Peytavin,G., Blanc,C., Agher,R., Soulie,C., Wirden,M., Katlama,C., Calvez,V. and Marcelin,A.G.
Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir
Antimicrob Agents Chemother52, 491-496. PubMed Europe PubMed DOI I
Liu,F., Kovalevsky,A.Y., Tie,Y., Ghosh,A.K., Harrison,R.W. and Weber,I.T.
Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir
J Mol Biol381, 102-115. PubMed Europe PubMed DOI S I
Margerison,E.S., Maguire,M., Pillay,D., Cane,P. and Elston,R.C.
The HIV-1 protease substitution K55R: a protease-inhibitor-associated substitution involved in restoring viral replication
J Antimicrob Chemother61, 786-791. PubMed Europe PubMed DOI
Matsumura,H., Adachi,M., Sugiyama,S., Okada,S., Yamakami,M., Tamada,T., Hidaka,K., Hayashi,Y., Kimura,T., Kiso,Y., Kitatani,T., Maki,S., Yoshikawa,H.Y., Adachi,H., Takano,K., Murakami,S., Inoue,T., Kuroki,R. and Mori,Y.
Crystallization and preliminary neutron diffraction studies of HIV-1 protease cocrystallized with inhibitor KNI-272
Acta Crystallograph Sect F Struct Biol Cryst Commun64, 1003-1006. PubMed Europe PubMed DOI I
Mihara,H., Sohtome,Y., Matsunaga,S. and Shibasaki,M.
Chiral-catalyst-based convergent synthesis of HIV protease inhibitor GRL-06579A
Chem Asian J3, 359-366. PubMed Europe PubMed DOI I
Miklossy,G., Tozser,J., Kadas,J., Ishima,R., Louis,J.M. and Bagossi,P.
Novel macromolecular inhibitors of human immunodeficiency virus-1 protease
Protein Eng Des Sel21, 453-461. PubMed Europe PubMed DOI I
Mimoto,T., Nojima,S., Terashima,K., Takaku,H., Shintani,M. and Hayashi,H.
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure
Bioorg Med Chem16, 1299-1308. PubMed Europe PubMed DOI I
Mosebi,S., Morris,L., Dirr,H.W. and Sayed,Y.
Active-site mutations in the South african human immunodeficiency virus type 1 subtype C protease have a significant impact on clinical inhibitor binding: kinetic and thermodynamic study
J Virol82, 11476-11479. PubMed Europe PubMed DOI I
Nakatani,S., Hidaka,K., Ami,E., Nakahara,K., Sato,A., Nguyen,J.T., Hamada,Y., Hori,Y., Ohnishi,N., Nagai,A., Kimura,T., Hayashi,Y. and Kiso,Y.
Combination of non-natural d-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV
J Med Chem51, 2992-3004. PubMed Europe PubMed DOI I
Nalam,M.N. and Schiffer,C.A.
New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors
Curr Opin HIV AIDS3, 642-646. PubMed Europe PubMed DOI V I
Narendra Babu,S.N. and Rangappa,K.S.
Design, synthesis and structure-activity study of shorter hexa peptide analogues as HIV-1 protease inhibitors
Bioorg Med Chem16, 874-880. PubMed Europe PubMed DOI I
Nie,Z., Bren,G.D., Rizza,S.A. and Badley,A.D.
HIV Protease cleavage of procaspase 8 is necessary for death of HIV-infected cells
Open Virol J2, 1-7. PubMed Europe PubMed DOI
Nijhuis,M., van Maarseveen,N.M., Verheyen,J. and Boucher,C.A.
Novel mechanisms of HIV protease inhibitor resistance
Curr Opin HIV AIDS3, 627-632. PubMed Europe PubMed DOI I
Nunthanavanit,P., Anthony,N.G., Johnston,B.F., Mackay,S.P. and Ungwitayatorn,J.
3D-QSAR Studies on chromone derivatives as HIV-1 protease inhibitors: application of molecular field analysis
Arch Pharm (Weinheim)341, 357-364. PubMed Europe PubMed DOI I
Poveda,E.
New resistance score for tipranavir
AIDS Rev10, 127-127. PubMed Europe PubMed I
Purohit,R., Rajasekaran,R., Sudandiradoss,C., George Priya Doss,C., Ramanathan,K. and Rao,S.
Studies on flexibility and binding affinity of Asp25 of HIV-1 protease mutants
Int J Biol Macromol42, 386-391. PubMed Europe PubMed DOI I
Raza,A., Sham,Y.Y. and Vince,R.
Design and synthesis of sulfoximine based inhibitors for HIV-1 protease
Bioorg Med Chem Lett18, 5406-5410. PubMed Europe PubMed DOI I
Saskova,K.G., Kozisek,M., Lepsik,M., Brynda,J., Rezacova,P., Vaclavikova,J., Kagan,R.M., Machala,L. and Konvalinka,J.
Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir
Protein Sci17, 1555-1564. PubMed Europe PubMed DOI S I
Sayer,J.M., Liu,F., Ishima,R., Weber,I.T. and Louis,J.M.
Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease
J Biol Chem283, 13459-13470. PubMed Europe PubMed DOI
Schlick,P. and Skern,T.
Investigating human immunodeficiency virus-1 proteinase specificity at positions P4 to P2 using a bacterial screening system
Anal Biochem377, 162-169. PubMed Europe PubMed DOI P
Sherman,W. and Tidor,B.
Novel method for probing the specificity binding profile of ligands: applications to HIV protease
Chem Biol Drug Des71, 387-407. PubMed Europe PubMed DOI
Singh,G. and Senapati,S.
Molecular dynamics simulations of ligand-induced flap closing in HIV-1 protease approach X-ray resolution: establishing the role of bound water in the flap closing mechanism
Biochemistry47, 10657-10664. PubMed Europe PubMed DOI S
Sista,P., Wasikowski,B., Lecocq,P., Pattery,T. and Bacheler,L.
The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contexts
J Clin Virol42, 405-408. PubMed Europe PubMed DOI
Stoica,I., Sadiq,S.K. and Coveney,P.V.
Rapid and accurate prediction of binding free energies for saquinavir-bound HIV-1 proteases
J Am Chem Soc130, 2639-2648. PubMed Europe PubMed DOI I
Suresh,C.H., Vargheese,A.M., Vijayalakshmi,K.P., Mohan,N. and Koga,N.
Role of structural water molecule in HIV protease-inhibitor complexes: a QM/MM study
J Comput Chem29, 1840-1849. PubMed Europe PubMed DOI I
Tang,C., Louis,J.M., Aniana,A., Suh,J.Y. and Clore,G.M.
Visualizing transient events in amino-terminal autoprocessing of HIV-1 protease
Nature455, 693-696. PubMed Europe PubMed DOI
Torbeev,V.Y., Mandal,K., Terechko,V.A. and Kent,S.B.
Crystal structure of chemically synthesized HIV-1 protease and a ketomethylene isostere inhibitor based on the p2/NC cleavage site
Bioorg Med Chem Lett18, 4554-4557. PubMed Europe PubMed DOI S I
Tyndall,J.D., Pattenden,L.K., Reid,R.C., Hu,S.H., Alewood,D., Alewood,P.F., Walsh,T., Fairlie,D.P. and Martin,J.L.
Crystal structures of highly constrained substrate and hydrolysis products bound to HIV-1 protease. Implications for the catalytic mechanism
Biochemistry47, 3736-3744. PubMed Europe PubMed DOI S
Verkhivker,G., Tiana,G., Camilloni,C., Provasi,D. and Broglia,R.A.
Atomistic simulations of the HIV-1 protease folding inhibition
Biophys J95, 550-562. PubMed Europe PubMed DOI I
Wollmann,J., Baumert,C., Erlenkamp,G., Sippl,W. and Hilgeroth,A.
Novel insight into inhibitor binding of highly symmetric HIV-1 protease
Chembiochem9, 874-878. PubMed Europe PubMed DOI I
Wu,X., Ohrngren,P., Ekegren,J.K., Unge,J., Unge,T., Wallberg,H., Samuelsson,B., Hallberg,A. and Larhed,M.
Two-carbon-elongated HIV-1 protease inhibitors with a tertiary-alcohol-containing transition-state mimic
J Med Chem51, 1053-1057. PubMed Europe PubMed DOI S I
Yan,M.C., Sha,Y., Wang,J., Xiong,X.Q., Ren,J.H. and Cheng,M.S.
Molecular dynamics simulations of HIV-1 protease monomer: Assembly of N-terminus and C-terminus into beta-sheet in water solution
Proteins70, 731-738. PubMed Europe PubMed DOI
Zimmer,J.M., Roman,F., Lambert,C., Jonckheer,A., Vazquez,A., Plesseria,J.M., Servais,J.Y., Covens,K., Weber,J., Van Laethem,K., Schmit,J.C., Vandamme,A.M., Quinones-Mateu,M.E. and De Maeyer,M.
Impact on replicative fitness of the G48E substitution in the protease of HIV-1: an in vitro and in silico evaluation
J Acquir Immune Defic Syndr48, 255-262. PubMed Europe PubMed DOI

2007

Amano,M., Koh,Y., Das,D., Li,J., Leschenko,S., Wang,Y.F., Boross,P.I., Weber,I.T., Ghosh,A.K. and Mitsuya,H.
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro
Antimicrob Agents Chemother51, 2143-2155. PubMed Europe PubMed DOI I
Bannwarth,L. and Reboud-Ravaux,M.
An alternative strategy for inhibiting multidrug-resistant mutants of the dimeric HIV-1 protease by targeting the subunit interface
Biochem Soc Trans35, 551-554. PubMed Europe PubMed DOI I
Bonomi,M., Gervasio,F.L., Tiana,G., Provasi,D., Broglia,R.A. and Parrinello,M.
Insight into the folding inhibition of the HIV-1 protease by a small peptide
Biophys J93, 2813-2821. PubMed Europe PubMed DOI
Chang,C.E., Trylska,J., Tozzini,V. and McCammon,J.A.
Binding pathways of ligands to HIV-1 protease: coarse-grained and atomistic simulations
Chem Biol Drug Des69, 5-13. PubMed Europe PubMed DOI I
Chellappan,S., Kiran Kumar Reddy,G.S., Ali,A., Nalam,M.N., Anjum,S.G., Cao,H., Kairys,V., Fernandes,M.X., Altman,M.D., Tidor,B., Rana,T.M., Schiffer,C.A. and Gilson,M.K.
Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis
Chem Biol Drug Des69, 298-313. PubMed Europe PubMed DOI I
Chellappan,S., Kairys,V., Fernandes,M.X., Schiffer,C. and Gilson,M.K.
Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease
Proteins68, 561-567. PubMed Europe PubMed DOI
Coman,R.M., Robbins,A., Goodenow,M.M., McKenna,R. and Dunn,B.M.
Expression, purification and preliminary X-ray crystallographic studies of the human immunodeficiency virus 1 subtype C protease
Acta Crystallograph Sect F Struct Biol Cryst Commun63, 320-323. PubMed Europe PubMed DOI S
Czodrowski,P., Sotriffer,C.A. and Klebe,G.
Atypical protonation states in the active site of HIV-1 protease: a computational study
J Chem Inf Model47, 1590-1598. PubMed Europe PubMed DOI
Dandache,S., Sevigny,G., Yelle,J., Stranix,B.R., Parkin,N., Schapiro,J.M., Wainberg,M.A. and Wu,J.J.
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1
Antimicrob Agents Chemother51, 4036-4043. PubMed Europe PubMed DOI I
Das,A., Rao,D.R. and Hosur,M.V.
X-Ray structure of HIV-1 protease tethered dimer complexed to Ritonavir
Protein Pept Lett14, 565-568. PubMed Europe PubMed S
Dierynck,I., De Wit,M., Gustin,E., Keuleers,I., Vandersmissen,J., Hallenberger,S. and Hertogs,K.
Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier
J Virol81, 13845-13851. PubMed Europe PubMed DOI I
Duan,L.L., Tong,Y., Mei,Y., Zhang,Q.G. and Zhang,J.Z.
Quantum study of HIV-1 protease-bridge water interaction
J Chem Phys127, 145101-145101. PubMed Europe PubMed DOI
Foulkes-Murzycki,J.E., Scott,W.R. and Schiffer,C.A.
Hydrophobic sliding: a possible mechanism for drug resistance in human immunodeficiency virus type 1 protease
Structure15, 225-233. PubMed Europe PubMed DOI I
Frutos,S., Tulla-Puche,J., Albericio,F. and Giralt,E.
Chemical synthesis of 19F-labeled HIV-1 protease using Fmoc-chemistry and chemmatrix resin
Int J Pept Res Ther13, 221-227. DOI
Galiano,L., Bonora,M. and Fanucci,G.E.
Interflap distances in HIV-1 protease determined by pulsed EPR measurements
J Am Chem Soc129, 11004-11005. PubMed Europe PubMed DOI
Garriga,C., Perez-Elias,M.J., Delgado,R., Ruiz,L., Najera,R., Pumarola,T., Alonso-Socas,M., Garcia-Bujalance,S. and Menendez-Arias,L.
Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments
J Med Virol79, 1617-1628. PubMed Europe PubMed DOI I
Heaslet,H., Rosenfeld,R., Giffin,M., Lin,Y.C., Tam,K., Torbett,B.E., Elder,J.H., McRee,D.E. and Stout,C.D.
Conformational flexibility in the flap domains of ligand-free HIV protease
Acta Crystallogr D Biol Crystallogr63, 866-875. PubMed Europe PubMed DOI S
Hou,T. and Yu,R.
Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with Amprenavir and two Amprenavir-related inhibitors: mechanism for binding and drug resistance
J Med Chem50, 1177-1188. PubMed Europe PubMed DOI I
Ishima,R., Torchia,D.A. and Louis,J.M.
Mutational and structural studies aimed at characterizing the monomer of HIV-1 protease and its precursor
J Biol Chem282, 17190-17199. PubMed Europe PubMed DOI
Johnson,E.C., Malito,E., Shen,Y., Pentelute,B., Rich,D., Florian,J., Tang,W.J. and Kent,S.B.
Insights from atomic-resolution X-Ray structures of chemically synthesized HIV-1 protease in complex with inhibitors
J Mol Biol373, 573-586. PubMed Europe PubMed DOI S I
Johnson,E.C., Malito,E., Shen,Y., Rich,D., Tang,W.J. and Kent,S.B.
Modular total chemical synthesis of a human immunodeficiency virus type 1 protease
J Am Chem Soc129, 11480-11490. PubMed Europe PubMed DOI S
Johnson,V.A., Brun-Vezinet,F., Clotet,B., Gunthard,H.F., Kuritzkes,D.R., Pillay,D., Schapiro,J.M. and Richman,D.D.
Update of the drug resistance mutations in HIV-1: 2007
Top HIV Med15, 119-125. PubMed Europe PubMed
Kerman,K., Mahmoud,K.A. and Kraatz,H.B.
An electrochemical approach for the detection of HIV-1 protease
Chem Commun (Camb)2007, 3829-3831. DOI
Klei,H.E., Kish,K., Lin,P.F., Guo,Q., Friborg,J., Rose,R.E., Zhang,Y., Goldfarb,V., Langley,D.R., Wittekind,M. and Sheriff,S.
X-ray crystal structures of human immunodeficiency virus type 1 protease mutants complexed with atazanavir
J Virol81, 9525-9535. PubMed Europe PubMed DOI S I
Koh,Y., Matsumi,S., Das,D., Amano,M., Davis,D.A., Li,J., Leschenko,S., Baldridge,A., Shioda,T., Yarchoan,R., Ghosh,A.K. and Mitsuya,H.
Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization
J Biol Chem282, 28709-28720. PubMed Europe PubMed DOI I
Kontijevskis,A., Prusis,P., Petrovska,R., Yahorava,S., Mutulis,F., Mutule,I., Komorowski,J. and Wikberg,J.E.
A look inside HIV resistance through retroviral protease interaction maps
PLoS Comput Biol3, e48-e48. PubMed Europe PubMed DOI P
Kovalevsky,A.Y., Chumanevich,A.A., Liu,F., Louis,J.M. and Weber,I.T.
Caught in the act: the 1.5 A resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate
Biochemistry46, 14854-14864. PubMed Europe PubMed DOI S
Kozisek,M., Bray,J., Rezacova,P., Saskova,K., Brynda,J., Pokorna,J., Mammano,F., Rulisek,L. and Konvalinka,J.
Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants
J Mol Biol374, 1005-1016. PubMed Europe PubMed DOI S I
Lafont,V., Armstrong,A.A., Ohtaka,H., Kiso,Y., Mario Amzel,L. and Freire,E.
Compensating enthalpic and entropic changes hinder binding affinity optimization
Chem Biol Drug Des69, 413-422. PubMed Europe PubMed DOI I
Lauria,A., Ippolito,M. and Almerico,A.M.
Molecular dynamics studies on HIV-1 protease: a comparison of the flap motions between wild type protease and the M46I/G51D double mutant
J Mol Model13, 1151-1156. PubMed Europe PubMed DOI
Lee,V.S., Nimmanpipug,P., Aruksakunwong,O., Promsri,S., Sompornpisut,P. and Hannongbua,S.
Structural analysis of lead fullerene-based inhibitor bound to human immunodeficiency virus type 1 protease in solution from molecular dynamics simulations
J Mol Graph Model26, 558-570. PubMed Europe PubMed DOI I
Louis,J.M., Ishima,R., Torchia,D.A. and Weber,I.T.
HIV-1 protease: structure, dynamics, and inhibition
Adv Pharmacol55, 261-298. PubMed Europe PubMed DOI V
Lu,D. and Vince,R.
Discovery of potent HIV-1 protease inhibitors incorporating sulfoximine functionality
Bioorg Med Chem Lett17, 5614-5619. PubMed Europe PubMed DOI I
Mastrolorenzo,A., Rusconi,S., Scozzafava,A., Barbaro,G. and Supuran,C.T.
Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors
Curr Med Chem14, 2734-2748. PubMed Europe PubMed DOI V I
Mo,H., Parkin,N., Stewart,K.D., Lu,L., Dekhtyar,T., Kempf,D.J. and Molla,A.
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication
Antimicrob Agents Chemother51, 732-735. PubMed Europe PubMed DOI
Muzammil,S., Armstrong,A.A., Kang,L.W., Jakalian,A., Bonneau,P.R., Schmelmer,V., Amzel,L.M. and Freire,E.
Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations
J Virol81, 5144-5154. PubMed Europe PubMed DOI I
Nalam,M.N., Peeters,A., Jonckers,T.H., Dierynck,I. and Schiffer,C.A.
Crystal structure of lysine sulfonamide inhibitor reveals the displacement of the conserved flap water molecule in human immunodeficiency virus type 1 protease
J Virol81, 9512-9518. PubMed Europe PubMed DOI S I
Nie,Z., Bren,G.D., Vlahakis,S.R., Schimnich,A.A., Brenchley,J.M., Trushin,S.A., Warren,S., Schnepple,D.J., Kovacs,C.M., Loutfy,M.R., Douek,D.C. and Badley,A.D.
Human immunodeficiency virus type 1 protease cleaves procaspase 8 in vivo
J Virol81, 6947-6956. PubMed Europe PubMed DOI
[YEAR:16-1-2007]Nijhuis,M., van Maarseveen,N.M., Lastere,S., Schipper,P., Coakley,E., Glass,B., Rovenska,M., de Jong,D., Chappey,C., Goedegebuure,I.W., Heilek-Snyder,G., Dulude,D., Cammack,N., Brakier-Gingras,L., Konvalinka,J., Parkin,N., Krausslich,H.G., Brun-Vezinet,F. and Boucher,C.A.
A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism
PLoS Medicine4, e36-e36. PubMed Europe PubMed DOI
Ode,H., Matsuyama,S., Hata,M., Neya,S., Kakizawa,J., Sugiura,W. and Hoshino,T.
Computational characterization of structural role of the non-active site mutation M36I of human immunodeficiency virus type 1 protease
J Mol Biol370, 598-607. PubMed Europe PubMed DOI
Orsenigo,C. and Vercellis,C.
Predicting HIV protease-cleavable peptides by discrete support vector machines
Lect Notes Comput Sci4447 LNCS, 197-206.
Parera,M., Fernandez,G., Clotet,B. and Martinez,M.A.
HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions
Mol Biol Evol24, 382-387. PubMed Europe PubMed DOI
Perez,M.A., Fernandes,P.A. and Ramos,M.J.
Drug design: new inhibitors for HIV-1 protease based on nelfinavir as lead
J Mol Graph Model26, 634-642. PubMed Europe PubMed DOI I
Poon,A.F., Kosakovsky Pond,S.L., Richman,D.D. and Frost,S.D.
Mapping protease inhibitor resistance to human immunodeficiency virus type 1 sequence polymorphisms within patients
J Virol81, 13598-13607. PubMed Europe PubMed DOI
Raghavan,S., Lu,Z., Beeson,T., Chapman,K.T., Schleif,W.A., Olsen,D.B., Stahlhut,M., Rutkowski,C.A., Gabryelski,L., Emini,E. and Tata,J.R.
Synthesis of novel HIV protease inhibitors (PI) with activity against PI-resistant virus
Bioorg Med Chem Lett17, 5432-5436. PubMed Europe PubMed DOI I
Reddy,G.S., Ali,A., Nalam,M.N., Anjum,S.G., Cao,H., Nathans,R.S., Schiffer,C.A. and Rana,T.M.
Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres
J Med Chem50, 4316-4328. PubMed Europe PubMed DOI I
Rognvaldsson,T., You,L. and Garwicz,D.
Bioinformatic approaches for modeling the substrate specificity of HIV-1 protease: an overview
Expert Rev Mol Diagn7, 435-451. PubMed Europe PubMed DOI P
Sadiq,S.K., Wan,S. and Coveney,P.V.
Insights into a mutation-assisted lateral drug escape mechanism from the HIV-1 protease active site
Biochemistry46, 14865-14877. PubMed Europe PubMed DOI
Sanches,M., Krauchenco,S., Martins,N.H., Gustchina,A., Wlodawer,A. and Polikarpov,I.
Structural characterization of B and non-B subtypes of HIV-protease: insights into the natural susceptibility to drug resistance development
J Mol Biol369, 1029-1040. PubMed Europe PubMed DOI S I
Seibold,S.A. and Cukier,R.I.
A molecular dynamics study comparing a wild-type with a multiple drug resistant HIV protease: differences in flap and aspartate 25 cavity dimensions
Proteins69, 551-565. PubMed Europe PubMed DOI
Staudt,T.M., Krausslich,H.G., Knemeyer,J.P. and Marme,N.
New HIV-protease assays applying self-quenching peptide substrates in combination with time-resolved fluorescence single-molecule spectroscopy
Int J Environ Anal Chem87, 731-743. DOI A
Tie,Y., Kovalevsky,A.Y., Boross,P., Wang,Y.F., Ghosh,A.K., Tozser,J., Harrison,R.W. and Weber,I.T.
Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir
Proteins67, 232-242. PubMed Europe PubMed DOI S I
Torbeev,V.Y. and Kent,S.B.
Convergent chemical synthesis and crystal structure of a 203 amino acid "covalent dimer" HIV-1 protease enzyme molecule
Angew Chem Int Ed Engl46, 1667-1670. PubMed Europe PubMed DOI S
Tozzini,V., Trylska,J., Chang,C.E. and McCammon,J.A.
Flap opening dynamics in HIV-1 protease explored with a coarse-grained model
J Struct Biol157, 606-615. PubMed Europe PubMed DOI
Tripathi,A., Fornabaio,M., Spyrakis,F., Mozzarelli,A., Cozzini,P. and Kellogg,G.E.
Complexity in modeling and understanding protonation states: computational titration of HIV-1-protease-inhibitor complexes
Chem Biodivers4, 2564-2577. PubMed Europe PubMed DOI
Volarath,P., Harrison,R.W. and Weber,I.T.
Structure based drug design for HIV protease: from molecular modeling to cheminformatics
Curr Top Med Chem7, 1030-1038. PubMed Europe PubMed DOI I
Waheed,A.A., Ablan,S.D., Roser,J.D., Sowder,R.C., Schaffner,C.P., Chertova,E. and Freed,E.O.
HIV-1 escape from the entry-inhibiting effects of a cholesterol-binding compound via cleavage of gp41 by the viral protease
Proc Natl Acad Sci U S A104, 8467-8471. PubMed Europe PubMed DOI
Wang,Y.F., Tie,Y., Boross,P.I., Tozser,J., Ghosh,A.K., Harrison,R.W. and Weber,I.T.
Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease
J Med Chem50, 4509-4515. PubMed Europe PubMed DOI I

2006

[YEAR:14-12-2006]Ali,A., Reddy,G.S., Cao,H., Anjum,S.G., Nalam,M.N., Schiffer,C.A. and Rana,T.M.
Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands
J Med Chem49, 7342-7356. PubMed Europe PubMed DOI I
[YEAR:1-6-2006]Alvarez,E., Castello,A., Menendez-Arias,L. and Carrasco,L.
HIV protease cleaves poly(A)-binding protein
Biochem J396, 219-226. PubMed Europe PubMed DOI P
Aruksakunwong,O., Wolschann,P., Hannongbua,S. and Sompornpisut,P.
Molecular dynamic and free energy studies of primary resistance mutations in HIV-1 protease-ritonavir complexes
J Chem Inf Model46, 2085-2092. PubMed Europe PubMed DOI I
[YEAR:24-2-2006]Aruksakunwong,O., Wittayanarakul,K., Sompornpisut,P., Sanghiran,V., Parasuk,V. and Hannongbua,S.
Structural and dynamical properties of different protonated states of mutant HIV-1 protease complexed with the saquinavir inhibitor studied by molecular dynamics simulations
J Mol Graph Model25, 324-332. PubMed Europe PubMed DOI I
Bandyopadhyay,P. and Meher,B.R.
Drug resistance of HIV-1 protease against JE-2147: I47V mutation investigated by molecular dynamics simulation
Chem Biol Drug Des67, 155-161. PubMed Europe PubMed DOI I
[YEAR:27-7-2006]Bannwarth,L., Kessler,A., Pethe,S., Collinet,B., Merabet,N., Boggetto,N., Sicsic,S., Reboud-Ravaux,M. and Ongeri,S.
Molecular tongs containing amino acid mimetic fragments: new inhibitors of wild-type and mutated HIV-1 protease dimerization
J Med Chem49, 4657-4664. PubMed Europe PubMed DOI I
[YEAR:23-8-2006]Baxter,J.D., Schapiro,J.M., Boucher,C.A., Kohlbrenner,V.M., Hall,D.B., Scherer,J.R. and Mayers,D.L.
Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir
J Virol80, 10794-10801. PubMed Europe PubMed DOI I
[YEAR:27-6-2006]Bjelic,S. and Aqvist,J.
Catalysis and linear free energy relationships in aspartic proteases
Biochemistry45, 7709-7723. PubMed Europe PubMed DOI
[YEAR:2-5-2006]Clemente,J.C., Coman,R.M., Thiaville,M.M., Janka,L.K., Jeung,J.A., Nukoolkarn,S., Govindasamy,L., Agbandje-McKenna,M., McKenna,R., Leelamanit,W., Goodenow,M.M. and Dunn,B.M.
Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir
Biochemistry45, 5468-5477. PubMed Europe PubMed DOI I
[YEAR:1-6-2006]Collier,B. and Gray,N.K.
Cleavage, a real turn-off? HIV-mediated proteolysis of PABP1
Biochem J396, e9-e11. PubMed Europe PubMed DOI P
Das,A., Prashar,V., Mahale,S., Serre,L., Ferrer,J.L. and Hosur,M.V.
Crystal structure of HIV-1 protease in situ product complex and observation of a low-barrier hydrogen bond between catalytic aspartates
Proc Natl Acad Sci U S A103, 18464-18469. PubMed Europe PubMed DOI S
[YEAR:21-4-2006]Davis,D.A., Brown,C.A., Singer,K.E., Wang,V., Kaufman,J., Stahl,S.J., Wingfield,P., Maeda,K., Harada,S., Yoshimura,K., Kosalaraksa,P., Mitsuya,H. and Yarchoan,R.
Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease
Antiviral Res72, 89-99. PubMed Europe PubMed DOI I
[YEAR:24-4-2006]de Mendoza,C., Valer,L., Bacheler,L., Pattery,T., Corral,A. and Soriano,V.
Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance
AIDS20, 1071-1074. PubMed Europe PubMed DOI I
Duskova,J., Dohnalek,J., Skalova,T., Petrokova,H., Vondrackova,E., Hradilek,M., Konvalinka,J., Soucek,M., Brynda,J., Fabry,M., Sedlacek,J. and Hasek,J.
On the role of the R configuration of the reaction-intermediate isostere in HIV-1 protease-inhibitor binding: X-ray structure at 2.0 A resolution
Acta Crystallogr D Biol Crystallogr62, 489-497. PubMed Europe PubMed DOI I
Edwards,P.
Nonsymmetrical cyclic urea inhibitors of HIV-1 aspartic protease
Drug Discov Today11, 569-570. DOI I
[YEAR:9-3-2006]Ekegren,J.K., Ginman,N., Johansson,A., Wallberg,H., Larhed,M., Samuelsson,B., Unge,T. and Hallberg,A.
Microwave-accelerated synthesis of P1'-extended HIV-1 protease inhibitors encompassing a tertiary alcohol in the transition-state mimicking scaffold
J Med Chem49, 1828-1832. PubMed Europe PubMed DOI S I
[YEAR:29-9-2006]Fernandez,M. and Caballero,J.
Modeling of activity of cyclic urea HIV-1 protease inhibitors using regularized-artificial neural networks
Bioorg Med Chem14, 280-294. PubMed Europe PubMed DOI I
Foulkes,J.E., Prabu-Jeyabalan,M., Cooper,D., Henderson,G.J., Harris,J., Swanstrom,R. and Schiffer,C.A.
Role of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivity
J Virol80, 6906-6916. PubMed Europe PubMed DOI
Freire,E.
Overcoming HIV-1 resistance to protease inhibitors
Drug Discov Today Dis Mech3, 281-286. DOI V I
[YEAR:24-8-2006]Ghosh,A.K., Sridhar,P.R., Leshchenko,S., Hussain,A.K., Li,J., Kovalevsky,A.Y., Walters,D.E., Wedekind,J.E., Grum-Tokars,V., Das,D., Koh,Y., Maeda,K., Gatanaga,H., Weber,I.T. and Mitsuya,H.
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance
J Med Chem49, 5252-5261. PubMed Europe PubMed DOI S I
[YEAR:7-2-2006]Ghosh,A.K., Schiltz,G., Perali,R.S., Leshchenko,S., Kay,S., Walters,D.E., Koh,Y., Maeda,K. and Mitsuya,H.
Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands
Bioorg Med Chem Lett16, 1869-1873. PubMed Europe PubMed DOI I
Gohda,K.
A quantitative structure-activity relationship study for structurally diverse HIV-1 protease inhibitors: contribution of conformational flexibility to inhibitory activity
J Enzyme Inhib Med Chem21, 609-615. PubMed Europe PubMed DOI I
[YEAR:20-12-2006]Heaslet,H., Kutilek,V., Morris,G.M., Lin,Y.C., Elder,J.H., Torbett,B.E. and Stout,C.D.
Structural insights into the mechanisms of drug resistance in HIV-1 protease NL4-3
J Mol Biol356, 967-981. PubMed Europe PubMed DOI S I
[YEAR:6-6-2006]Hester,E.K., Chandler,H.V. and Sims,K.M.
Fosamprenavir: drug development for adherence
Ann Pharmacother40, 1301-1310. PubMed Europe PubMed DOI I
[YEAR:8-3-2006]Hornak,V., Okur,A., Rizzo,R.C. and Simmerling,C.
HIV-1 protease flaps spontaneously close to the correct structure in simulations following manual placement of an inhibitor into the open state
J Am Chem Soc128, 2812-2813. PubMed Europe PubMed DOI
[YEAR:24-1-2006]Hornak,V., Okur,A., Rizzo,R.C. and Simmerling,C.
HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations
Proc Natl Acad Sci U S A103, 915-920. PubMed Europe PubMed DOI
Johnson,V.A., Brun-Vezinet,F., Clotet,B., Kuritzkes,D.R., Pillay,D., Schapiro,J.M. and Richman,D.D.
Update of the drug resistance mutations in HIV-1: Fall 2006
Top HIV Med14, 125-130. PubMed Europe PubMed
[YEAR:1-10-2006]Kazmierski,W.M., Furfine,E., Spaltenstein,A. and Wright,L.L.
New, potent P1/P2-morpholinone-based HIV-protease inhibitors
Bioorg Med Chem Lett16, 5226-5230. PubMed Europe PubMed DOI I
[YEAR:4-8-2006]Kovalevsky,A.Y., Liu,F., Leshchenko,S., Ghosh,A.K., Louis,J.M., Harrison,R.W. and Weber,I.T.
Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114
J Mol Biol363, 161-173. PubMed Europe PubMed DOI S I
[YEAR:23-2-2006]Kovalevsky,A.Y., Tie,Y., Liu,F., Boross,P.I., Wang,Y.F., Leshchenko,S., Ghosh,A.K., Harrison,R.W. and Weber,I.T.
Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M
J Med Chem49, 1379-1387. PubMed Europe PubMed DOI I
[YEAR:18-10-2006]Layten,M., Hornak,V. and Simmerling,C.
The open structure of a multi-drug-resistant HIV-1 protease is stabilized by crystal packing contacts
J Am Chem Soc128, 13360-13361. PubMed Europe PubMed DOI
Lee,S.G. and Chmielewski,J.
Rapid synthesis and in situ screening of potent HIV-1 protease dimerization inhibitors
Chem Biol13, 421-426. PubMed Europe PubMed DOI I
[YEAR:20-3-2006]Liu,F., Kovalevsky,A.Y., Louis,J.M., Boross,P.I., Wang,Y.F., Harrison,R.W. and Weber,I.T.
Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53l mutation
J Mol Biol358, 1191-1199. PubMed Europe PubMed DOI S
Lumini,A. and Nanni,L.
Machine learning for HIV-1 protease cleavage site prediction
Pattern Recogn Lett27, 1537-1544. DOI P
[YEAR:14-4-2006]Masso,M., Lu,Z. and Vaisman,I.I.
Computational mutagenesis studies of protein structure-function correlations
Proteins64, 234-245. PubMed Europe PubMed DOI
Mastrolorenzo,A., Rusconi,S., Scozzafava,A. and Supuran,C.T.
Inhibitors of HIV-1 protease: 10 years after
Expert Opin Ther Pat16, 1067-1091. DOI V I
[YEAR:10-5-2006]Minh,D.D., Chang,C.E., Trylska,J., Tozzini,V. and McCammon,J.A.
The influence of macromolecular crowding on HIV-1 protease internal dynamics
J Am Chem Soc128, 6006-6007. PubMed Europe PubMed DOI
Nanni,L. and Lumini,A.
A reliable method for HIV-1 protease cleavage site prediction
Neurocomputing69, 838-841. P
[YEAR:1-6-2006]Ozer,N., Haliloglu,T. and Schiffer,C.A.
Substrate specificity in HIV-1 protease by a biased sequence search method
Proteins64, 444-456. PubMed Europe PubMed DOI P
Prabu-Jeyabalan,M., King,N.M., Nalivaika,E.A., Heilek-Snyder,G., Cammack,N. and Schiffer,C.A.
Substrate envelope and drug resistance: crystal structure of RO1 in complex with wild-type human immunodeficiency virus type 1 protease
Antimicrob Agents Chemother50, 1518-1521. PubMed Europe PubMed DOI S I
Prabu-Jeyabalan,M., Nalivaika,E.A., Romano,K. and Schiffer,C.A.
Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate
J Virol80, 3607-3616. PubMed Europe PubMed DOI S
[YEAR:24-2-2006]Randolph,J.T., Huang,P.P., Flosi,W.J., DeGoey,D., Klein,L.L., Yeung,C.M., Flentge,C., Sun,M., Zhao,C., Dekhtyar,T., Mo,H., Colletti,L., Kati,W., Marsh,K.C., Molla,A. and Kempf,D.J.
Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors
Bioorg Med Chem14, 4035-4046. PubMed Europe PubMed DOI I
[YEAR:20-1-2006]Sevigny,G., Stranix,B., Tian,B., Dubois,A., Sauve,G., Petropoulos,C., Lie,Y., Hellmann,N., Conway,B. and Yelle,J.
Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor
Antiviral Res70, 17-20. PubMed Europe PubMed DOI I
Simmerling,C. and Gomperts,R.
Simulating HIV-1 protease at its most vulnerable instant
Sci Comput23, 32-34. S
[YEAR:21-9-2006]Skalova,T., Dohnalek,J., Duskova,J., Petrokova,H., Hradilek,M., Soucek,M., Konvalinka,J. and Hasek,J.
HIV-1 protease mutations and inhibitor modifications monitored on a series of complexes. Structural basis for the effect of the A71V mutation on the active site
J Med Chem49, 5777-5784. PubMed Europe PubMed DOI I
[YEAR:17-11-2006]Smith,A.B., III, Charnley,A.K., Harada,H., Beiger,J.J., Cantin,L.D., Kenesky,C.S., Hirschmann,R., Munshi,S., Olsen,D.B., Stahlhut,M.W., Schleif,W.A. and Kuo,L.C.
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains
Bioorg Med Chem Lett16, 859-863. PubMed Europe PubMed DOI S I
[YEAR:16-1-2006]Specker,E., Bottcher,J., Brass,S., Heine,A., Lilie,H., Schoop,A., Muller,G., Griebenow,N. and Klebe,G.
Unexpected novel binding mode of pyrrolidine-based aspartyl protease inhibitors: design, synthesis and crystal structure in complex with HIV protease
ChemMedChem1, 106-117. PubMed Europe PubMed DOI S I
[YEAR:24-4-2006]Stranix,B.R., Lavallee,J.F., Sevigny,G., Yelle,J., Perron,V., LeBerre,N., Herbart,D. and Wu,J.J.
Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-acyl aromatic alpha-amino acids
Bioorg Med Chem Lett16, 3459-3462. PubMed Europe PubMed DOI I
[YEAR:23-9-2006]Toth,G. and Borics,A.
Flap opening mechanism of HIV-1 protease
J Mol Graph Model24, 465-474. PubMed Europe PubMed DOI
[YEAR:30-5-2006]Toth,G. and Borics,A.
Closing of the flaps of HIV-1 protease induced by substrate binding: a model of a flap closing mechanism in retroviral aspartic proteases
Biochemistry45, 6606-6614. PubMed Europe PubMed DOI
[YEAR:16-4-2006]Wannberg,J., Sabnis,Y.A., Vrang,L., Samuelsson,B., Karlen,A., Hallberg,A. and Larhed,M.
A new structural theme in C2-symmetric HIV-1 protease inhibitors: ortho-substituted P1/P1' side chains
Bioorg Med Chem14, 5303-5315. PubMed Europe PubMed DOI I
Whiting,M., Muldoon,J., Lin,Y.C., Silverman,S.M., Lindstrom,W., Olson,A.J., Kolb,H.C., Finn,M.G., Sharpless,K.B., Elder,J.H. and Fokin,V.V.
Inhibitors of HIV-1 protease by using in situ click chemistry
Angew Chem Int Ed Engl45, 1435-1439. PubMed Europe PubMed DOI I
[YEAR:28-12-2006]Whiting,M., Tripp,J.C., Lin,Y.C., Lindstrom,W., Olson,A.J., Elder,J.H., Sharpless,K.B. and Fokin,V.V.
Rapid discovery and structure-activity profiling of novel inhibitors of human immunodeficiency virus type 1 protease enabled by the copper(i)-catalyzed synthesis of 1,2,3-triazoles and their further functionalization
J Med Chem49, 7697-7710. PubMed Europe PubMed DOI I
You,L., Garwicz,D. and Rognvaldsson,T.
Erratum: Comprehensive bioinformatic analysis of the specificity of human immunodeficiency virus type 1 protease (Journal of Virology (2005) 79, 19 (12477-12486))
J Virol80, 4205- PubMed Europe PubMed DOI
You,L.
Detection of cleavage sites for HIV-1 protease in native proteins
Comput Syst Bioinformatics Conf2006, 249-256. PubMed Europe PubMed P

2005

[YEAR:1-2-2005]Ax,A., Schaal,W., Vrang,L., Samuelsson,B., Hallberg,A. and Karlen,A.
Cyclic sulfamide HIV-1 protease inhibitors, with sidechains spanning from P2/P2' to P1/P1'
Bioorg Med Chem13, 755-764. PubMed Europe PubMed DOI I
Bagossi,P., Sperka,T., Feher,A., Kadas,J., Zahuczky,G., Miklossy,G., Boross,P. and Tozser,J.
Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites
J Virol79, 4213-4218. PubMed Europe PubMed DOI P
[YEAR:1-3-2005]Bouzide,A., Sauve,G. and Yelle,J.
Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure-activity relationship studies
Bioorg Med Chem Lett15, 1509-1513. PubMed Europe PubMed DOI I
Bowman,M.J., Byrne,S. and Chmielewski,J.
Switching between allosteric and dimerization inhibition of HIV-1 protease
Chem Biol12, 439-444. PubMed Europe PubMed DOI I
Broglia,R.A., Tiana,G., Sutto,L., Provasi,D. and Simona,F.
Design of HIV-1-PR inhibitors that do not create resistance: blocking the folding of single monomers
Protein Sci14, 2668-2681. PubMed Europe PubMed DOI I
[YEAR:1-6-2005]Calazans,A., Brindeiro,R., Brindeiro,P., Verli,H., Arruda,M.B., Gonzalez,L.M., Guimaraes,J.A., Diaz,R.S., Antunes,O.A. and Tanuri,A.
Low accumulation of L90M in protease from subtype FHIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism
J Infect Dis191, 1961-1970. PubMed Europe PubMed DOI
[YEAR:4-1-2005]Chatterjee,A., Mridula,P., Mishra,R.K., Mittal,R. and Hosur,R.V.
Folding regulates autoprocessing of HIV-1 protease precursor
J Biol Chem280, 11369-11378. PubMed Europe PubMed DOI
[YEAR:25-10-2005]Cigler,P., Kozisek,M., Rezacova,P., Brynda,J., Otwinowski,Z., Pokorna,J., Plesek,J., Gruner,B., Doleckova-Maresova,L., Masa,M., Sedlacek,J., Bodem,J., Krausslich,H.G., Kral,V. and Konvalinka,J.
From nonpeptide toward noncarbon protease inhibitors: metallacarboranes as specific and potent inhibitors of HIV protease
Proc Natl Acad Sci U S A102, 15394-15399. PubMed Europe PubMed DOI I
De Meyer,S., Azijn,H., Surleraux,D., Jochmans,D., Tahri,A., Pauwels,R., Wigerinck,P. and de Bethune,M.P.
TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates
Antimicrob Agents Chemother49, 2314-2321. PubMed Europe PubMed DOI I
[YEAR:15-12-2005]Ekegren,J.K., Unge,T., Safa,M.Z., Wallberg,H., Samuelsson,B. and Hallberg,A.
A new class of HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold
J Med Chem48, 8098-8102. PubMed Europe PubMed DOI I
Ellis,J.M. and Ross,J.
A novel nonpeptidic protease inhibitor
Formulary40, I
Fuster,D. and Clotet,B.
Review of atazanavir: a novel HIV protease inhibitor
Expert Opin Pharmacother6, 1565-1572. PubMed Europe PubMed DOI I
[YEAR:19-5-2005]Ghosh,A.K., Swanson,L.M., Cho,H., Leshchenko,S., Hussain,K.A., Kay,S., Walters,D.E., Koh,Y. and Mitsuya,H.
Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors
J Med Chem48, 3576-3585. PubMed Europe PubMed DOI I
Hoffmann,D., Buchberger,B. and Nemetz,C.
In vitro synthesis of enzymatically active HIV-1 protease for rapid phenotypic resistance profiling
J Clin Virol32, 294-299. PubMed Europe PubMed DOI E
[YEAR:24-3-2005]Hwang,Y.S. and Chmielewski,J.
Development of low molecular weight HIV-1 protease dimerization inhibitors
J Med Chem48, 2239-2242. PubMed Europe PubMed DOI I
Johnson,V.A., Brun-Vezinet,F., Clotet,B., Conway,B., Kuritzkes,D.R., Pillay,D., Schapiro,J.M., Telenti,A. and Richman,D.D.
Update of the drug resistance mutations in HIV-1: Fall 2005
Top HIV Med13, 125-131. PubMed Europe PubMed
[YEAR:3-6-2005]Kagan,R.M., Shenderovich,M.D., Heseltine,P.N. and Ramnarayan,K.
Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir
Protein Sci14, 1870-1878. PubMed Europe PubMed DOI S I
Kandula,V.R., Khanlou,H. and Farthing,C.
Tipranavir: a novel second-generation nonpeptidic protease inhibitor
Expert Rev Anti Infect Ther3, 9-21. PubMed Europe PubMed DOI I
Kaplan,S.S. and Hicks,C.B.
Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection
Expert Opin Pharmacother6, 1573-1585. PubMed Europe PubMed DOI I
[YEAR:23-11-2005]Kovalskyy,D., Dubyna,V., Mark,A.E. and Kornelyuk,A.
A molecular dynamics study of the structural stability of HIV-1 protease under physiological conditions: the role of Na+ ions in stabilizing the active site
Proteins58, 450-458. PubMed Europe PubMed DOI
[YEAR:21-10-2005]Liu,F., Boross,P.I., Wang,Y.F., Tozser,J., Louis,J.M., Harrison,R.W. and Weber,I.T.
Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S
J Mol Biol354, 789-800. PubMed Europe PubMed DOI S I
[YEAR:1-12-2005]Lu,Z., Bohn,J., Rano,T., Rutkowski,C.A., Simcoe,A.L., Olsen,D.B., Schleif,W.A., Carella,A., Gabryelski,L., Jin,L., Lin,J.H., Emini,E., Chapman,K. and Tata,J.R.
Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus
Bioorg Med Chem Lett15, 5311-5314. PubMed Europe PubMed DOI I
Martin,P., Vickrey,J.F., Proteasa,G., Jimenez,Y.L., Wawrzak,Z., Winters,M.A., Merigan,T.C. and Kovari,L.C.
"Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target
Structure13, 1887-1895. PubMed Europe PubMed DOI S
[YEAR:1-11-2005]Meagher,K.L. and Carlson,H.A.
Solvation influences flap collapse in HIV-1 protease
Proteins58, 119-125. PubMed Europe PubMed DOI
Ohtaka,H. and Freire,E.
Adaptive inhibitors of the HIV-1 protease
Prog Biophys Mol Biol88, 193-208. PubMed Europe PubMed DOI I
[YEAR:1-11-2005]Pettit,S.C., Lindquist,J.N., Kaplan,A.H. and Swanstrom,R.
Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates
Retrovirology2, 66-66. PubMed Europe PubMed DOI
[YEAR:28-4-2005]Prasanna,M.D., Vondrasek,J., Wlodawer,A. and Bhat,T.N.
Application of InChI to curate, index, and query 3-D structures
Proteins60, 1-4. PubMed Europe PubMed DOI
[YEAR:20-6-2005]Sherrill,R.G., Furfine,E.S., Hazen,R.J., Miller,J.F., Reynolds,D.J., Sammond,D.M., Spaltenstein,A., Wheelan,P. and Wright,L.L.
Synthesis and antiviral activities of novel N-alkoxy-arylsulfonamide-based HIV protease inhibitors
Bioorg Med Chem Lett15, 3560-3564. PubMed Europe PubMed DOI I
[YEAR:3-1-2005]Sherrill,R.G., Andrews,C.W., Bock,W.J., Davis-Ward,R.G., Furfine,E.S., Hazen,R.J., Rutkowske,R.D., Spaltenstein,A. and Wright,L.L.
Optimization of pyrrolidinone based HIV protease inhibitors
Bioorg Med Chem Lett15, 81-84. PubMed Europe PubMed DOI I
Spaltenstein,A., Kazmierski,W.M., Miller,J.F. and Samano,V.
Discovery of next generation inhibitors of HIV protease
Curr Top Med Chem5, 1589-1607. PubMed Europe PubMed DOI V I
Specker,E., Bottcher,J., Lilie,H., Heine,A., Schoop,A., Muller,G., Griebenow,N. and Klebe,G.
An old target revisited: two new privileged skeletons and an unexpected binding mode for HIV-protease inhibitors
Angew Chem Int Ed Engl44, 3140-3144. PubMed Europe PubMed DOI I
[YEAR:20-10-2005]Specker,E., Bottcher,J., Heine,A., Sotriffer,C.A., Lilie,H., Schoop,A., Muller,G., Griebenow,N. and Klebe,G.
Hydroxyethylene sulfones as a new scaffold to address aspartic proteases: design, synthesis, and structural characterization
J Med Chem48, 6607-6619. PubMed Europe PubMed DOI S I
[YEAR:24-3-2005]Surleraux,D.L., Tahri,A., Verschueren,W.G., Pille,G.M., de Kock,H.A., Jonckers,T.H., Peeters,A., De Meyer,S., Azijn,H., Pauwels,R., de Bethune,M.P., King,N.M., Prabu-Jeyabalan,M., Schiffer,C.A. and Wigerinck,P.B.
Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor
J Med Chem48, 1813-1822. PubMed Europe PubMed DOI I
[YEAR:24-3-2005]Surleraux,D.L., de Kock,H.A., Verschueren,W.G., Pille,G.M., Maes,L.J., Peeters,A., Vendeville,S., De Meyer,S., Azijn,H., Pauwels,R., de Bethune,M.P., King,N.M., Prabu-Jeyabalan,M., Schiffer,C.A. and Wigerinck,P.B.
Design of HIV-1 protease inhibitors active on multidrug-resistant virus
J Med Chem48, 1965-1973. PubMed Europe PubMed DOI I
Svedhem,V., Lindkvist,A., Bergroth,T., Knut,L. and Sonnerborg,A.
Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir
J Med Virol76, 447-451. PubMed Europe PubMed DOI I
Svicher,V., Ceccherini-Silberstein,F., Erba,F., Santoro,M., Gori,C., Bellocchi,M.C., Giannella,S., Trotta,M.P., Monforte,A., Antinori,A. and Perno,C.F.
Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors
Antimicrob Agents Chemother49, 2015-2025. PubMed Europe PubMed DOI I
Tie,Y., Boross,P.I., Wang,Y.F., Gaddis,L., Liu,F., Chen,X., Tozser,J., Harrison,R.W. and Weber,I.T.
Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs
FEBS J272, 5265-5277. PubMed Europe PubMed DOI S I
Ventoso,I., Navarro,J., Munoz,M.A. and Carrasco,L.
Involvement of HIV-1 protease in virus-induced cell killing
Antiviral Res66, 47-55. PubMed Europe PubMed DOI
Weinheimer,S., Discotto,L., Friborg,J., Yang,H. and Colonno,R.
Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones
Antimicrob Agents Chemother49, 3816-3824. PubMed Europe PubMed DOI I
Winters,M.A., Kagan,R.M., Heseltine,P.N. and Merigan,T.C.
New two-amino acid insertion near codon 70 of the HIV type 1 protease gene
AIDS Res Hum Retroviruses21, 311-313. PubMed Europe PubMed DOI M
Winters,M.A. and Merigan,T.C.
Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms
Antimicrob Agents Chemother49, 2575-2582. PubMed Europe PubMed DOI
Yanchunas,J., Jr., Langley,D.R., Tao,L., Rose,R.E., Friborg,J., Colonno,R.J. and Doyle,M.L.
Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors
Antimicrob Agents Chemother49, 3825-3832. PubMed Europe PubMed DOI I
[YEAR:2-5-2005]Yeung,C.M., Klein,L.L., Flentge,C.A., Randolph,J.T., Zhao,C., Sun,M., Dekhtyar,T., Stoll,V.S. and Kempf,D.J.
Oximinoarylsulfonamides as potent HIV protease inhibitors
Bioorg Med Chem Lett15, 2275-2278. PubMed Europe PubMed DOI I
You,L., Garwicz,D. and Rognvaldsson,T.
Comprehensive bioinformatic analysis of the specificity of human immunodeficiency virus type 1 protease
J Virol79, 12477-12486. PubMed Europe PubMed DOI P
[YEAR:30-9-2005]Zhao,C., Sham,H.L., Sun,M., Stoll,V.S., Stewart,K.D., Lin,S., Mo,H., Vasavanonda,S., Saldivar,A., Park,C., McDonald,E.J., Marsh,K.C., Klein,L.L., Kempf,D.J. and Norbeck,D.W.
Synthesis and activity of N-acyl azacyclic urea HIV-1 protease inhibitors with high potency against multiple drug resistant viral strains
Bioorg Med Chem Lett15, 5499-5503. PubMed Europe PubMed DOI I

2004

Abdel-Rahman,H.M., Kimura,T., Hidaka,K., Kiso,A., Nezami,A., Freire,E., Hayashi,Y. and Kiso,Y.
Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases
Biol Chem385, 1035-1039. PubMed Europe PubMed DOI
Abdel-Rahman,H.M., el-Koussi,N.A., Alkaramany,G.S., Youssef,A.F. and Kiso,Y.
A novel dipeptide-based HIV protease inhibitor containing allophenylnorstatine
Arch Pharm (Weinheim)337, 587-598. PubMed Europe PubMed DOI I
Bagossi,P., Kadas,J., Miklossy,G., Boross,P., Weber,I.T. and Tozser,J.
Development of a microtiter plate fluorescent assay for inhibition studies on the HTLV-1 and HIV-1 proteinases
J Virol Methods119, 87-93. PubMed Europe PubMed DOI A I
Boyle,B.A., Elion,R.A., Moyle,G.J. and Cohen,C.J.
Considerations in selecting protease inhibitor therapy
AIDS Rev6, 218-225. PubMed Europe PubMed
Brynda,J., Rezacova,P., Fabry,M., Horejsi,M., Stouracova,R., Soucek,M., Hradilek,M., Konvalinka,J. and Sedlacek,J.
Inhibitor binding at the protein interface in crystals of a HIV-1 protease complex
Acta Crystallogr D Biol Crystallogr60, 1943-1948. PubMed Europe PubMed DOI S I
[YEAR:8-4-2004]Brynda,J., Rezacova,P., Fabry,M., Horejsi,M., Stouracova,R., Sedlacek,J., Soucek,M., Hradilek,M., Lepsik,M. and Konvalinka,J.
A phenylnorstatine inhibitor binding to HIV-1 protease: geometry, protonation, and subsite-pocket interactions analyzed at atomic resolution
J Med Chem47, 2030-2036. PubMed Europe PubMed DOI S I
[YEAR:20-8-2004]Ceccherini-Silberstein,F., Erba,F., Gago,F., Bertoli,A., Forbici,F., Bellocchi,M.C., Gori,C., D'Arrigo,R., Marcon,L., Balotta,C., Antinori,A., Monforte,A.D. and Perno,C.F.
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure
AIDS18, F11-F19. PubMed Europe PubMed DOI
[YEAR:28-9-2004]Chen,X., Weber,I.T. and Harrison,R.W.
Molecular dynamics simulations of 14 HIV protease mutants in complexes with indinavir
J Mol Model10, 373-381. PubMed Europe PubMed DOI I
[YEAR:28-9-2004]Clemente,J.C., Moose,R.E., Hemrajani,R., Whitford,L.R., Govindasamy,L., Reutzel,R., McKenna,R., Agbandje-McKenna,M., Goodenow,M.M. and Dunn,B.M.
Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease
Biochemistry43, 12141-12151. PubMed Europe PubMed DOI S I
de Mendoza,C. and Soriano,V.
Resistance to HIV protease inhibitors: mechanisms and clinical consequences
Curr Drug Metab5, 321-328. PubMed Europe PubMed DOI I
Dunn,B.M. and Rao,M.
Human immunodeficiency virus 1 retropepsin
[ISSN:0-12-079610-4]2, 144-154. V
[YEAR:15-9-2004]Gerencer,M. and Burek,V.
Identification of HIV-1 protease cleavage site in human C1-inhibitor
Virus Res105, 97-100. PubMed Europe PubMed DOI P
Gonzalez,L.M., Brindeiro,R.M., Aguiar,R.S., Pereira,H.S., Abreu,C.M., Soares,M.A. and Tanuri,A.
Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases
Antimicrob Agents Chemother48, 3552-3555. PubMed Europe PubMed DOI I
[YEAR:2-1-2004]Hamada,Y., Matsumoto,H., Yamaguchi,S., Kimura,T., Hayashi,Y. and Kiso,Y.
Water-soluble prodrugs of dipeptide HIV protease inhibitors based on O - >N intramolecular acyl migration: d esign, synthesis and kinetic study
Bioorg Med Chem12, 159-170. PubMed Europe PubMed DOI I
[YEAR:16-11-2004]Hanlon,M.H., Porter,D.J., Furfine,E.S., Spaltenstein,A., Carter,H.L., Danger,D., Shu,A.Y., Kaldor,I.W., Miller,J.F. and Samano,V.A.
Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides
Biochemistry43, 14500-14507. PubMed Europe PubMed DOI I
[YEAR:15-11-2004]Kazmierski,W.M., Andrews,W., Furfine,E., Spaltenstein,A. and Wright,L.
Discovery of potent pyrrolidone-based HIV-1 protease inhibitors with enhanced drug-like properties
Bioorg Med Chem Lett14, 5689-5692. PubMed Europe PubMed DOI I
[YEAR:15-11-2004]Kazmierski,W.M., Furfine,E., Gray-Nunez,Y., Spaltenstein,A. and Wright,L.
Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold
Bioorg Med Chem Lett14, 5685-5687. PubMed Europe PubMed DOI I
[YEAR:20-9-2004]Kim,R.M., Rouse,E.A., Chapman,K.T., Schleif,W.A., Olsen,D.B., Stahlhut,M., Rutkowski,C.A., Emini,E.A. and Tata,J.R.
P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1
Bioorg Med Chem Lett14, 4651-4654. PubMed Europe PubMed DOI I
King,N.M., Prabu-Jeyabalan,M., Nalivaika,E.A., Wigerinck,P., de Bethune,M.P. and Schiffer,C.A.
Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor
J Virol78, 12012-12021. PubMed Europe PubMed DOI S I
Kovalskyy,D.B., Dubina,V.M. and Kornelyuk,A.I.
Molecular dynamics simulation study of effect of the conservative Leu10-->Ile mutation on intramolecular mobility of HIV-1 protease
Biopolym Cell20, 321-324. DOI
Kumar,S. and Seth,P.
Immunogenicity of recombinant modified vaccinia Ankara viruses (rMVA) expressing HIV-1 Indian subtype C gag-protease and env-gp120 genes in mice
Viral Immunol17, 574-579. PubMed Europe PubMed DOI
Leigh Brown,A.J., Frost,S.D., Good,B., Daar,E.S., Simon,V., Markowitz,M., Collier,A.C., Connick,E., Conway,B., Margolick,J.B., Routy,J.P., Corbeil,J., Hellmann,N.S., Richman,D.D. and Little,S.J.
Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection
J Virol78, 2242-2246. PubMed Europe PubMed DOI I
Lindberg,J., Pyring,D., Lowgren,S., Rosenquist,A., Zuccarello,G., Kvarnstrom,I., Zhang,H., Vrang,L., Classon,B., Hallberg,A., Samuelsson,B. and Unge,T.
Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy
Eur J Biochem271, 4594-4602. PubMed Europe PubMed DOI I
Logsdon,B.C., Vickrey,J.F., Martin,P., Proteasa,G., Koepke,J.I., Terlecky,S.R., Wawrzak,Z., Winters,M.A., Merigan,T.C. and Kovari,L.C.
Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity
J Virol78, 3123-3132. PubMed Europe PubMed DOI S I
Mahalingam,B., Wang,Y.F., Boross,P.I., Tozser,J., Louis,J.M., Harrison,R.W. and Weber,I.T.
Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site
Eur J Biochem271, 1516-1524. PubMed Europe PubMed DOI S I
[YEAR:2-12-2004]Merabet,N., Dumond,J., Collinet,B., Van Baelinghem,L., Boggetto,N., Ongeri,S., Ressad,F., Reboud-Ravaux,M. and Sicsic,S.
New constrained "molecular tongs" designed to dissociate HIV-1 protease dimer
J Med Chem47, 6392-6400. PubMed Europe PubMed DOI I
[YEAR:23-2-2004]Miller,J.F., Furfine,E.S., Hanlon,M.H., Hazen,R.J., Ray,J.A., Robinson,L., Samano,V. and Spaltenstein,A.
Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains
Bioorg Med Chem Lett14, 959-963. PubMed Europe PubMed DOI I
[YEAR:2-1-2004]Mimoto,T., Terashima,K., Nojima,S., Takaku,H., Nakayama,M., Shintani,M., Yamaoka,T. and Hayashi,H.
Structure-activity and structure-metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure
Bioorg Med Chem12, 281-293. PubMed Europe PubMed DOI I
[YEAR:1-7-2004]Musial,B.L., Chojnacki,J.K. and Coleman,C.I.
Atazanavir: a new protease inhibitor to treat HIV infection
Am J Health Syst Pharm61, 1365-1374. PubMed Europe PubMed I
[YEAR:18-6-2004]Parreira,R., Santos,M., Piedade,J. and Esteves,A.
Natural polymorphism of HIV-1 subtype G protease and cleavage sites
AIDS18, 1345-1346. PubMed Europe PubMed DOI M
Petrokova,H., Duskova,J., Dohnalek,J., Skalova,T., Vondrackova-Buchtelova,E., Soucek,M., Konvalinka,J., Brynda,J., Fabry,M., Sedlacek,J. and Hasek,J.
Role of hydroxyl group and R/S configuration of isostere in binding properties of HIV-1 protease inhibitors
Eur J Biochem271, 4451-4461. PubMed Europe PubMed DOI I
Pettit,S.C., Everitt,L.E., Choudhury,S., Dunn,B.M. and Kaplan,A.H.
Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism
J Virol78, 8477-8485. PubMed Europe PubMed DOI
Piliero,P.J.
Atazanavir: a novel once-daily protease inhibitor
Drugs Today (Barc)40, 901-912. PubMed Europe PubMed DOI I
Prabu-Jeyabalan,M., Nalivaika,E.A., King,N.M. and Schiffer,C.A.
Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease
J Virol78, 12446-12454. PubMed Europe PubMed DOI
[YEAR:29-10-2004]Prashar,V. and Hosur,M.V.
1.8A X-ray structure of C95M/C1095F double mutant of tethered HIV-1 protease dimer complexed with acetyl pepstatin
Biochem Biophys Res Commun323, 1229-1235. PubMed Europe PubMed DOI S I
[YEAR:26-2-2004]Rognvaldsson,T. and You,L.
Why neural networks should not be used for HIV-1 protease cleavage site prediction
Bioinformatics20, 1702-1709. PubMed Europe PubMed DOI
Sanches,M., Helena Martins,N., Calazans,A., de Moraes Brindeiro,R., Tanuri,A., Antunes,O.A. and Polikarpov,I.
Crystallization of a non-B and a B mutant HIV protease
Acta Crystallogr D Biol Crystallogr60, 1625-1627. PubMed Europe PubMed DOI M S I
[YEAR:23-4-2004]Tie,Y., Boross,P.I., Wang,Y.F., Gaddis,L., Hussain,A.K., Leshchenko,S., Ghosh,A.K., Louis,J.M., Harrison,R.W. and Weber,I.T.
High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains
J Mol Biol338, 341-352. PubMed Europe PubMed DOI S I
[YEAR:13-4-2004]Tozser,J., Shulenin,S., Louis,J.M., Copeland,T.D. and Oroszlan,S.
In vitro processing of HIV-1 nucleocapsid protein by the viral proteinase: effects of amino acid substitutions at the scissile bond in the proximal zinc finger sequence
Biochemistry43, 4304-4312. PubMed Europe PubMed DOI
Trylska,J., Grochowski,P. and McCammon,J.A.
The role of hydrogen bonding in the enzymatic reaction catalyzed by HIV-1 protease
Protein Sci13, 513-528. PubMed Europe PubMed DOI
[YEAR:15-5-2004]Vega,S., Kang,L.W., Velazquez-Campoy,A., Kiso,Y., Amzel,L.M. and Freire,E.
A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease
Proteins55, 594-602. PubMed Europe PubMed DOI S I

2003

Alvarez,E., Menendez-Arias,L. and Carrasco,L.
The eukaryotic translation initiation factor 4GI is cleaved by different retroviral proteases
J Virol77, 12392-12400. PubMed Europe PubMed DOI
Andersson,H.O., Fridborg,K., Lowgren,S., Alterman,M., Muhlman,A., Bjorsne,M., Garg,N., Kvarnstrom,I., Schaal,W., Classon,B., Karlen,A., Danielsson,U.H., Ahlsen,G., Nillroth,U., Vrang,L., Oberg,B., Samuelsson,B., Hallberg,A. and Unge,T.
Optimization of P1-P3 groups in symmetric and asymmetric HIV-1 protease inhibitors
Eur J Biochem270, 1746-1758. PubMed Europe PubMed DOI I
[YEAR:30-5-2003]Bhavesh,N.S., Sinha,R., Mohan,P.M. and Hosur,R.V.
NMR elucidation of early folding hierarchy in HIV-1 protease
J Biol Chem278, 19980-19985. PubMed Europe PubMed DOI
[YEAR:10-1-2003]Blanco,R., Carrasco,L. and Ventoso,I.
Cell killing by HIV-1 protease
J Biol Chem278, 1086-1093. PubMed Europe PubMed DOI
[YEAR:20-11-2003]Breccia,P., Boggetto,N., Perez-Fernandez,R., Van Gool,M., Takahashi,M., Rene,L., Prados,P., Badet,B., Reboud-Ravaux,M. and de Mendoza,J.
Dimerization inhibitors of HIV-1 protease based on a bicyclic guanidinium subunit
J Med Chem46, 5196-5207. PubMed Europe PubMed DOI I
[YEAR:3-11-2003]Chen,X., Kempf,D.J., Li,L., Sham,H.L., Vasavanonda,S., Wideburg,N.E., Saldivar,A., Marsh,K.C., McDonald,E. and Norbeck,D.W.
Synthesis and SAR studies of potent HIV protease inhibitors containing novel dimethylphenoxyl acetates as P2 ligands
Bioorg Med Chem Lett13, 3657-3660. PubMed Europe PubMed DOI I
[YEAR:30-12-2003]Clemente,J.C., Hemrajani,R., Blum,L.E., Goodenow,M.M. and Dunn,B.M.
Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N
Biochemistry42, 15029-15035. PubMed Europe PubMed DOI M I
Dautin,N., Karimova,G. and Ladant,D.
Human immunodeficiency virus (HIV) type 1 transframe protein can restore activity to a dimerization-deficient HIV protease variant
J Virol77, 8216-8226. PubMed Europe PubMed DOI
Davis,D.A., Brown,C.A., Newcomb,F.M., Boja,E.S., Fales,H.M., Kaufman,J., Stahl,S.J., Wingfield,P. and Yarchoan,R.
Reversible oxidative modification as a mechanism for regulating retroviral protease dimerization and activation
J Virol77, 3319-3325. PubMed Europe PubMed DOI
[YEAR:30-9-2003]Hoffman,N.G., Schiffer,C.A. and Swanstrom,R.
Covariation of amino acid positions in HIV-1 protease
Virology314, 536-548. PubMed Europe PubMed DOI
Ingr,M., Uhlikova,T., Strisovsky,K., Majerova,E. and Konvalinka,J.
Kinetics of the dimerization of retroviral proteases: the "fireman's grip" and dimerization
Protein Sci12, 2173-2182. PubMed Europe PubMed DOI
[YEAR:31-10-2003]Ishima,R., Torchia,D.A., Lynch,S.M., Gronenborn,A.M. and Louis,J.M.
Solution structure of the mature HIV-1 protease monomer: insight into the tertiary fold and stability of a precursor
J Biol Chem278, 43311-43319. PubMed Europe PubMed DOI S
Karlsson,A.C., Deeks,S.G., Barbour,J.D., Heiken,B.D., Younger,S.R., Hoh,R., Lane,M., Sallberg,M., Ortiz,G.M., Demarest,J.F., Liegler,T., Grant,R.M., Martin,J.N. and Nixon,D.F.
Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene
J Virol77, 6743-6752. PubMed Europe PubMed DOI
[YEAR:17-11-2003]Kevin,N.J., Duffy,J.L., Kirk,B.A., Chapman,K.T., Schleif,W.A., Olsen,D.B., Stahlhut,M., Rutkowski,C.A., Kuo,L.C., Jin,L., Lin,J.H., Emini,E.A. and Tata,J.R.
Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir
Bioorg Med Chem Lett13, 4027-4030. PubMed Europe PubMed DOI I
Kumar,M. and Hosur,M.V.
Adaptability and flexibility of HIV-1 protease
Eur J Biochem270, 1231-1239. PubMed Europe PubMed DOI S
[YEAR:15-5-2003]Kurt,N., Scott,W.R., Schiffer,C.A. and Haliloglu,T.
Cooperative fluctuations of unliganded and substrate-bound HIV-1 protease: a structure-based analysis on a variety of conformations from crystallography and molecular dynamics simulations
Proteins51, 409-422. PubMed Europe PubMed DOI
[YEAR:4-6-2003]Li,Z. and Lazaridis,T.
Thermodynamic contributions of the ordered water molecule in HIV-1 protease
J Am Chem Soc125, 6636-6637. PubMed Europe PubMed DOI
Lin,Y.C., Beck,Z., Morris,G.M., Olson,A.J. and Elder,J.H.
Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases
J Virol77, 6589-6600. PubMed Europe PubMed DOI I
[YEAR:21-2-2003]Louis,J.M., Ishima,R., Nesheiwat,I., Pannell,L.K., Lynch,S.M., Torchia,D.A. and Gronenborn,A.M.
Revisiting monomeric HIV-1 protease. Characterization and redesign for improved properties
J Biol Chem278, 6085-6092. PubMed Europe PubMed DOI
Mehandru,S. and Markowitz,M.
Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection
Expert Opin Investig Drugs12, 1821-1828. PubMed Europe PubMed DOI I
[YEAR:20-3-2003]Oscarsson,K., Lahmann,M., Lindberg,J., Kangasmetsa,J., Unge,T., Oscarson,S., Hallberg,A. and Samuelsson,B.
Design and synthesis of HIV-1 protease inhibitors. Novel tetrahydrofuran P2/P2'-groups interacting with Asp29/30 of the HIV-1 protease. Determination of binding from X-ray crystal structure of inhibitor protease complex
Bioorg Med Chem11, 1107-1115. PubMed Europe PubMed DOI I
Prabu-Jeyabalan,M., Nalivaika,E.A., King,N.M. and Schiffer,C.A.
Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy
J Virol77, 1306-1315. PubMed Europe PubMed DOI I
[YEAR:1-1-2003]Rhee,S.Y., Gonzales,M.J., Kantor,R., Betts,B.J., Ravela,J. and Shafer,R.W.
Human immunodeficiency virus reverse transcriptase and protease sequence database
Nucleic Acids Res31, 298-303. PubMed Europe PubMed DOI
Schaller,M., Bein,M., Korting,H.C., Baur,S., Hamm,G., Monod,M., Beinhauer,S. and Hube,B.
The secreted aspartyl proteinases Sap1 and Sap2 cause tissue damage in an in vitro model of vaginal candidiasis based on reconstituted human vaginal epithelium
Infect Immun71, 3227-3234. PubMed Europe PubMed DOI I
[YEAR:15-7-2003]Sirois,S., Proynov,E.I., Truchon,J.F., Tsoukas,C.M. and Salahub,D.R.
A density functional study of the hydrogen-bond network within the HIV-1 protease catalytic site cleft
J Comput Chem24, 1110-1119. PubMed Europe PubMed DOI
Skalova,T., Hasek,J., Dohnalek,J., Petrokova,H., Buchtelova,E., Duskova,J., Soucek,M., Majer,P., Uhlikova,T. and Konvalinka,J.
An ethylenamine inhibitor binds tightly to both wild type and mutant HIV-1 proteases. Structure and energy study
J Med Chem46, 1636-1644. PubMed Europe PubMed DOI S I
Smith,A.B., III, Cantin,L.D., Pasternak,A., Guise-Zawacki,L., Yao,W., Charnley,A.K., Barbosa,J., Sprengeler,P.A., Hirschmann,R., Munshi,S., Olsen,D.B., Schleif,W.A. and Kuo,L.C.
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors
J Med Chem46, 1831-1844. PubMed Europe PubMed DOI S I
[YEAR:24-4-2003]Tamamura,H., Koh,Y., Ueda,S., Sasaki,Y., Yamasaki,T., Aoki,M., Maeda,K., Watai,Y., Arikuni,H., Otaka,A., Mitsuya,H. and Fujii,N.
Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 strains
J Med Chem46, 1764-1768. PubMed Europe PubMed DOI I
[YEAR:25-5-2003]Tozser,J., Shulenin,S., Kadas,J., Boross,P., Bagossi,P., Copeland,T.D., Nair,B.C., Sarngadharan,M.G. and Oroszlan,S.
Human immunodeficiency virus type 1 capsid protein is a substrate of the retroviral proteinase while integrase is resistant toward proteolysis
Virology310, 16-23. PubMed Europe PubMed DOI
Yeni,P.
Tipranavir: a protease inhibitor from a new class with distinct antiviral activity
J Acquir Immune Defic Syndr34 Suppl 1, S91-S94. PubMed Europe PubMed DOI I
[YEAR:11-2-2003]Zhu,Z., Schuster,D.I. and Tuckerman,M.E.
Molecular dynamics study of the connection between flap closing and binding of fullerene-based inhibitors of the HIV-1 protease
Biochemistry42, 1326-1333. PubMed Europe PubMed DOI I

2002

Badalassi,F., Nguyen,H.K., Crotti,P. and Reymond,J.L.
A selective HIV-protease assay based on a chromogenic amino acid
Helv Chim Acta85, 3090-3098. A
Baraz,L., Hutoran,M., Blumenzweig,I., Katzenellenbogen,M., Friedler,A., Gilon,C., Steinitz,M. and Kotler,M.
Human immunodeficiency virus type 1 Vif binds the viral protease by interaction with its N-terminal region
J Gen Virol83, 2225-2230. PubMed Europe PubMed
[YEAR:12-4-2002]Blumenzweig,I., Baraz,L., Friedler,A., Danielson,U.H., Gilon,C., Steinitz,M. and Kotler,M.
HIV-1 vif-derived peptide inhibits drug-resistant HIV proteases
Biochem Biophys Res Commun292, 832-840. PubMed Europe PubMed DOI
Dang,J., Blandford,S., Sadek,M., Grobelny,D. and Brownlee,R.T.C.
The solution structures of the HIV protease inhibitor DG35-VIII
Mol Simul28, 827-843. DOI I
Dauber,D.S., Ziermann,R., Parkin,N., Maly,D.J., Mahrus,S., Harris,J.L., Ellman,J.A., Petropoulos,C. and Craik,C.S.
Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease
J Virol76, 1359-1368. PubMed Europe PubMed
Dohnalek,J., Hasek,J., Duskova,J., Petrokova,H., Hradilek,M., Soucek,M., Konvalinka,J., Brynda,J., Sedlacek,J. and Fabry,M.
Hydroxyethylamine isostere of an HIV-1 protease inhibitor prefers its amine to the hydroxy group in binding to catalytic aspartates. A synchrotron study of HIV-1 protease in complex with a peptidomimetic inhibitor
J Med Chem45, 1432-1438. PubMed Europe PubMed DOI S I
Freedberg,D.I., Ishima,R., Jacob,J., Wang,Y.X., Kustanovich,I., Louis,J.M. and Torchia,D.A.
Rapid structural fluctuations of the free HIV protease flaps in solution: relationship to crystal structures and comparison with predictions of dynamics calculations
Protein Sci11, 221-232. PubMed Europe PubMed DOI
Ghosh,A.K., Pretzer,E., Cho,H., Hussain,K.A. and Duzgunes,N.
Antiviral activity of UIC-PI, a novel inhibitor of the human immunodeficiency virus type 1 protease
Antiviral Res54, 29-36. PubMed Europe PubMed DOI I
[YEAR:5-1-2002]Goodenow,M.M., Bloom,G., Rose,S.L., Pomeroy,S.M., O'Brien,P.O., Perez,E.E., Sleasman,J.W. and Dunn,B.M.
Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease
Virology292, 137-149. PubMed Europe PubMed DOI M
King,N.M., Melnick,L., Prabu-Jeyabalan,M., Nalivaika,E.A., Yang,S.S., Gao,Y., Nie,X., Zepp,C., Heefner,D.L. and Schiffer,C.A.
Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease
Protein Sci11, 418-429. PubMed Europe PubMed DOI S I
Kovalsky,D.B. and Kornelyuk,A.I.
Conformational changes in HIV-1 protease: molecular dynamic simulation study in picoseond and nanosecond timescales
Biopolym Cell18, 117-123. DOI
Kumar,M., Kannan,K.K., Hosur,M.V., Bhavesh,N.S., Chatterjee,A., Mittal,R. and Hosur,R.V.
Effects of remote mutation on the autolysis of HIV-1 PR: X-ray and NMR investigations
Biochem Biophys Res Commun294, 395-401. PubMed Europe PubMed DOI S
[YEAR:1-7-2002]Mahalingam,B., Boross,P., Wang,Y.F., Louis,J.M., Fischer,C.C., Tozser,J., Harrison,R.W. and Weber,I.T.
Combining mutations in HIV-1 protease to understand mechanisms of resistance
Proteins48, 107-116. PubMed Europe PubMed DOI
Menendez-Arias,L.
Targeting HIV: antiretroviral therapy and development of drug resistance
Trends Pharmacol Sci23, 381-388. PubMed Europe PubMed DOI
[YEAR:29-1-2002]Porter,D.J., Hanlon,M.H. and Furfine,E.S.
HIV-1 protease: characterization of a catalytically competent enzyme-substrate intermediate
Biochemistry41, 1302-1307. PubMed Europe PubMed DOI
Prabu-Jeyabalan,M., Nalivaika,E. and Schiffer,C.A.
Substrate shape determines specificity of recognition for HIV-1 protease: Analysis of crystal structures of six substrate complexes
Structure10, 369-381. PubMed Europe PubMed DOI
[YEAR:9-4-2002]Reiling,K.K., Endres,N.F., Dauber,D.S., Craik,C.S. and Stroud,R.M.
Anisotropic dynamics of the JE-2147-HIV protease complex: drug resistance and thermodynamic binding mode examined in a 1.09 A structure
Biochemistry41, 4582-4594. PubMed Europe PubMed DOI S I
Resch,W., Ziermann,R., Parkin,N., Gamarnik,A. and Swanstrom,R.
Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly
J Virol76, 8659-8666. PubMed Europe PubMed DOI I
[YEAR:1-7-2002]Stoffler,D., Sanner,M.F., Morris,G.M., Olson,A.J. and Goodsell,D.S.
Evolutionary analysis of HIV-1 protease inhibitors: methods for design of inhibitors that evade resistance
Proteins48, 63-74. PubMed Europe PubMed DOI
Stoll,V., Qin,W., Stewart,K.D., Jakob,C., Park,C., Walter,K., Simmer,R.L., Helfrich,R., Bussiere,D., Kao,J., Kempf,D., Sham,H.L. and Norbeck,D.W.
X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease
Bioorg Med Chem10, 2803-2806. PubMed Europe PubMed DOI S I
Tong,L.
Viral proteases
Chem Rev102, 4609-4626. PubMed Europe PubMed DOI V
Trylska,J., Bala,P., Geller,M. and Grochowski,P.
Molecular dynamics simulations of the first steps of the reaction catalyzed by HIV-1 protease
Biophys J83, 794-807. PubMed Europe PubMed DOI I
[YEAR:1-12-2002]Vondrasek,J. and Wlodawer,A.
HIVdb: a database of the structures of human immunodeficiency virus protease
Proteins49, 429-431. PubMed Europe PubMed DOI
Weber,J., Mesters,J.R., Lepsik,M., Prejdova,J., Svec,M., Sponarova,J., Mlcochova,P., Skalicka,K., Strisovsky,K., Uhlikova,T., Soucek,M., Machala,L., Stankova,M., Vondrasek,J., Klimkait,T., Kraeusslich,H.G., Hilgenfeld,R. and Konvalinka,J.
Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains
J Mol Biol324, 739-754. PubMed Europe PubMed DOI I
Wlodawer,A.
Rational approach to AIDS drug design through structural biology
Annu Rev Med53, 595-614. PubMed Europe PubMed DOI

2001

Beck,Z.Q., Lin,Y.C. and Elder,J.H.
Molecular basis for the relative substrate specificity of human immunodeficiency virus type 1 and feline immunodeficiency virus proteases
J Virol75, 9458-9469. PubMed Europe PubMed DOI
Cote,H.C.F., Brumme,Z.L. and Harrigan,P.R.
Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir
J Virol75, 589-594. PubMed Europe PubMed DOI I
[YEAR:26-1-2001]Dash,C. and Rao,M.
Interactions of a novel inhibitor from an extremophilic Bacillus sp. with HIV-1 protease: implications for the mechanism of inactivation
J Biol Chem276, 2487-2493. PubMed Europe PubMed DOI I
Dohnalek ,J., Hasek ,J., Duskova ,J., Petrokova ,H., Hradilek ,M., Soucek ,M., Konvalinka ,J., Brynda ,J., Sedlacek ,J. and Fabry ,M.
A distinct binding mode of a hydroxyethylamine isostere inhibitor of HIV-1 protease
Acta Crystallogr D Biol Crystallogr57, 472-476. PubMed Europe PubMed DOI S I
Furfine,E.S.
HIV protease assays
Curr Protoc PharmacolChapter 3, Unit-Unit. PubMed Europe PubMed DOI A
Huff,J.R. and Kahn,J.
Discovery and clinical development of HIV-1 protease inhibitors
Adv Protein Chem56, 213-251. PubMed Europe PubMed DOI V I
[YEAR:19-1-2001]Ishima,R., Louis,J.M. and Torchia,D.A.
Characterization of two hydrophobic methyl clusters in HIV-1 protease by NMR spin relaxation in solution
J Mol Biol305, 515-521. PubMed Europe PubMed DOI
Le,V.D., Mak,C.C., Lin,Y.C., Elder,J.H. and Wong,C.H.
Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine
Bioorg Med Chem9, 1185-1195. PubMed Europe PubMed DOI I
Lindsten,K., Uhlikova,T., Konvalinka,J., Masucci,M.G. and Dantuma,N.P.
Cell-based fluorescence assay for human immunodeficiency virus type 1 protease activity
Antimicrobial Agents Chemother45, 2616-2622. PubMed Europe PubMed DOI A
Mager,P.P.
The active site of HIV-1 protease
Med Res Rev21, 348-353. PubMed Europe PubMed DOI
[YEAR:1-6-2001]Mahalingam,B., Louis,J.M., Hung,J., Harrison,R.W. and Weber,I.T.
Structural implications of drug-resistant mutants of HIV-1 protease: High-resolution crystal structures of the mutant protease/substrate analogue complexes
Proteins43, 455-464. PubMed Europe PubMed DOI
Muhlman,A., Lindberg,J., Classon,B., Unge,T., Hallberg,A. and Samuelsson,B.
Synthesis of novel, potent, diol-based HIV-1 protease inhibitors via intermolecular pinacol homocoupling of (2S)-2-benzyloxymethyl-4-phenylbutanal
J Med Chem44, 3407-3416. PubMed Europe PubMed I
[YEAR:12-9-2001]Piana,S., Sebastiani,D., Carloni,P. and Parrinello,M.
Ab initio molecular dynamics-based assignment of the protonation state of pepstatin A/HIV-1 protease cleavage site
J Am Chem Soc123, 8730-8737. PubMed Europe PubMed DOI I
[YEAR:1-4-2001]Pillai,B., Kannan,K.K. and Hosur,M.V.
1.9 A X-ray study shows closed flap conformation in crystals of tethered HIV-1PR
Proteins43, 57-64. PubMed Europe PubMed DOI S
[YEAR:18-9-2001]Porter,D.J., Hanlon,M.H., Carter,L.H., III, Danger,D.P. and Furfine,E.S.
Effectors of HIV-1 protease peptidolytic activity
Biochemistry40, 11131-11139. PubMed Europe PubMed DOI I
Qari,S.H., Magre,S., Garcia-Lerma,J.G., Hussain,A.I., Takeuchi,Y., Patience,C., Weiss,R.A. and Heneine,W.
Susceptibility of the porcine endogenous retrovirus to reverse transcriptase and protease inhibitors
J Virol75, 1048-1053. PubMed Europe PubMed DOI I
Schaal,W., Karlsson,A., Ahlsen,G., Lindberg,J., Andersson,H.O., Danielson,U.H., Classon,B., Unge,T., Samuelsson,B., Hulten,J., Hallberg,A. and Karlen,A.
Synthesis and comparative molecular field analysis (CoMFA) of symmetric and nonsymmetric cyclic sulfamide HIV-1 protease inhibitors
J Med Chem44, 155-169. PubMed Europe PubMed DOI S I
[YEAR:22-5-2001]Velazquez-Campoy,A., Todd,M.J., Vega,S. and Freire,E.
Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes
Proc Natl Acad Sci U S A98, 6062-6067. PubMed Europe PubMed DOI M I
[YEAR:15-6-2001]Velazquez-Campoy,A., Kiso,Y. and Freire,E.
The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design
Arch Biochem Biophys390, 169-175. PubMed Europe PubMed DOI I
[YEAR:6-11-2001]Ventoso,I., Blanco,R., Perales,C. and Carrasco,L.
HIV-1 protease cleaves eukaryotic initiation factor 4G and inhibits cap-dependent translation
Proc Natl Acad Sci U S A98, 12966-12971. PubMed Europe PubMed DOI

2000

[YEAR:1-9-2000]Beck,Z.Q., Hervio,L., Dawson,P.E., Elder,J.H. and Madison,E.L.
Identification of efficiently cleaved substrates for HIV-1 protease using a phage display library and use in inhibitor development
Virology274, 391-401. PubMed Europe PubMed DOI P I
Gong,Y.F., Robinson,B.S., Rose,R.E., Deminie,C., Spicer,T.P., Stock,D., Colonno,R.J. and Lin,P.F.
In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632
Antimicrobial Agents Chemother44, 2319-2326. PubMed Europe PubMed DOI I
Hong,L., Zhang,X.J.C., Hartsuck,J.A. and Tang,J.
Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistance
Protein Sci9, 1898-1904. PubMed Europe PubMed DOI S
Ikuta,K., Suzuki,S., Horikoshi,H., Mukai,T. and Luftig,R.B.
Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis
Microbiol Mol Biol Rev64, 725-745. PubMed Europe PubMed DOI
[YEAR:1-1-2000]Li,M., Morris,G.M., Lee,T., Laco,G.S., Wong,C.H., Olson,A.J., Elder,J.H., Wlodawer,A. and Gustchina,A.
Structural studies of FIV and HIV-1 proteases complexed with an efficient inhibitor of FIV protease
Proteins38, 29-40. PubMed Europe PubMed DOI I
Mammano,F., Trouplin,V., Zennou,V. and Clavel,F.
Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug
J Virol74, 8524-8531. PubMed Europe PubMed DOI I
[YEAR:1-9-2000]Prabu-Jeyabalan,M., Nalivaika,E. and Schiffer,C.A.
How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease
J Mol Biol301, 1207-1220. PubMed Europe PubMed DOI S
Robinson,B.S., Riccardi,K.A., Gong,Y.F., Guo,Q., Stock,D.A., Blair,W.S., Terry,B.J., Deminie,C.A., Djang,F., Colonno,R.J. and Lin,P.F.
BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents
Antimicrobial Agents Chemother44, 2093-2099. PubMed Europe PubMed DOI I
[YEAR:15-12-2000]Scott,W.R. and Schiffer,C.A.
Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance
Structure8, 1259-1265. PubMed Europe PubMed DOI
Sheha,M.M., Mahfouz,N.M., Hassan,H.Y., Youssef,A.F., Mimoto,T. and Kiso,Y.
Synthesis of di- and tripeptide analogues containing alpha-ketoamide as a new core structure for inhibition of HIV-1 protease
Eur J Med Chem35, 887-894. PubMed Europe PubMed DOI I
[YEAR:1-8-2000]Short,G.F., III, Laikhter,A.L., Lodder,M., Shayo,Y., Arslan,T. and Hecht,S.M.
Probing the S1/S1' substrate binding pocket geometry of HIV-1 protease with modified aspartic acid analogues
Biochemistry39, 8768-8781. PubMed Europe PubMed DOI
[YEAR:15-5-2000]Snasel,J., Shoeman,R., Horejsi,M., Hruskova-Heidingsfeldova,O., Sedlacek,J., Ruml,T. and Pichova,I.
Cleavage of vimentin by different retroviral proteases
Arch Biochem Biophys377, 241-245. PubMed Europe PubMed DOI
Strisovsky,K., Tessmer,U., Langner,J., Konvalinka,J. and Krausslich,H.G.
Systematic mutational analysis of the active-site threonine of HIV-1 proteinase: Rethinking the "fireman's grip" hypothesis
Protein Sci9, 1631-1641. PubMed Europe PubMed DOI
[YEAR:3-10-2000]Todd,M.J., Luque,I., Velazquez-Campoy,A. and Freire,E.
Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant
Biochemistry39, 11876-11883. PubMed Europe PubMed DOI I
Tozser,J., Zahuczky,G., Bagossi,P., Louis,J.M., Copeland,T.D., Oroszlan,S., Harrison,R.W. and Weber,I.T.
Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases
Eur J Biochem267, 6287-6295. PubMed Europe PubMed DOI
[YEAR:21-9-2000]Tyndall,J.D., Reid,R.C., Tyssen,D.P., Jardine,D.K., Todd,B., Passmore,M., March,D.R., Pattenden,L.K., Bergman,D.A., Alewood,D., Hu,S.H., Alewood,P.F., Birch,C.J., Martin,J.L. and Fairlie,D.P.
Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease
J Med Chem43, 3495-3504. PubMed Europe PubMed DOI I
[YEAR:7-3-2000]Wlodawer,A. and Gustchina,A.
Structural and biochemical studies of retroviral proteases
Biochim Biophys Acta1477, 16-34. PubMed Europe PubMed DOI

1999

Dunn,B.M., Pennington,M.W., Frase,D.C. and Nash,K.
Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem
Biopolymers51, 69-77. PubMed Europe PubMed DOI I
Kashparov,I.V., Popov,M.E., Rumsh,L.D. and Popov,E.M.
[Mechanism of action of aspartic proteinases. V. Conformational characteristics of fragments of substrate-binding sites in rhizopuspepsin and HIV-1 proteinase]
Bioorg Khim25, 597-602. PubMed Europe PubMed
Kashparov,I.V., Popov,M.E., Rumsh,L.D. and Popov,E.M.
[Mechanism of action of aspartyl proteinases. VI. Noncovalent enzyme-inhibitory and enzyme-substrate complexes of the aspartyl proteinase rhizopus pepsin]
Bioorg Khim25, 747-762. PubMed Europe PubMed
Kiso,Y., Matsumoto,H., Mizumoto,S., Kimura,T., Fujiwara,Y. and Akaji,K.
Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic
Biopolymers51, 59-68. PubMed Europe PubMed DOI I
Mahalingam,B., Louis,J.M., Reed,C.C., Adomat,J.M., Krouse,J., Wang,Y.F., Harrison,R.W. and Weber,I.T.
Structural and kinetic analysis of drug resistant mutants of HIV-1 protease
Eur J Biochem263, 238-245. PubMed Europe PubMed DOI S
[YEAR:22-6-1999]Martin,J.L., Begun,J., Schindeler,A., Wickramasinghe,W.A., Alewood,D., Alewood,P.F., Bergman,D.A., Brinkworth,R.I., Abbenante,G., March,D.R., Reid,R.C. and Fairlie,D.P.
Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease
Biochemistry38, 7978-7988. PubMed Europe PubMed DOI I
Martinez-Picado,J., Savara,A.V., Sutton,L. and D'Aquila,R.T.
Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
J Virol73, 3744-3752. PubMed Europe PubMed
Nijhuis,M., Schuurman,R., de Jong,D., Erickson,J., Gustchina,E., Albert,J., Schipper,P., Gulnik,S. and Boucher,C.A.
Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy
AIDS13, 2349-2359. PubMed Europe PubMed DOI
[YEAR:5-3-1999]Ringhofer,S., Kallen,J., Dutzler,R., Billich,A., Visser,A.J., Scholz,D., Steinhauser,O., Schreiber,H., Auer,M. and Kungl,A.J.
X-ray structure and conformational dynamics of the HIV-1 protease in complex with the inhibitor SDZ283-910: agreement of time-resolved spectroscopy and molecular dynamics simulations
J Mol Biol286, 1147-1159. PubMed Europe PubMed DOI I
Thaisrivongs,S. and Strohbach,J.W.
Structure-based discovery of Tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor
Biopolymers51, 51-58. PubMed Europe PubMed DOI I
[YEAR:1-8-1999]Todd,M.J. and Freire,E.
The effect of inhibitor binding on the structural stability and cooperativity of the HIV-1 protease
Proteins36, 147-156. PubMed Europe PubMed DOI I
[YEAR:20-7-1999]Yoshimura,K., Kato,R., Yusa,K., Kavlick,M.F., Maroun,V., Nguyen,A., Mimoto,T., Ueno,T., Shintani,M., Falloon,J., Masur,H., Hayashi,H., Erickson,J. and Mitsuya,H.
JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1
Proc Natl Acad Sci U S A96, 8675-8680. PubMed Europe PubMed DOI S I

1998

Ala,P.J., DeLoskey,R.J., Huston,E.E., Jadhav,P.K., Lam,P.Y., Eyermann,C.J., Hodge,C.N., Schadt,M.C., Lewandowski,F.A., Weber,P.C., McCabe,D.D., Duke,J.L. and Chang,C.H.
Molecular recognition of cyclic urea HIV-1 protease inhibitors
J Biol Chem273, 12325-12331. PubMed Europe PubMed DOI S I
Ala,P.J., Huston,E.E., Klabe,R.M., Jadhav,P.K., Lam,P.Y. and Chang,C.H.
Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities
Biochemistry37, 15042-15049. PubMed Europe PubMed DOI S I
Bagossi,P., Cheng,Y.S., Oroszlan,S. and Tozser,J.
Comparison of the specificity of homo- and heterodimeric linked HIV-1 and HIV-2 proteinase dimers
Protein Eng11, 439-445. PubMed Europe PubMed
Bold,G., Fassler,A., Capraro,H.G., Cozens,R., Klimkait,T., Lazdins,J., Mestan,J., Poncioni,B., Rosel,J., Stover,D., Tintelnot-Blomley,M., Acemoglu,F., Beck,W., Boss,E., Eschbach,M., Hurlimann,T., Masso,E., Roussel,S., Ucci-Stoll,K., Wyss,D. and Lang,M.
New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development
J Med Chem41, 3387-3401. PubMed Europe PubMed DOI I
Dergousova,N.I., Rumsh,L.D. and Andreeva,N.S.
[HIV-1 proteinase mutant with an altered region of the active center]
Mol Biol (Mosk)32, 678-685. PubMed Europe PubMed
[YEAR:30-4-1998]Flexner,C.
HIV-protease inhibitors
N Engl J Med338, 1281-1292. PubMed Europe PubMed DOI V I
Ghosh,A.K., Kincaid,J.F., Cho,W., Walters,D.E., Krishnan,K., Hussain,K.A., Koo,Y., Cho,H., Rudall,C., Holland,L. and Buthod,J.
Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere
Bioorg Med Chem Lett8, 687-690. PubMed Europe PubMed DOI I
[YEAR:12-2-1998]Kempf,D.J., Sham,H.L., Marsh,K.C., Flentge,C.A., Betebenner,D., Green,B.E., McDonald,E., Vasavanonda,S., Saldivar,A., Wideburg,N.E., Kati,W.M., Ruiz,L., Zhao,C., Fino,L., Patterson,J., Molla,A., Plattner,J.J. and Norbeck,D.W.
Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy
J Med Chem41, 602-617. PubMed Europe PubMed DOI I
Kervinen,J., Lubkowski,J., Zdanov,A., Bhatt,D., Dunn,B.M., Hui,K.Y., Powell,D.J., Kay,J., Wlodawer,A. and Gustchina,A.
Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAV
Protein Sci7, 2314-2323. PubMed Europe PubMed DOI S I
[YEAR:24-2-1998]Louis,J.M., Dyda,F., Nashed,N.T., Kimmel,A.R. and Davies,D.R.
Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease
Biochemistry37, 2105-2110. PubMed Europe PubMed DOI
[YEAR:29-9-1998]Ridky,T.W., Kikonyogo,A., Leis,J., Gulnik,S., Copeland,T., Erickson,J., Wlodawer,A., Kurinov,I., Harrison,R.W. and Weber,I.T.
Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate
Biochemistry37, 13835-13845. PubMed Europe PubMed DOI
Sham,H.L., Kempf,D.J., Molla,A., Marsh,K.C., Kumar,G.N., Chen,C.M., Kati,W., Stewart,K., Lal,R., Hsu,A., Betebenner,D., Korneyeva,M., Vasavanonda,S., McDonald,E., Saldivar,A., Wideburg,N., Chen,X., Niu,P., Park,C., Jayanti,V., Grabowski,B., Granneman,G.R., Sun,E., Japour,A.J., Leonard,J.M., Plattner,J.J. and Norbeck,D.W.
ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease
Antimicrob Agents Chemother42, 3218-3224. PubMed Europe PubMed I
[YEAR:11-2-1998]Venturini,A., Lopez-Ortiz,F., Alvarez,J.M. and Gonzalez,J.
Theoretical proposal of a catalytic mechanism for the HIV-1 protease involving an enzyme-bound tetrahedral intermediate
J Am Chem Soc120, 1110-1111. DOI
Wlodawer,A. and Vondrasek,J.
Inhibitors of HIV-1 protease: a major success of structure-assisted drug design
Annu Rev Biophys Biomol Struct27, 249-284. PubMed Europe PubMed DOI V I
[YEAR:31-3-1998]Wu,J., Adomat,J.M., Ridky,T.W., Louis,J.M., Leis,J., Harrison,R.W. and Weber,I.T.
Structural basis for specificity of retroviral proteases
Biochemistry37, 4518-4526. PubMed Europe PubMed DOI

1997

[YEAR:18-2-1997]Ala,P.J., Huston,E.E., Klabe,R.M., McCabe,D.D., Duke,J.L., Rizzo,C.J., Korant,B.D., DeLoskey,R.J., Lam,P.Y., Hodge,C.N. and Chang,C.H.
Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors
Biochemistry36, 1573-1580. PubMed Europe PubMed DOI S I
[YEAR:14-11-1997]Babe,L.M. and Craik,C.S.
Viral proteases: evolution of diverse structural motifs to optimize function
Cell91, 427-430. PubMed Europe PubMed
Bardi,J.S., Luque,I. and Freire,E.
Structure-based thermodynamic analysis of HIV-1 protease inhibitors
Biochemistry36, 6588-6596. PubMed Europe PubMed DOI I
Bukovsky,A.A., Dorfman,T., Weimann,A. and Gottlinger,H.G.
Nef association with human immunodeficiency virus type 1 virions and cleavage by the viral protease
J Virol71, 1013-1018. PubMed Europe PubMed I
Cornelissen,M., van den Burg,R., Zorgdrager,F., Lukashov,V. and Goudsmit,J.
pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D
J Virol71, 6348-6358. PubMed Europe PubMed I
Fournout,S., Roquet,F., Salhi,S.L., Seyer,R., Valverde,V., Masson,J.M., Jouin,P., Pau,B., Nicolas,M. and Hanin,V.
Development and standardization of an immuno-quantified solid phase assay for HIV-1 aspartyl protease activity and its application to the evaluation of inhibitors
Anal Chem69, 1746-1752. PubMed Europe PubMed A
Geller,M., Miller,M., Swanson,S.M. and Maizel,J.
Analysis of the structure of HIV-1 protease complexed with a hexapeptide inhibitor. Part II: Molecular dynamic studies of the active site region
Proteins27, 195-203. PubMed Europe PubMed DOI S I
Hong,L., Zhang,X.J., Foundling,S., Hartsuck,J.A. and Tang,J.
Structure of a G48H mutant of HIV-1 protease explains how glycine-48 replacements produce mutants resistant to inhibitor drugs
FEBS Lett420, 11-16. PubMed Europe PubMed DOI S
[YEAR:17-1-1997]Jadhav,P.K., Ala,P., Woerner,F.J., Chang,C.H., Garber,S.S., Anton,E.D. and Bacheler,L.T.
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV
J Med Chem40, 181-191. PubMed Europe PubMed DOI I
Janetka,J.W., Raman,P., Satyshur,K., Flentke,G.R. and Rich,D.H.
Novel cyclic biphenyl ether peptide beta-strand mimetics and HIV-protease inhibitors
J Am Chem Soc119, 441-442. DOI I
Kaldor,S.W., Kalish,V.J., Davies,J.F., Shetty,B.V., Fritz,J.E., Appelt,K., Burgess,J.A., Campanale,K.M., Chirgadze,N.Y., Clawson,D.K., Dressman,B.A., Hatch,S.D., Khalil,D.A., Kosa,M.B., Lubbehusen,P.P., Muesing,M.A., Patick,A.K., Reich,S.H., Su,K.S. and Tatlock,J.H.
Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease
J Med Chem40, 3979-3985. PubMed Europe PubMed DOI I
Kempf,D.J., Molla,A., Marsh,K.C., Park,C., Rodrigues,A.D., Korneyeva,M., Vasavanonda,S., McDonald,E., Flentge,C.A., Muchmore,S., Wideburg,N.E., Saldivar,A., Cooper,A., Kati,W.M., Stewart,K.D. and Norbeck,D.W.
Lack of stereospecificity in the binding of the P2 amino acid of ritonavir to HIV protease
Bioorg Med Chem Lett7, 699-704. S I
Lange-Savage,G., Berchtold,H., Liesum,A., Budt,K.H., Peyman,A., Knolle,J., Sedlacek,J., Fabry,M. and Hilgenfeld,R.
Structure of HOE/BAY 793 complexed to human immunodeficiency virus (HIV-1) protease in two different crystal forms - structure/function relationship and influence of crystal packing
Eur J Biochem248, 313-322. PubMed Europe PubMed S I
Miller,M., Geller,M., Gribskov,M. and Kent,S.B.
Analysis of the structure of chemically synthesized HIV-1 protease complexed with a hexapeptide inhibitor. Part I: Crystallographic refinement of 2 A data
Proteins27, 184-194. PubMed Europe PubMed DOI S I
Misumi,S., Kudo,A., Azuma,R., Tomonaga,M., Furuishi,K. and Shoji,S.
The p2gag peptide, AEAMSQVTNTATIM, processed from HIV-1 pr55gag was found to be a suicide inhibitor of HIV-1 protease
Biochem Biophys Res Commun241, 275-280. PubMed Europe PubMed DOI I
Okimoto,N., Makiyama,M., Hata,M. and Tsuda,M.
Gag protein hydrolysis mechanism by HIV-1 protease - investigation by semiempirical molecular orbital method
Nippon Kagaku Kaishi Chem Soc Japan Chem Indus Chem J1997, 260-266.
Peyman,A., Budt,K.H., Stowasser,B., Hansen,J., Jian-Qi,L., Knolle,J., Meichsner,C., Paessens,A., Ruppert,D., Spanig,J. and Winkler,I.
Structure-activity relationships in a series of C2-symmetric HIV-protease inhibitors
Pharmacochem Libr28, 397-408. DOI I
Skulnick,H.I., Johnson,P.D., Aristoff,P.A., Morris,J.K., Lovasz,K.D., Howe,W.J., Watenpaugh,K.D., Janakiraman,M.N., Anderson,D.J., Reischer,R.J., Schwartz,T.M., Banitt,L.S., Tomich,P.K., Lynn,J.C., Horng,M.M., Chong,K.T., Hinshaw,R.R., Dolak,L.A., Seest,E.P., Schwende,F.J., Rush,B.D., Howard,G.M., Toth,L.N., Wilkinson,K.R. and Romines,K.R.
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones
J Med Chem40, 1149-1164. PubMed Europe PubMed DOI S I
Stebbins,J. and Debouck,C.
A microtiter colorimetric assay for the HIV-1 protease
Anal Biochem248, 246-250. PubMed Europe PubMed DOI A
[YEAR:4-7-1997]Tozser,J., Bagossi,P., Weber,I.T., Louis,J.M., Copeland,T.D. and Oroszlan,S.
Studies on the symmetry and sequence context dependence of the HIV-1 proteinase specificity
J Biol Chem272, 16807-16814. PubMed Europe PubMed DOI
Tozser,J.
Specificity of retroviral proteinases based on substrates containing tyrosine and proline at the site of cleavage
Pathol Oncol Res3, 142-146. PubMed Europe PubMed P
Vance,J.E., LeBlanc,D.A., Wingfield,P. and London,R.E.
Conformational selectivity of HIV-1 protease cleavage of X-Pro peptide bonds and its implications
J Biol Chem272, 15603-15606. PubMed Europe PubMed DOI P
Vondrasek,J., van Buskirk,C.P. and Wlodawer,A.
Database of three-dimensional structures of HIV proteinases
Nat Struct Biol4, 8-8. PubMed Europe PubMed DOI S
[YEAR:5-12-1997]Wilkerson,W.W., Dax,S. and Cheatham,W.W.
Nonsymmetrically substituted cyclic urea HIV protease inhibitors
J Med Chem40, 4079-4088. PubMed Europe PubMed DOI I
Wilson,S.I., Phylip,L.H., Mills,J.S., Gulnik,S.V., Erickson,J.W., Dunn,B.M. and Kay,J.
Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition
Biochim Biophys Acta1339, 113-125. PubMed Europe PubMed DOI I

1996

Abbenante,G., Bergman,D.A., Brinkworth,R.I., March,D.R., Reid,R.C., Hunt,P.A., James,I.W., Dancer,R.J., Garnham,B., Stoermer,M.L. and Fairlie,D.P.
Structure-activity relationships for macrocyclic peptidomimetic inhibitors of HIV-1 protease
Bioorg Med Chem Lett6, 2531-2536. I
Dergousova,N.I., Amerik,A.Y., Volynskaya,A.M. and Rumsh,L.D.
HIV-I protease. Cloning, expression, and purification
Appl Biochem Biotechnol61, 97-107. PubMed Europe PubMed
Hong,L., Treharne,A., Hartsuck,J.A., Foundling,S. and Tang,J.
Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases
Biochemistry35, 10627-10633. PubMed Europe PubMed DOI S I
Hoog,S.S., Towler,E.M., Zhao,B., Doyle,M.L., Debouck,C. and Abdel-Meguid,S.S.
Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity
Biochemistry35, 10279-10286. PubMed Europe PubMed DOI S
Kervinen,J., Thanki,N., Zdanov,A., Tino,J., Barrish,J., Lin,P.F., Colonno,R., Riccardi,K., Samanta,H. and Wlodawer,A.
Structural analysis of the native and drug-resistant HIV-1 proteinases complexed with an aminodiol inhibitor
Protein Pept Lett3, 399-406. S I
Kozal,M.J., Shah,N., Shen,N., Yang,R., Fucini,R., Merigan,T.C., Richman,D.D., Morris,D., Hubbell,E., Chee,M. and Gingeras,T.R.
Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays
Nat Med2, 753-759. PubMed Europe PubMed DOI M
March,D.R., Abbenante,G., Bergman,D.A., Brinkworth,R.I., Wickramasinghe,W., Begun,J., Martin,J.L. and Fairlie,D.P.
Substrate-based cyclic peptidomimetics of Phe-Ile-Val that inhibit HIV-1 protease using a novel enzyme-binding mode
J Am Chem Soc118, 3375-3379. DOI S I
Maschera,B., Darby,G., Palu,G., Wright,L.L., Tisdale,M., Myers,R., Blair,E.D. and Furfine,E.S.
Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex
J Biol Chem271, 33231-33235. PubMed Europe PubMed DOI I
Molla,A., Korneyeva,M., Gao,Q., Vasavanonda,S., Schipper,P.J., Mo,H.M., Markowitz,M., Chernyavskiy,T., Niu,P., Lyons,N., Hsu,A., Granneman,G.R., Ho,D.D., Boucher,C.A., Leonard,J.M., Norbeck,D.W. and Kempf,D.J.
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
Nat Med2, 760-766. PubMed Europe PubMed DOI I
Ott,D.E., Coren,L.V., Kane,B.P., Busch,L.K., Johnson,D.G., Sowder,R.C., Chertova,E.N., Arthur,L.O. and Henderson,L.E.
Cytoskeletal proteins inside human immunodeficiency virus type 1 virions
J Virol70, 7734-7743. PubMed Europe PubMed
Rose,R.B., Craik,C.S., Douglas,N.L. and Stroud,R.M.
Three-dimensional structures of HIV-1 and SIV protease product complexes
Biochemistry35, 12933-12944. PubMed Europe PubMed DOI
Rutenber,E.E., McPhee,F., Kaplan,A.P., Gallion,S.L., Hogan,J.C., Jr., Craik,C.S. and Stroud,R.M.
A new class of HIV-1 protease inhibitor: the crystallographic structure, inhibition and chemical synthesis of an aminimide peptide isostere
Bioorg Med Chem4, 1545-1558. PubMed Europe PubMed DOI S I
[YEAR:13-12-1996]Schock,H.B., Garsky,V.M. and Kuo,L.C.
Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity
J Biol Chem271, 31957-31963. PubMed Europe PubMed DOI I
Sham,H.L., Zhao,C., Stewart,K.D., Betebenner,D.A., Lin,S., Park,C.H., Kong,X.P., Rosenbrook,W., Jr., Herrin,T., Madigan,D., Vasavanonda,S., Lyons,N., Molla,A., Saldivar,A., Marsh,K.C., McDonald,E., Wideburg,N.E., Denissen,J.F., Robins,T., Kempf,D.J., Plattner,J.J. and Norbeck,D.W.
A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease
J Med Chem39, 392-397. PubMed Europe PubMed DOI S I
[YEAR:19-1-1996]Silva,A.M., Cachau,R.E., Sham,H.L. and Erickson,J.W.
Inhibition and catalytic mechanism of HIV-1 aspartic protease
J Mol Biol255, 321-346. PubMed Europe PubMed DOI I
Smith,R., Brereton,I.M., Chai,R.Y. and Kent,S.B.
Ionization states of the catalytic residues in HIV-1 protease
Nat Struct Biol3, 946-950. PubMed Europe PubMed DOI I
Stebbins,J., Deckman,I.C., Richardson,S.B. and Debouck,C.
A heterologous substrate assay for the HIV-1 protease engineered in Escherichia coli
Anal Biochem242, 90-94. PubMed Europe PubMed DOI A
Thaisrivongs,S., Skulnick,H.I., Turner,S.R., Strohbach,J.W., Tommasi,R.A., Johnson,P.D., Aristoff,P.A., Judge,T.M., Gammill,R.B., Morris,J.K., Romines,K.R., Chrusciel,R.A., Hinshaw,R.R., Chong,K.T., Tarpley,W.G., Poppe,S.M., Slade,D.E., Lynn,J.C., Horng,M.M., Tomich,P.K., Seest,E.P., Dolak,L.A., Howe,W.J., Howard,G.M. and Watenpaugh,K.D.
Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors
J Med Chem39, 4349-4353. PubMed Europe PubMed DOI S I
[YEAR:6-8-1996]Wang,Y.X., Freedberg,D.I., Yamazaki,T., Wingfield,P.T., Stahl,S.J., Kaufman,J.D., Kiso,Y. and Torchia,D.A.
Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272
Biochemistry35, 9945-9950. PubMed Europe PubMed DOI I
[YEAR:1-10-1996]Wang,Y.X., Freedberg,D.I., Grzesiek,S., Torchia,D.A., Wingfield,P.T., Kaufman,J.D., Stahl,S.J., Chang,C.H. and Hodge,C.N.
Mapping hydration water molecules in the HIV-1 protease/DMP323 complex in solution by NMR spectroscopy
Biochemistry35, 12694-12704. PubMed Europe PubMed DOI I
Wondrak,E.M., Nashed,N.T., Haber,M.T., Jerina,D.M. and Louis,J.M.
A transient precursor of the HIV-1 protease. Isolation, characterization, and kinetics of maturation
J Biol Chem271, 4477-4481. PubMed Europe PubMed

1995

Abbenante,G., March,D.R., Bergman,D.A., Hunt,P.A., Garnham,B., Dancer,R.J., Martin,J.L. and Fairlie,D.P.
Regioselective structural and functional mimicry of peptides. Design of hydrolytically-stable cyclic peptidomimetic inhibitors of HIV-1 protease
J Am Chem Soc117, 10220-10226. DOI S I
[YEAR:15-6-1995]Baldwin,E.T., Bhat,T.N., Gulnik,S., Liu,B., Topol,I.A., Kiso,Y., Mimoto,T., Mitsuya,H. and Erickson,J.W.
Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine
Structure3, 581-590. PubMed Europe PubMed S I
Bergman,D.A., Alewood,D., Alewood,P.F., Andrews,J.L., Brinkworth,R.I., Englebretsen,D.R. and Kent,S.B.H.
Kinetic properties of HIV-1 protease produced by total chemical synthesis with cysteine residues replaced by isosteric L-alpha-amino-n-butyric acid
Lett Pept Sci2, 99-107. DOI
Cameron,C.E., Burstein,H., Bizub-Bender,D., Ridky,T., Weber,I.T., Wlodawer,A., Skalka,A.M. and Leis,J.
Identification of amino acid residues of the retroviral aspartic proteinases important for substrate specificity and catalytic efficiency
Adv Exp Med Biol362, 399-406. PubMed Europe PubMed
[YEAR:15-9-1995]Chen,Z., Li,Y., Schock,H.B., Hall,D., Chen,E. and Kuo,L.C.
Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials
J Biol Chem270, 21433-21436. PubMed Europe PubMed DOI S
Collins,J.R., Burt,S.K. and Erickson,J.W.
Flap opening in HIV-1 protease simulated by 'activated' molecular dynamics
Nat Struct Biol2, 334-338. PubMed Europe PubMed
[YEAR:6-4-1995]Condra,J.H., Schleif,W.A., Blahy,O.M., Gabryelski,L.J., Graham,D.J., Quintero,J.C., Rhodes,A., Robbins,H.L., Roth,E. and Shivaprakash,M.
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
Nature374, 569-571. PubMed Europe PubMed DOI I
Eberle,J., Bechowsky,B., Rose,D., Hauser,U., von der Helm,K., Gurtler,L. and Nitschko,H.
Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959
AIDS Res Hum Retroviruses11, 671-676. PubMed Europe PubMed I
Fan,N., Rank,K.B., Leone,J.W., Heinrikson,R.L., Bannow,C.A., Smith,C.W., Evans,D.B., Poppe,S.M., Tarpley,W.G. and Rothrock,D.J.
The differential processing of homodimers of reverse transcriptases from human immunodeficiency viruses type 1 and 2 is a consequence of the distinct specificities of the viral proteases
J Biol Chem270, 13573-13579. PubMed Europe PubMed
Gulnik,S.V., Suvorov,L.I., Liu,B., Yu,B., Anderson,B., Mitsuya,H. and Erickson,J.W.
Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure
Biochemistry34, 9282-9287. PubMed Europe PubMed DOI I
Gustafson,M.E., Junger,K.D., Foy,B.A., Baez,J.A., Bishop,B.F., Rangwala,S.H., Michener,M.L., Leimgruber,R.M., Houseman,K.A. and Mueller,R.A.
Large-scale production of HIV-1 protease from Escherichia coli using selective extraction and membrane fractionation
Protein Expr Purif6, 512-518. PubMed Europe PubMed DOI E
[YEAR:18-8-1995]Hoog,S.S., Zhao,B., Winborne,E., Fisher,S., Green,D.W., DesJarlais,R.L., Newlander,K.A., Callahan,J.F., Moore,M.L. and Huffman,W.F.
A check on rational drug design: crystal structure of a complex of human immunodeficiency virus type 1 protease with a novel gamma-turn mimetic inhibitor
J Med Chem38, 3246-3252. PubMed Europe PubMed DOI S I
[YEAR:10-1-1995]Jacobsen,H., Yasargil,K., Winslow,D.L., Craig,J.C., Krohn,A., Duncan,I.B. and Mous,J.
Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959
Virology206, 527-534. PubMed Europe PubMed DOI I
[YEAR:28-3-1995]Kempf,D.J., Marsh,K.C., Denissen,J.F., McDonald,E., Vasavanonda,S., Flentge,C.A., Green,B.E., Fino,L., Park,C.H. and Kong,X.P.
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans
Proc Natl Acad Sci U S A92, 2484-2488. PubMed Europe PubMed DOI I
Kim,E.E., Baker,C.T., Dwyer,M.D., Murcko,M.A., Rao,B.G., Tung,R.D. and Navia,M.A.
Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme
J Am Chem Soc117, 1181-1182. DOI S I
Nicholson,L.K., Yamazaki,T., Torchia,D.A., Grzesiek,S., Bax,A., Stahl,S.J., Kaufman,J.D., Wingfield,P.T., Lam,P.Y.S., Jadhav,P.K., Hodge,C.N., Domaille,P.J. and Chang,C.H.
Flexibility and function in HIV-1 protease
Nat Struct Biol2, 274-280. PubMed Europe PubMed
Priestle,J.P., Fassler,A., Rosel,J., Tintelnot-Blomley,M., Strop,P. and Grutter,M.G.
Erratum: Comparative analysis of the X-ray structures of HIV-1 and HIV-2 proteases in complex with CGP 53820, a novel pseudosymmetric inhibitor (vol 3, pg 381, 1995)
Structure3, 629-629. PubMed Europe PubMed I
Thaisrivongs,S., Watenpaugh,K.D., Howe,W.J., Tomich,P.K., Dolak,L.A., Chong,K.T., Tomich,C.C., Tomasselli,A.G., Turner,S.R. and Strohbach,J.W.
Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors
J Med Chem38, 3624-3637. PubMed Europe PubMed S I
Tisdale,M., Myers,R.E., Maschera,B., Parry,N.R., Oliver,N.M. and Blair,E.D.
Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors
Antimicrobial Agents Chemother39, 1704-1710. PubMed Europe PubMed I

1994

Abdel-Meguid,S.S., Metcalf,B.W., Carr,T.J., Demarsh,P., DesJarlais,R.L., Fisher,S., Green,D.W., Ivanoff,L., Lambert,D.M. and Murthy,K.H.
An orally bioavailable HIV-1 protease inhibitor containing an imidazole-derived peptide bond replacement: crystallographic and pharmacokinetic analysis
Biochemistry33, 11671-11677. PubMed Europe PubMed DOI S I
Cameron,C.E., Ridky,T.W., Shulenin,S., Leis,J., Weber,I.T., Copeland,T., Wlodawer,A., Burstein,H., Bizub-Bender,D. and Skalka,A.M.
Mutational analysis of the substrate binding pockets of the Rous sarcoma virus and human immunodeficiency virus-1 proteases
J Biol Chem269, 11170-11177. PubMed Europe PubMed
[YEAR:14-10-1994]Dorsey,B.D., Levin,R.B., McDaniel,S.L., Vacca,J.P., Guare,J.P., Darke,P.L., Zugay,J.A., Emini,E.A., Schleif,W.A. and Quintero,J.C.
L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor
J Med Chem37, 3443-3451. PubMed Europe PubMed DOI I
Dunn,B.M., Gustchina,A., Wlodawer,A. and Kay,J.
Subsite preferences of retroviral proteinases
Methods Enzymol241, 254-278. PubMed Europe PubMed V
[YEAR:15-4-1994]Greer,J., Erickson,J.W., Baldwin,J.J. and Varney,M.D.
Application of the three-dimensional structures of protein target molecules in structure-based drug design
J Med Chem37, 1035-1054. PubMed Europe PubMed I
Harte,W.E., Jr. and Beveridge,D.L.
Probing structure-function relationships in human immunodeficiency virus type 1 protease via molecular dynamics simulation
Methods Enzymol241, 178-195. PubMed Europe PubMed
Hellen,C.U.
Assay methods for retroviral proteases
Methods Enzymol241, 46-58. PubMed Europe PubMed V
Ho,D.D., Toyoshima,T., Mo,H., Kempf,D.J., Norbeck,D., Chen,C.M., Wideburg,N.E., Burt,S.K., Erickson,J.W. and Singh,M.K.
Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor
J Virol68, 2016-2020. PubMed Europe PubMed I
Hoeprich,P.D., Jr.
Chemical synthesis of the aspartic proteinase from human immunodeficiency virus (HIV)
Methods Mol Biol36, 287-304. PubMed Europe PubMed DOI
Hosur,M.V., Bhat,T.N., Kempf,D.J., Baldwin,E.T., Liu,B., Gulnik,S., Wideburg,N.E., Norbeck,D.W., Appelt,K. and Erickson,J.W.
Influence of stereochemistry on activity and binding modes for C2 symmetry-based diol inhibitors of HIV-1 protease
J Am Chem Soc116, 847-855. I
Katz,R.A. and Skalka,A.M.
The retroviral enzymes
Annu Rev Biochem63, 133-173. PubMed Europe PubMed DOI
Kempf,D.J.
Design of symmetry-based, peptidomimetic inhibitors of human immunodeficiency virus protease
Methods Enzymol241, 334-354. PubMed Europe PubMed V I
Lin,X.L., Lin,Y.Z. and Tang,J.
Relationships of human immunodeficiency virus protease with eukaryotic aspartic proteases
Methods Enzymol241, 195-224. PubMed Europe PubMed V
Mildner,A.M., Rothrock,D.J., Leone,J.W., Bannow,C.A., Lull,J.M., Reardon,I.M., Sarcich,J.L., Howe,W.J., Tomich,C.S.C., Smith,C.W., Heinrikson,R.L. and Tomasselli,A.G.
The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties
Biochemistry33, 9405-9413. PubMed Europe PubMed
Polgar,L., Szeltner,Z. and Boros,I.
Substrate-dependent mechanisms in the catalysis of human immunodeficiency virus protease
Biochemistry33, 9351-9357. PubMed Europe PubMed
Ringe,D.
X-ray structures of retroviral proteases and their inhibitor-bound complexes
Methods Enzymol241, 157-177. PubMed Europe PubMed S
Rose,J.R. and Craik,C.S.
Structure-assisted design of nonpeptide human immunodeficiency virus-1 protease inhibitors
Am J Respir Crit Care Med150, S176-S182. PubMed Europe PubMed DOI I
Sardana,V.V., Schlabach,A.J., Graham,P., Bush,B.L., Condra,J.H., Culberson,J.C., Gotlib,L., Graham,D.J., Kohl,N.E., LaFemina,R.L., Schneider,C.L., Wolanski,B.S., Wolfgang,J.A. and Emini,E.A.
Human immunodeficiency virus type 1 protease inhibitors: evaluation of resistance engendered by amino acid substitutions in the enzyme's substrate binding site
Biochemistry33, 2004-2010. PubMed Europe PubMed I
Thompson,S.K., Murthy,K.H., Zhao,B., Winborne,E., Green,D.W., Fisher,S.M., DesJarlais,R.L., Tomaszek,T.A., Jr., Meek,T.D. and Gleason,J.G.
Rational design, synthesis, and crystallographic analysis of a hydroxyethylene-based HIV-1 protease inhibitor containing a heterocyclic P1'-P2' amide bond isostere
J Med Chem37, 3100-3107. PubMed Europe PubMed DOI S I
Tomasselli,A.G. and Heinrikson,R.L.
Specificity of retroviral proteases: an analysis of viral and nonviral protein substrates
Methods Enzymol241, 279-301. PubMed Europe PubMed P
[YEAR:26-4-1994]Vacca,J.P., Dorsey,B.D., Schleif,W.A., Levin,R.B., McDaniel,S.L., Darke,P.L., Zugay,J., Quintero,J.C., Blahy,O.M. and Roth,E.
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor
Proc Natl Acad Sci U S A91, 4096-4100. PubMed Europe PubMed I
Vacca,J.P.
Design of tight-binding human immunodeficiency virus type 1 protease inhibitors
Methods Enzymol241, 311-334. PubMed Europe PubMed I

1993

Appelt,K.
Crystal structures of HIV-1 protease-inhibitor complexes
Perspect Drug Discov Design1, 23-48. DOI S I
Athauda,S.B., Ido,E., Arakawa,H., Nishigai,M., Kyushiki,H., Yoshinaka,Y., Takahashi,T., Ikai,A., Tang,J. and Takahashi,K.
Entrapment and inhibition of human immunodeficiency virus proteinase by alpha2-macroglobulin and structural changes in the inhibitor
J Biochem113, 742-746. PubMed Europe PubMed
[YEAR:5-6-1993]Cameron,C.E., Grinde,B., Jacques,P., Jentoft,J., Leis,J., Wlodawer,A. and Weber,I.T.
Comparison of the substrate-binding pockets of the Rous sarcoma virus and human immunodeficiency virus type 1 proteases
J Biol Chem268, 11711-11720. PubMed Europe PubMed
Dougherty,W.G. and Semler,B.L.
Expression of virus-encoded proteinases: functional and structural similarities with cellular enzymes
Microbiol Rev57, 781-822. PubMed Europe PubMed
Dreyer,G.B., Boehm,J.C., Chenera,B., DesJarlais,R.L., Hassell,A.M., Meek,T.D., Tomaszek,T.A. and Lewis,M.
A symmetric inhibitor binds HIV-1 protease asymmetrically
Biochemistry32, 937-947. PubMed Europe PubMed DOI S I
Erickson,J.W.
Design and structure of symmetry-based inhibitors of HIV-1 protease
Perspect Drug Discov Design1, 109-128. DOI I
Moore,M.L. and Dreyer,G.B.
Substrate-based inhibitors of HIV-1 protease
Perspect Drug Discov Design1, 85-108. DOI I
[YEAR:15-8-1993]Otto,M.J., Garber,S., Winslow,D.L., Reid,C.D., Aldrich,P., Jadhav,P.K., Patterson,C.E., Hodge,C.N. and Cheng,Y.S.
In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease
Proc Natl Acad Sci U S A90, 7543-7547. PubMed Europe PubMed I
Pettit,S.C., Michael,S.F. and Swanstrom,R.
The specificity of the HIV-1 protease
Perspect Drug Discov Design1, 69-83. DOI P
[YEAR:25-7-1993]Rutenber,E., Fauman,E.B., Keenan,R.J., Fong,S., Furth,P.S., Ortiz,d.M., Meng,E., Kuntz,I.D., DeCamp,D.L. and Salto,R.
Structure of a non-peptide inhibitor complexed with HIV-1 protease. Developing a cycle of structure-based drug design
J Biol Chem268, 15343-15346. PubMed Europe PubMed S I
[YEAR:30-7-1993]Schramm,H.J., Billich,A., Jaeger,E., Rucknagel,K.P., Arnold,G. and Schramm,W.
The inhibition of HIV-1 protease by interface peptides
Biochem Biophys Res Commun194, 595-600. PubMed Europe PubMed DOI I
[YEAR:23-8-1993]Sham,H.L., Betebenner,D.A., Wideburg,N., Saldivar,A.C., Kohlbrenner,W.E., Craig-Kennard,A., Vasavanonda,S., Kempf,D.J., Clement,J.J. and Erickson,J.E.
Pseudo-symmetrical difluoroketones. Highly potent and specific inhibitors of HIV-1 protease
FEBS Lett329, 144-146. PubMed Europe PubMed DOI I
Wlodawer,A. and Erickson,J.W.
Structure-based inhibitors of HIV-1 protease
Annu Rev Biochem62, 543-585. PubMed Europe PubMed DOI V I

1992

Ainsztein,A.M. and Purich,D.L.
Cleavage of bovine brain microtubule-associated protein-2 by human immunodeficiency virus proteinase
J Neurochem59, 874-880. PubMed Europe PubMed
Grinde,B., Cameron,C.E., Leis,J., Weber,I.T., Wlodawer,A., Burstein,H. and Skalka,A.M.
Analysis of substrate interactions of the Rous sarcoma virus wild type and mutant proteases and human immunodeficiency virus-1 protease using a set of systematically altered peptide substrates
J Biol Chem267, 9491-9498. PubMed Europe PubMed
[YEAR:5-6-1992]Milton,R.C., Milton,S.C. and Kent,S.B.
Total chemical synthesis of a D-enzyme: the enantiomers of HIV-1 protease show reciprocal chiral substrate specificity [corrected]
Science256, 1445-1448. PubMed Europe PubMed
[YEAR:15-11-1992]Murthy,K.H., Winborne,E.L., Minnich,M.D., Culp,J.S. and Debouck,C.
The crystal structures at 2.2-A resolution of hydroxyethylene-based inhibitors bound to human immunodeficiency virus type 1 protease show that the inhibitors are present in two distinct orientations
J Biol Chem267, 22770-22778. PubMed Europe PubMed S I
Tam,T.F., Carriere,J., MacDonald,I.D., Castelhano,A.L., Pliura,D.H., Dewdney,N.J., Thomas,E.M., Bach,C., Barnett,J. and Chan,H.
Intriguing structure-activity relations underlie the potent inhibition of HIV protease by norstatine-based peptides
J Med Chem35, 1318-1320. PubMed Europe PubMed DOI I
Thanki,N., Rao,J.K., Foundling,S.I., Howe,W.J., Moon,J.B., Hui,J.O., Tomasselli,A.G., Heinrikson,R.L., Thaisrivongs,S. and Wlodawer,A.
Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling
Protein Sci1, 1061-1072. PubMed Europe PubMed DOI S I
Tomaszek,T.A., Jr., Moore,M.L., Strickler,J.E., Sanchez,R.L., Dixon,J.S., Metcalf,B.W., Hassell,A., Dreyer,G.B., Brooks,I. and Debouck,C.
Proteolysis of an active site peptide of lactate dehydrogenase by human immunodeficiency virus type 1 protease
Biochemistry31, 10153-10168. PubMed Europe PubMed DOI P
Urban,J., Konvalinka,J., Stehlikova,J., Gregorova,E., Majer,P., Soucek,M., Andreansky,M., Fabry,M. and Strop,P.
Reduced-bond tight-binding inhibitors of HIV-1 protease. Fine tuning of the enzyme subsite specificity
FEBS Lett298, 9-13. PubMed Europe PubMed DOI I

1991

Craig,J.C., Duncan,I.B., Hockley,D., Grief,C., Roberts,N.A. and Mills,J.S.
Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase
Antiviral Res16, 295-305. PubMed Europe PubMed DOI I
Debouck,C.
Substrate specificity of the human (type 1) and simian immunodeficiency virus proteases
Adv Exp Med Biol306, 407-415. PubMed Europe PubMed
Goobar,L., Danielson,U.H., Brodin,P., Grundstrom,T., Oberg,B. and Norrby,E.
High-yield purification of HIV-1 proteinase expressed by a synthetic gene in Escherichia coli
Protein Expr Purif2, 15-23. PubMed Europe PubMed E
Graves,B.J., Hatada,M.H., Miller,J.K., Graves,M.C., Roy,S., Cook,C.M., Krohn,A., Martin,J.A. and Roberts,N.A.
The three-dimensional x-ray crystal structure of HIV-1 protease complexed with a hydroxyethylene inhibitor
Adv Exp Med Biol306, 455-460. PubMed Europe PubMed S I
Ido,E., Han,H.P., Kezdy,F.J. and Tang,J.
Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S
J Biol Chem266, 24359-24366. PubMed Europe PubMed
[YEAR:12-2-1991]Jaskolski,M., Tomasselli,A.G., Sawyer,T.K., Staples,D.G., Heinrikson,R.L., Schneider,J., Kent,S.B. and Wlodawer,A.
Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor
Biochemistry30, 1600-1609. PubMed Europe PubMed S
Kempf,D.J., Marsh,K.C., Paul,D.A., Knigge,M.F., Norbeck,D.W., Kohlbrenner,W.E., Codacovi,L., Vasavanonda,S., Bryant,P. and Wang,X.C.
Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease
Antimicrob Agents Chemother35, 2209-2214. PubMed Europe PubMed I
Meier,U.C., Billich,A., Mann,K., Schramm,H.J. and Schramm,W.
alpha2-Macroglobulin is cleaved by HIV-1 protease in the bait region but not in the C-terminal inter-domain region
Biol Chem Hoppe Seyler372, 1051-1056. PubMed Europe PubMed
Oswald,M. and von der Helm,K.
Fibronectin is a non-viral substrate for the HIV proteinase
FEBS Lett292, 298-300. PubMed Europe PubMed DOI
Pettit,S.C., Simsic,J., Loeb,D.D., Everitt,L., Hutchison,C.A., III and Swanstrom,R.
Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid
J Biol Chem266, 14539-14547. PubMed Europe PubMed
Poorman,R.A., Tomasselli,A.G., Heinrikson,R.L. and Kezdy,F.J.
A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base
J Biol Chem266, 14554-14561. PubMed Europe PubMed
[YEAR:29-3-1991]Sham,H.L., Betebenner,D.A., Wideburg,N.E., Saldivar,A.C., Kohlbrenner,W.E., Vasavanonda,S., Kempf,D.J., Norbeck,D.W., Zhao,C. and Clement,J.J.
Potent HIV-1 protease inhibitors with antiviral activities in vitro
Biochem Biophys Res Commun175, 914-919. PubMed Europe PubMed DOI I
Spinelli,S., Liu,Q.Z., Alzari,P.M., Hirel,P.H. and Poljak,R.J.
The three-dimensional structure of the aspartyl protease from the HIV-1 isolate BRU
Biochimie73, 1391-1396. PubMed Europe PubMed DOI S
[YEAR:5-8-1991]Tomasselli,A.G., Hui,J.O., Adams,L., Chosay,J., Lowery,D., Greenberg,B., Yem,A., Deibel,M.R., Zurcher-Neely,H. and Heinrikson,R.L.
Actin, troponin C, Alzheimer amyloid precursor protein and pro-interleukin 1 beta as substrates of the protease from human immunodeficiency virus
J Biol Chem266, 14548-14553. PubMed Europe PubMed
Tomasselli,A.G., Howe,W.J., Hui,J.O., Sawyer,T.K., Reardon,I.M., DeCamp,D.L., Craik,C.S. and Heinrikson,R.L.
Calcium-free calmodulin is a substrate of proteases from human immunodeficiency viruses 1 and 2
Proteins10, 1-9. PubMed Europe PubMed DOI
Weber,I.T.
Modeling of structure of human immunodeficiency virus-1 protease with substrate based on crystal structure of Rous sarcoma virus protease
Methods Enzymol202, 727-741. PubMed Europe PubMed

1990

Cheng,Y.S., Yin,F.H., Foundling,S., Blomstrom,D. and Kettner,C.A.
Stability and activity of human immunodeficiency virus protease: comparison of the natural dimer with a homologous, single-chain tethered dimer
Proc Natl Acad Sci U S A87, 9660-9664. PubMed Europe PubMed DOI
[YEAR:15-3-1990]Cheng,Y.S., McGowan,M.H., Kettner,C.A., Schloss,J.V., Erickson-Viitanen,S. and Yin,F.H.
High-level synthesis of recombinant HIV-1 protease and the recovery of active enzyme from inclusion bodies
Gene87, 243-248. PubMed Europe PubMed DOI E
[YEAR:31-5-1990]Copeland,T.D., Wondrak,E.M., Tozser,J., Roberts,M.M. and Oroszlan,S.
Substitution of proline with pipecolic acid at the scissile bond converts a peptide substrate of HIV proteinase into a selective inhibitor
Biochem Biophys Res Commun169, 310-314. PubMed Europe PubMed DOI I
DesJarlais,R.L., Seibel,G.L., Kuntz,I.D., Furth,P.S., Alvarez,J.C., Ortiz de Montellano,P.R., DeCamp,D.L., Babe,L.M. and Craik,C.S.
Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease
Proc Natl Acad Sci U S A87, 6644-6648. PubMed Europe PubMed I
[YEAR:3-8-1990]Erickson,J., Neidhart,D.J., VanDrie,J., Kempf,D.J., Wang,X.C., Norbeck,D.W., Plattner,J.J., Rittenhouse,J.W., Turon,M. and Wideburg,N.
Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease
Science249, 527-533. PubMed Europe PubMed I
[YEAR:29-6-1990]Grobelny,D., Wondrak,E.M., Galardy,R.E. and Oroszlan,S.
Selective phosphinate transition-state analogue inhibitors of the protease of human immunodeficiency virus
Biochem Biophys Res Commun169, 1111-1116. PubMed Europe PubMed DOI I
[YEAR:20-8-1990]Gustchina,A. and Weber,I.T.
Comparison of inhibitor binding in HIV-1 protease and in non-viral aspartic proteases: the role of the flap
FEBS Lett269, 269-272. PubMed Europe PubMed DOI S
Kempf,D.J., Norbeck,D.W., Codacovi,L., Wang,X.C., Kohlbrenner,W.E., Wideburg,N.E., Paul,D.A., Knigge,M.F., Vasavanonda,S. and Craig-Kennard,A.
Structure-based, C2 symmetric inhibitors of HIV protease
J Med Chem33, 2687-2689. PubMed Europe PubMed I
[YEAR:26-1-1990]McQuade,T.J., Tomasselli,A.G., Liu,L., Karacostas,V., Moss,B., Sawyer,T.K., Heinrikson,R.L. and Tarpley,W.G.
A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation
Science247, 454-456. PubMed Europe PubMed I
Phylip,L.H., Richards,A.D., Kay,J., Konvalinka,J., Strop,P., Blaha,I., Velek,J., Kostka,V., Ritchie,A.J., Broadhurst,A.V., Farmerie,W.G., Scarborough,P.E. and Dunn,B.M.
Hydrolysis of synthetic chromogenic substrates by HIV-1 and HIV- 2 proteinases
Biochem Biophys Res Commun171, 439-444. PubMed Europe PubMed DOI A P
Rao,J.K.M. and Wlodawer,A.
Is the pseudo-dyad in retroviral proteinase monomers structural or evolutionary?
FEBS Lett260, 201-205. PubMed Europe PubMed
[YEAR:15-5-1990]Richards,A.D., Phylip,L.H., Farmerie,W.G., Scarborough,P.E., Alvarez,A., Dunn,B.M., Hirel,P.H., Konvalinka,J., Strop,P. and Pavlickova,L.
Sensitive, soluble chromogenic substrates for HIV-1 proteinase
J Biol Chem265, 7733-7736. PubMed Europe PubMed
[YEAR:20-4-1990]Roberts,N.A., Martin,J.A., Kinchington,D., Broadhurst,A.V., Craig,J.C., Duncan,I.B., Galpin,S.A., Handa,B.K., Kay,J. and Krohn,A.
Rational design of peptide-based HIV proteinase inhibitors
Science248, 358-361. PubMed Europe PubMed I
Swain,A.L., Miller,M.M., Green,J., Rich,D.H., Schneider,J., Kent,S.B. and Wlodawer,A.
X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor
Proc Natl Acad Sci U S A87, 8805-8809. PubMed Europe PubMed DOI I
[YEAR:25-8-1990]Tomasselli,A.G., Hui,J.O., Sawyer,T.K., Staples,D.J., Bannow,C., Reardon,I.M., Howe,W.J., DeCamp,D.L., Craik,C.S. and Heinrikson,R.L.
Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2
J Biol Chem265, 14675-14683. PubMed Europe PubMed

1989

Blumenstein,J.J., Copeland,T.D., Oroszlan,S. and Michejda,C.J.
Synthetic non-peptide inhibitors of HIV protease
Biochem Biophys Res Commun163, 980-987. PubMed Europe PubMed I
Copeland,T.D., Wondrak,E.M., Tozser,J., Roberts,M.M. and Oroszlan,S.
Substitution of proline with pipecolic acid at the scissile bond converts a peptide substrate of HIV proteinase into selective inhibitor
Biochem Biophys Res Commun169, 310-314. I
Hatfield,D., Feng,Y.X., Lee,B.J., Rein,A., Levin,J.G. and Oroszlan,S.
Chromatographic analysis of the aminoacyl-tRNAs which are required for translation of codons at and around the ribosomal frameshift sites of HIV, HTLV-1, and BLV
Virology173, 736-742. PubMed Europe PubMed DOI
[YEAR:30-6-1989]Hostomsky,Z., Appelt,K. and Ogden,R.C.
High-level expression of self-processed HIV-1 protease in Escherichia coli using a synthetic gene
Biochem Biophys Res Commun161, 1056-1063. PubMed Europe PubMed E
Lapatto,R., Blundell,T., Hemmings,A., Overington,J., Wilderspin,A., Wood,S., Merson,J.R., Whittle,P.J., Danley,D.E., Geoghegan,K.F., Hawrylik,S.J., Lee,S.E., Scheld,K.G. and Hobart,P.M.
X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among retroviral enzymes
Nature342, 299-302. PubMed Europe PubMed DOI S
Loeb,D.D., Hutchison,C.A., III, Edgell,M.H., Farmerie,W.G. and Swanstrom,R.
Mutational analysis of human immunodeficiency virus type 1 protease suggests functional homology with aspartic proteinases
J Virol63, 111-121. PubMed Europe PubMed
[YEAR:5-2-1989]McKeever,B.M., Navia,M.A., Fitzgerald,P.M., Springer,J.P., Leu,C.T., Heimbach,J.C., Herbert,W.K., Sigal,I.S. and Darke,P.L.
Crystallization of the aspartylprotease from the human immunodeficiency virus, HIV-1
J Biol Chem264, 1919-1921. PubMed Europe PubMed
[YEAR:16-2-1989]Navia,M.A., Fitzgerald,P.M., McKeever,B.M., Leu,C.T., Heimbach,J.C., Herber,W.K., Sigal,I.S., Darke,P.L. and Springer,J.P.
Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1
Nature337, 615-620. PubMed Europe PubMed DOI S
[YEAR:10-4-1989]Richards,A.D., Roberts,R., Dunn,B.M., Graves,M.C. and Kay,J.
Effective blocking of HIV-1 proteinase activity by characteristic inhibitors of aspartic proteinases
FEBS Lett247, 113-117. PubMed Europe PubMed DOI I

1988

Kohl,N.E., Emini,E.A., Schleif,W.A., Davis,L.J., Heimbach,J.C., Dixon,R.A., Scolnick,E.M. and Sigal,I.S.
Active human immunodeficiency virus protease is required for viral infectivity
Proc Natl Acad Sci U S A85, 4686-4690. PubMed Europe PubMed
Krausslich,H.G. and Wimmer,E.
Viral proteinases
Annu Rev Biochem57, 701-754. PubMed Europe PubMed DOI
Le Grice,S.F., Mills,J. and Mous,J.
Active site mutagenesis of the AIDS virus protease and its alleviation by trans complementation
EMBO J7, 2547-2553. PubMed Europe PubMed
Nutt,R.F., Brady,S.F., Darke,P.L., Ciccarone,T.M., Colton,C.D., Nutt,E.M., Rodkey,J.A., Bennett,C.D., Waxman,L.H. and Sigal,I.S.
Chemical synthesis and enzymatic activity of a 99-residue peptide with a sequence proposed for the human immunodeficiency virus protease
Proc Natl Acad Sci U S A85, 7129-7133. PubMed Europe PubMed
[YEAR:29-7-1988]Schneider,J. and Kent,S.B.
Enzymatic activity of a synthetic 99 residue protein corresponding to the putative HIV-1 protease
Cell54, 363-368. PubMed Europe PubMed
Seelmeier,S., Schmidt,H., Turk,V. and von der Helm,K.
Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A
Proc Natl Acad Sci U S A85, 6612-6616. PubMed Europe PubMed I

1987

Debouck,C., Gorniak,J.G., Strickler,J.E., Meek,T.D., Metcalf,B.W. and Rosenberg,M.
Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor
Proc Natl Acad Sci U S A84, 8903-8906. PubMed Europe PubMed I

1985

Sanchez-Pescador,R., Power,M.D., Barr,P.J., Steimer,K.S., Stempien,M.M., Brown-Shimer,S.L., Gee,W.W., Renard,A., Randolph,A. and Levy,J.A.
Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2)
Science227, 484-492. PubMed Europe PubMed
Wain-Hobson,S., Sonigo,P., Danos,O., Cole,S. and Alizon,M.
Nucleotide sequence of the AIDS virus, LAV
Cell40, 9-17. PubMed Europe PubMed